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Abstract  
 
The emergence of a serious adverse effect from a recently marketed drug is a great 
concern. The earlier we can detect and evaluate those unwanted effects, the better we can 
prevent them. Regulatory authorities play an important role in detecting, assessing and 
informing healthcare professionals and consumers on drug safety issues. Regulatory 
authorities use drug safety warnings as a communication tool for notifying prescribers 
about the risk and providing the recommendation for their practices. Expected outcomes of 
drug safety warnings are prescribers’ awareness of these risks and a change in their 
prescribing according to the safety information. However, effectiveness of these safety 
warnings on clinical practice had been reviewed and led to recommendation for reform in 
Australia. 
Several studies in the US and Europe have investigated the effect of regulatory warnings 
on clinical practice with the ultimate aim to improve the effectiveness of drug warning 
systems. To date limited studies are available on the effects of regulatory warning systems 
in Australia. Given global access to medicines and the importance of timely post-marketing 
surveillance on new drugs, drug safety regulation has an international focus. Medicine use 
in Australia is influenced not only by the local drug authority, Therapeutic Goods 
Administration (TGA), but also key international drug regulatory bodies such as the United 
States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 
Therefore, an understanding of the impact of national and international drug warnings on 
clinical practice is needed. Recent drug warnings on risks related to the thiazolidinedione 
drug class (rosiglitazone and pioglitazone) and the proposed drug-drug interaction 
between clopidogrel and proton pump inhibitors (PPIs) provide excellent case studies to 
assess the impact of drug safety warnings on medicine use in Australia.  
First, a time series analysis was used to examine the changes of rosiglitazone and 
pioglitazone use after the release of international and local warnings. The impact size of 
each warning on i) dispensing patterns in the Pharmaceutical Benefit Scheme (PBS)—
national dispensing database and ii) prescribing patterns in the AsteRx clinical database 
was investigated using an auto regressive, integrated, moving average (ARIMA) statistical 
model. The PBS data displayed a nationwide trend of drug dispensing, whereas the 
prescribing trend in the AsteRx provided more specific details on switching choices and 
other factors associated with prescribing decisions. For warnings on a definite and serious 
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cardiovascular effect related to rosiglitazone, a decline in the use of rosiglitazone was 
observed immediately after the warning from the FDA and EMA in May 2007. No 
significant further effect on the use of rosiglitazone was observed following the warning by 
the TGA, announced in December 2007. Warnings on the risk of bladder cancer, a low 
incidence outcome related to long-term pioglitazone treatment in June–July 2011 did not 
have any significant effect on the ongoing decline of pioglitazone use.  
Second, a similar time-series analysis was used to assess the effect of warnings regarding 
a possible drug-drug interaction between clopidogrel and proton pump inhibitors in AsteRx 
coprescribing data. Compared to the warnings on adverse effects of thiazolidinediones, 
warnings regarding the clopidogrel-PPI interaction were inconsistent, largely due to the 
conflicting and inconclusive clinical evidence. The FDA and EMA suggested avoiding 
concomitant esomeprazole and omeprazole with clopidogrel in 2009, and recommended 
use of pantoprazole. However, the TGA refrained from providing specific advice. Although 
esomeprazole was the most commonly coprescribed PPIs with clopidogrel in Australian 
clinical practice during 2006–2012, an increasing trend of coprescribing pantoprazole was 
observed after international warnings in 2009. This increasing trend found to be a result of 
switching from omeprazole and esomeprazole to pantoprazole. 
The third component of this thesis developed and piloted a survey tool to elicit the beliefs 
and behaviour of Australian prescribers in response to safety warnings. Results show that 
a large proportion of survey responders did not receive any direct drug safety 
communication from the TGA (e.g. TGA’s safety advisory email or TGA’s website). NPS 
MedicineWise and Australian prescriber were popular sources of drug safety information 
among survey participants. The changes in patterns of rosiglitazone and pioglitazone 
corresponded to a high awareness of the cardiovascular risk associated with rosiglitazone 
and a low awareness of the bladder cancer risk related to pioglitazone. Despite a non-
specific warning from the TGA, half of responders knew of the interaction between 
clopidogrel and PPIs.  
These results suggest that changes in patterns of concerned drugs were associated with 
international warnings, which may get through to Australian prescribers via NPS 
MedicineWise or other medical associations. In summary, the impact on drug use depends 
on the intensity and clarity of warnings as well as the certainty, severity and prevalence of 
adverse effects. This thesis expands the current understanding of the impact of regulatory 
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safety warnings on prescriptions and also provides the scope for possible improvement to 
the warning system in Australia.  
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 1 
Chapter 1. Introduction 1 
1. Drug safety warning system 2 
A drug safety warning system helps to create a virtual community in the form of a network 3 
of stakeholders who communicate with each other on unwanted adverse drug reactions 4 
(ADRs) of medicines in post-marketing situations. The system consists of a set of activities 5 
taken by different parties, with the aim of improving the safety of medicine use and 6 
preventing drug-related harms. 7 
1.1 Why is a drug warning system needed? 8 
Pharmaceutical development has provided better medical treatment but a greater risk has 9 
also been encountered. Studies indicate that ADRs may occur in 16.88% of patients 10 
during hospitalisation and 20–70% of those events are related to preventable 11 
pharmacological properties of the involved medicines (Kongkaew et al. 2008; Miguel et al. 12 
2012). A systemic review showed that 2–4% of all hospital admissions in Australia were 13 
from adverse drug reactions (Runciman et al. 2003). At least 80,000 drug-related 14 
hospitalisations were estimated annually in Australia, of those numbers between 32% and 15 
69% were considered preventable events (Roughead 1999; Kalisch et al. 2012). 16 
Approximately 3–30% of all adverse drug reactions are caused by drug–drug interactions 17 
and result in hospitalisation or morbidity every year, making their early identification vital 18 
(Stanton et al. 1994; Dechanont et al. 2014; Iyer et al. 2014).  19 
Monitoring risks of innovative products is necessary based on the fact that the pre-20 
approval data of newly-marketed drugs is not enough to establish a complete risk-benefit 21 
profile (Berlin et al. 2008). Preclinical testing of a compound in laboratories and animals 22 
suggests possible therapeutic and adverse effects for testing in humans. Clinical testing in 23 
approximately 1,000–3,000 human participants during the drug development process is 24 
limited in the length of time, sample size, and certain subgroups of patients (Stricker et al. 25 
2004). Moreover, clinical trials of some chronic diseases measure biomarkers or 26 
surrogates as study outcomes instead of clinical endpoints. For example, the level of 27 
haemoglobin A1c is often used as a surrogate outcome to measure the effect of new drugs 28 
for diabetes (Phillips et al. 2001; Gerstein et al. 2006). Therefore, the real risk and benefit 29 
of these medicines are not entirely known at the end of the approval process. 30 
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 2 
Clinical trials required for the current drug approval process are generally divided into 3 1 
phases. Phase I trials are conducted in a small number of healthy volunteers (20–100) to 2 
determine the pharmacodynamics, pharmacokinetics and intoxicated dosage in humans. 3 
Typically 100–300 patients who have the target disease are included in the Phase II 4 
testing to obtain the efficacy and possible side effects. The daily dosage and regimen are 5 
also identified in Phase II. During Phase III trials, ten to thousands of patients (depending 6 
on prevalence of the disease) are randomly assigned the treatments to examine the rate of 7 
primary outcomes and to generate adverse event profiles. Although a larger number of 8 
patients are exposed to a drug in Phase III testing, only relatively frequent adverse events 9 
can be detected. For example, a total of 3000 patients would provide a 95% chance of 10 
detecting any adverse events, which occur in at least one out of 1000 exposed patients. A 11 
smaller sample of 1000 patients would detect any adverse events that occur at a rate of 6 12 
in 1000 patients (Berlin et al. 2008).  13 
Therefore the sample sizes in these premarketing phases are insufficient to detect less 14 
common adverse events or establish a full safety profile at the time of approval (Wahab et 15 
al. 2013). There are several other reasons why adverse reactions emerge after approval 16 
and widespread use of a drug (WHO 2004). For example, some adverse drug events are 17 
only identified in specific groups of patients who were excluded in pre-marketing studies, 18 
e.g. the elderly, children, and pregnant women. Other comorbidities and concomitant 19 
medicines (both for the same indication or others) can also modify the effect of drugs and 20 
enhance some adverse reactions. Moreover, the delayed effects from exposure to certain 21 
drugs are impossible to identify in a limited premarketing period. For instance, the 22 
incidence of developing bladder cancer related to more than a 2 year-exposure to 23 
pioglitazone (Mamtani et al. 2012) and carcinoma of the reproductive system from a 20 24 
year-exposure to diethylstibestrol (Herbst et al. 1971).  25 
A suitable system is essential to ensure the safety of post-marketing drug use. Such a 26 
system should involve monitoring safety signals, gathering data, evaluating the association 27 
between adverse events and the drug concerned, balancing the risk-benefit profile, and 28 
preventing adverse events (WHO 2004). 29 
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 3 
1.2 Components and objectives of a drug warning system 1 
Safety issues can emerge at any stage throughout the drug lifecycle and be obtained from 2 
different data sources. Consequently, the practice of drug safety monitoring and warning 3 
requires a complex relationship between a wide range of partners. These partners include 4 
patients, health professionals, regulatory bodies, policy makers, and the pharmaceutical 5 
industry. Each partner needs to understand their role in contributing to the information on 6 
the risk related to drug use and how to respond to potential harms of the drugs available in 7 
the market (WHO 2000).  8 
Pharmacovigilance tools are usually employed to approach the safety issue related to the 9 
use of drugs after approval. WHO defines pharmacovigilance as “the science and activities 10 
mainly emphasized on the detection, assessment, understanding and prevention of 11 
adverse effects of postmarketing pharmaceutical products” (WHO 2000). The two main 12 
components of a drug warning system are risk identification and risk minimisation. 13 
1.2.1 Risk identification 14 
Risk identification is the first half of a drug warning system focusing on identifying safety 15 
signals and characterising the risks related to drug use in populations (WHO 2004; Strom 16 
2006). Specific aims of risk identification are: 17 
§ To early detect the adverse drug effects and interactions 18 
§ To identify the possible association between adverse effects and the concerned 19 
drug 20 
§ To classify the severity of the adverse effects 21 
§ To evaluate the risk and benefit of the concerned drug in each population group  22 
Data on adverse events or risk related to the use of a drug can be obtained from 23 
spontaneous reports, electronic databases, and data collected in post-marketing studies 24 
(Strom 2006). Spontaneous adverse event reports are unsolicited reports of clinical 25 
observations in patients administered the product outside a formal clinical study (Ahmad 26 
2003). These reports are acquired directly from consumers or healthcare professionals 27 
through the established voluntary spontaneous reporting systems from drug manufacturers 28 
or regulatory agencies. Studies show increasing reporting activities through spontaneous 29 
reporting systems in many countries (Kimura et al. 2011; Srba et al. 2012), which can be 30 
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linked and contribute to global pharmacovigilance databases. However, signals from 1 
spontaneous reporting systems require careful analyses from regulatory authorities and 2 
industry before they can be used to inform decision making.  3 
Adverse effects are also collected from the growing availability of electronic health 4 
databases such as claims-based health insurance (e.g. Medicaid-Medicare in the United 5 
States) (Rodriguez et al. 2001) and medical practice databases (e.g. the General Practices 6 
Research Database in the United Kingdom) (Garcia Rodriguez et al. 1998). Recently, the 7 
Asian Pharmacoepidemiology Network (AsPEN) was formed as a multi-national research 8 
network to promptly identify and validate emerging safety issues. Participating countries 9 
include Taiwan, Japan, Korea, Hong Kong, China, Singapore and Australia as well as 10 
collaborating nations: Sweden and the USA (Andersen et al. 2013). Currently, eight 11 
different databases from six countries have been used in collaboration between AsPEN 12 
nations to conduct pharmacoepidemiology studies. These databases provide a proactive 13 
approach to detecting adverse effects and a better chance of establishing a relationship 14 
between prescriptions and diagnoses at the patient level. However, a substantial amount 15 
of time is needed after the marketing of a new drug in order to obtain information on the 16 
adverse events. Typically, the adverse events identified from databases are used to 17 
generate hypotheses for further investigation (Strom 2005).  18 
In many countries including Australia pharmaceutical companies are obligated to conduct 19 
Phase IV clinical trials or post-marketing studies on the safety and monitoring of their 20 
products (WHO 2004). The collection of adverse event data during observational studies 21 
or clinical trials also provides information on possible adverse events even when safety 22 
was not the main outcome of interest. For example, the incidence of cardiovascular events 23 
in a clinical study investigating the primary gastrointestinal endpoint of rofecoxib (Vioxx®)—24 
a cyclooxygenase-2 selective inhibitors—was found to be higher than a traditional non-25 
steroidal anti-inflammatory drug (NSAID) (Mukherjee et al. 2001). The association 26 
between adverse effects and specific conditions or certain characteristics can be 27 
investigated using data from these observational or randomised clinical studies (WHO 28 
2004).  29 
The emerging serious cardiovascular events related to Vioxx® along with other withdrawn 30 
drugs have raised media attention on the effectiveness of post-marketing surveillance 31 
(Olsen et al. 2009). Risk identification as a part of drug warning systems has been 32 
Chapter 1 
 5 
extensively reviewed and is under increasing pressure by the public for a reform (Ray et 1 
al. 2006; Olsen et al. 2009; McGee et al. 2012). Pharmaceutical companies together with 2 
drug authorities are demanding close monitoring and characterisation of the severity of 3 
adverse effects. Close cooperation is required with academia to identify the signals and 4 
conduct further analysis investigating these signals and determining an association. The 5 
evaluation of risk and benefit data from the risk identification process informs what 6 
regulatory action takes place.  7 
1.2.2 Risk minimisation 8 
After a drug safety risk has been identified and evaluated, risk minimisation strategies are 9 
needed to prevent these unwanted events related to the use of the drug concerned. The 10 
risk minimisation process requires industry, regulatory authorities, healthcare providers, 11 
and consumers to interact through the use of effective communication methods (WHO 12 
2004; Strom 2006). The specific aims of risk minimisation are:  13 
§ To decide the action needed to reduce risk or increase benefit of using the 14 
concerned drug 15 
§ To communicate the risks or interventions 16 
• To promote understanding of the risk of the concerned drug to the public 17 
• To improve rational use of the concerned drug in specific conditions or in 18 
populations who benefit from that medicine 19 
• To provide practical implications and different therapeutic strategies for 20 
prescribing decisions  21 
• To provide education or clinical training related to the concerned drug and 22 
other therapeutic options available 23 
Both the regulator and manufacturer are responsible for responding to safety issues and 24 
informing the public. The drug label (or package insert, patient information leaflet, product 25 
information) is the official route for providing information to practitioners and patients 26 
(Meadows 2002; WHO 2004; Edwards et al. 2012). However, the content on the drug label 27 
is drafted by the pharmaceutical industry and requires time consuming negotiations and 28 
modifications (Ray et al. 2006). Without notification from the supplier or drug regulator, 29 
most of practitioners and consumers would not know that changes had been made to drug 30 
labels. Therefore, drug safety communications in various forms are used to alert health 31 
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care professionals and patients on this emerging risk of a medicine. The choice of 1 
communication depends on the urgency and severity of the safety issue (WHO 2004). One 2 
of the biggest challenges is to translate important safety information into clinical practice 3 
(Ray et al. 2006). Drug safety communication should specify the use of medicine in 4 
patients with different risk profiles including treatment strategies and choices.  5 
Changes to prescribing or use of the drug do not always appear to follow the 6 
recommendations on the safety communication (Lexchin 2005). In Canada, the 2000 7 
change in the contraindication of cerivastatin product to include the risk of rhabdomyolysis 8 
did not slow down its prescribed rate before it was withdrawn in 2001. This growth in 9 
prescribing might have been increased by the huge spend on the marketing campaign on 10 
cerivastatin (Lexchin 2005). Continued follow-ups of communication from evolving safety 11 
evidence among diverse populations have substantial effects in refining the efficient use of 12 
the drug (Esterly et al. 2011). In order to enhance prescribing decisions for health care 13 
providers, medical associations together with academia have the ability to revise clinical 14 
guidelines and provide infrastructure to enhance the knowledge for risk benefit 15 
assessment (Edwards et al. 2012). 16 
Cases of liver failure and death were reported spontaneously soon after the 1997 17 
introduction of troglitazone for the treatment of type 2 diabetes mellitus in the United 18 
States (Gitlin et al. 1998). As a result of the increasing number of cases, four “Dear 19 
Healthcare Professional” letters were sent by the manufacturer to doctors countrywide to 20 
recommend they monitor liver enzymes in patients taking troglitazone (Graham et al. 21 
2001). The manufacturer and the US drug authority updated the label and recommended 22 
monitoring hepatic enzymes. Subsequently, the pharmaceutical company decided to 23 
withdraw this drug from the market in 1999. After its withdrawal, researchers from health 24 
care, insurance companies and academia conducted observational studies and found that 25 
the risk related to troglitazone was actually much smaller than what was estimated from 26 
the spontaneous reports (Graham et al. 2001). 27 
There is no single system in place for the dissemination of safety information (Woosley 28 
2000). Globalisation and increasing use of the internet have all contributed to enhanced 29 
communication across borders and the way people access medical products and 30 
information (WHO 2004). However, these various sources presenting different risk 31 
conclusions can create difficulties for clinical practice. National regulators have the 32 
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responsibility for making judgements of acceptance and action towards risks for public 1 
safety. 2 
2. Role of regulatory authorities on drug safety warnings 3 
There are diverse views of risk and benefit among pharmaceutical industry, medical 4 
experts, healthcare professionals, and consumers (i.e. where some value the benefit of the 5 
drug differently from the others). Emerging adverse events associated with a drug can lead 6 
to fear among patients and the immediate discontinuation of drug use or the switching to 7 
another drug class (de Vries et al. 1998).  8 
Regulatory bodies play an important role in investigating an emerging event and ensuring 9 
understanding of the situation by all stakeholders. Governments of most developed 10 
countries have increased their involvement in regulatory actions in order to ensure the 11 
safety of drugs and public confidence in using the medications (WHO 2004). The majority 12 
of regulatory authorities are established by governments as part of the public section (or 13 
public authority) to protect the health of general population from the industry sector and 14 
potential risks from their products. The role of the regulatory authority is to enact legislation 15 
and establish the rules by which the industry must act, including the development process, 16 
licensing of the drug, monitoring safety, and marketing of the products. The regulation of 17 
the medical products involves three primary areas: quality, safety and effectiveness. 18 
Regulators approach these topics by making evidence-based decisions and balancing 19 
risk-benefit profiles from the public perspective (Strom 2006; TGA 2014). 20 
In addition to the approval of new drugs, regulatory authorities undertake the judgment on 21 
acceptable limits of risk related to marketed products. Actions taken by the regulators to 22 
ensure the safety of drugs in the market range from termination of the licence, suspension 23 
of marketing/licence, changes to product indications, adding a warning to the product 24 
information or labelling, or putting the drug on a watch list, depending on the risk/benefit 25 
assessment (FDA 2009; TGA 2014).  26 
When an emerging signal is detected, regulatory agencies need to determine if the 27 
adverse event is a result of the drug. Regulatory authorities therefore implement several 28 
approaches (depending on the system in each country) to re-evaluate risk and benefit of 29 
the drug concerned. After a benefit-risk assessment if the risk outweighs the benefit, the 30 
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regulator can remove the drug of the market. However, if the risk is not certain or can be 1 
minimised by specific strategies, a removal is not necessary and safety information can be 2 
updated on the drug label in accordance with decisions by the regulatory authority. 3 
Regulatory processes differ according to the nation in which the authority is established as 4 
such decisions in regard to a drug causing concern can also differ. For example, 5 
rosiglitazone, an antidiabetic drug with an increased risk of cardiovascular event, was 6 
withdrawn throughout Europe whereas it is still in the US market with warnings and some 7 
restrictions. Restriction programs are used to limit access in a specific population or to 8 
closely monitor drug exposure. Prescribers or patients are required to enrol into a 9 
specialised program for access to the drug. The AVANDIA-Rosiglitazone Medicines 10 
Access Program is one such program established by the American regulatory authority, 11 
the Food and Drug Administration (FDA), in order to assess authority restricted medicines 12 
(FDA 2010). The challenge is to minimise the removal of potentially useful products (as a 13 
result of false signals) whilst, acting in a fast enough manner to prevent additional harm 14 
from a delay in withdrawal. The delay in the withdrawal of Vioxx® is one example of this 15 
challenge as there were more than 139,000 cardiovascular and cerebrovascular cases 16 
reported involved with Vioxx treatment prior to removal (Armstrong 2006; Olsen et al. 17 
2009). 18 
Regulatory warnings 19 
National regulators have a major role in raising public awareness of drug safety. 20 
Furthermore, they are involved in providing the recommendation and developing the health 21 
policy with regards to the use of concerning medicines (FDA 2007). Regulatory activities 22 
have been extended to include communication of risk, benefit, and effectiveness of 23 
medical products to healthcare providers, patients and the public. Improving the public’s 24 
understanding of the risk is also essential to achieve the expected outcome of the safe use 25 
of medicines (Yu et al. 2010; Thomas et al. 2013). 26 
Safety communication from a regulatory authority, also called a regulatory warning is a risk 27 
minimisation tool utilised to help prevent further harm from a concerned product. An 28 
effective safety communication must operate under a publicly trusted system in order to 29 
satisfy all parties including pharmaceutical industry, government, health professionals, and 30 
consumers (WHO 2000; Strom 2006). Safety communications need to consider the 31 
differences in perception and understanding of healthcare professionals and lay people. 32 
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Medical experts require sufficient scientific evidence of safety and appropriate 1 
recommendations for their practice, while patients may need to be assured about the 2 
concerned medicine. The pressure regulatory bodies have been under regarding the 3 
effectiveness of regulatory actions toward an emerging risk of a medical product and the 4 
release of risk communications has led to an increased transparency in the regulatory 5 
process, in order to gain more public trust and understanding (Ray et al. 2006; Cook et al. 6 
2009; Buckley et al. 2011; TGA 2011; McGee et al. 2012; Health_Canada 2013). 7 
2.1 International regulatory authorities 8 
Each country has their own national drug warning system to take into account the 9 
differences in legislative requirements, distribution, drug use (e.g. indications, dose, 10 
availability), genetics and health care systems. Drug safety communications issued by 11 
each national authority is an intervention tool that aims to minimise the risk related to the 12 
concerned drug in addition to updated labelling.  13 
There are several methods for delivering safety communications (Nkeng et al. 2012). 14 
Among the most widely known safety communications are ‘Direct Healthcare Professional’ 15 
(DHCP) letters so-called ‘Dear Doctor’ letters released by the United States Food and 16 
Drug Administration (FDA) and Health Canada (FDA ; MedEffect™). Similarly, ‘Dear 17 
Healthcare Professional communications’ (DHPCs) are issued by several authority bodies 18 
(Mol et al. 2010; Piening et al. 2012). A study from the Netherlands showed an increase in 19 
the number of DHPC letters issued in the past decade. This increase is likely a result from 20 
a greater awareness by the public, media, regulatory bodies and other stakeholders as 21 
well as the proactive screening of large databases (Mol et al. 2010).  22 
Another communication strategy is a ‘Black Box Warning’ that is mostly used by the FDA 23 
to indicate a serious adverse event or life-threatening risk of a medicine. Box warnings or 24 
Black box warnings are also used on drug labels in the UK and Australia but with a less 25 
frequent and higher threshold for issue compared to the US (Buckley et al. 2011). 26 
Safety alerts and public advisory warnings are commonly announced by the Medicines 27 
and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK), the 28 
FDA, and Health Canada (FDA ; MedEffect™ ; MHRA). The Pharmaceutical and Medical 29 
Devices Agency (PMDA) in Japan usually uses ‘Pharmaceuticals safety information’ and a 30 
‘Yellow Letter’ for emergent safety communications, and a ‘Blue Letter’ for rapid safety 31 
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communication (PMDA). ‘Press Release’ and ‘Public statement’ are the terms used by the 1 
European Medicines Agency (EMA). In Australia, the safety communication of an 2 
emerging risk is distributed by the Therapeutic Goods Administration (TGA). Some 3 
communication is directly targeted to patients such as the patient alert cards in the UK.  4 
The global connection of drug information and the rapid spread of safety communications 5 
between national regulatory authorities is well recognised with medical media and online 6 
drug information resources frequently publishing drug safety warnings released by the 7 
major regulatory bodies. Hence, it is likely that prescribers would receive these new safety 8 
communications from a range of international sources. The FDA and the EMA are the key 9 
regulatory authorities, which are under the spotlight of the media and medical experts. This 10 
is due to the United States and the European Union being the two main regions that have 11 
early access to innovative products (Nkeng et al. 2012; Moore et al. 2014). Clinical trials 12 
for new drugs and post-marketing surveillance data are essential sources for development 13 
of benefit-risk profiles (FDA ; FDA ; Xu et al. 2014). Data collection on adverse events in 14 
addition to the increasing resources for research infrastructure from manufactures, 15 
academia, and regulatory bodies provide further opportunity to investigate the emerging 16 
risk of medicines (Mol et al. 2013). Cardiovascular adverse events associated with 17 
rofecoxib were collected from clinical trials and reports in the US during 1999–2002, while 18 
there was no report in Australia. This is likely to have resulted in the time difference seen 19 
between warnings issued by the FDA in 2002 and by the TGA in 2003 (Wahab et al. 20 
2014). 21 
Decisions on the registration and risk management of new medicines by less resourced 22 
regulatory agencies are often based on either the FDA or EMA. Moreover, the FDA and 23 
the EMA collaborate on the development of new guidelines and risk management plans 24 
including risk minimisation activities. The initial release and implementation of these 25 
guidelines occurred in 2006 with the aim to improve the regulatory intervention in 26 
instances of individual safety issues of a concerned drug (FDA ; EMA 2005; Zomerdijk et 27 
al. 2012). The safety warning processes of the FDA and the EMA including public opinions 28 
on their performances are reviewed below. The process of drug safety warnings in 29 
Australia by the TGA is also discussed in the following section.  30 
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2.1.1 U.S. Food and Drug Administration  1 
The Food and Drug Administration (FDA) is an agency of the Department of Health and 2 
Human Services of the United States. Its purpose is the regulation and supervision of food, 3 
tobacco, dietary supplements, cosmetics and medical products by approving, restricting, 4 
issuing safety warnings, and recalling products (FDA 2012). The Center for Drug 5 
Evaluation and Research (CDER) is responsible for the collection of adverse drug reaction 6 
reports, regulation of advertising for the approved drug indication, and providing 7 
information to health professionals and consumers. The CDER also conducts post-8 
marketing drug surveillance from data collected in the Adverse Event Reporting System 9 
(AERS), the monitoring system of licensed drugs’ safety after distribution into the market 10 
(FDA 2014).  11 
If an adverse event is reported and a trend begins to emerge, an advisory committee will 12 
form to investigate and issue recommendations. Depending on the adverse effect and/or 13 
medicine that is reviewed, certain offices (e.g. Office of Surveillance and Epidemiology, 14 
Office of Biostatistics) and divisions (e.g. Division of Metabolism and Endocrine Products, 15 
Division of Cardiology Products) will review the evidence and/or conduct their own 16 
analyses, eventually comparing their analyses to those of the pharmaceutical companies. 17 
This information will be provided to the over-seeing advisory committee who evaluates and 18 
votes for the appropriate actions regarding the adverse effect (FDA). Regulatory actions 19 
range from market withdrawal to minor revisions to the drug’s label. 20 
Significant funds and workforce have been put into post-marketing drug safety monitoring 21 
since the withdrawal of rofecoxib (Vioxx®). Rofecoxib was approved by the FDA in May 22 
1999. Preliminary results of the Vioxx GI Outcome Research (VIGOR) study in 2000 23 
showed a four times higher risk of cardiovascular disease in the Vioxx group over the 24 
naproxen group. However, authors interpreted this as a coronary protective effect of 25 
naproxen over the risk of Vioxx (Armstrong 2006). Following this study, in April 2002, the 26 
FDA required labelling changes in the “Precautions section” of Vioxx to recognise the 27 
potential of cardiovascular effects instead of a more serious “Black Box Warnings” (FDA 28 
2002). After being marketed for 5 years, heart attacks and strokes were shown to be 29 
significantly associated with Vioxx, finally, the pharmaceutical company voluntarily 30 
withdrew Vioxx in September 2004 (FDA 2004). A number of on-going trials on rofecoxib 31 
were discontinued. The APPROVe (Adenomatous Polyp Prevention on Vioxx) study that 32 
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showed a two times higher risk of fatal cardiovascular events compared to the placebo 1 
group was discontinued (Bresalier et al. 2005; Armstrong 2006). 2 
The whole drug approval and monitoring process was under scrutiny and required major 3 
reform. In 2005, the Drug Safety and Effectiveness Monitoring program (DSEM) and the 4 
Drug Safety Oversight Board (DSB) were created to assist CDER in handling emerging 5 
drug safety concerns. The Institute of Medicine of the National Academies was assigned to 6 
assess the US drug safety system and later release recommendations for improvement 7 
(FDA 2005). The FDA also created the Risk Communication Advisory Committee in 2007 8 
to advise on methods of effective risk communication (FDA 2009). The Food and Drug 9 
Administration Amendments Act of 2007 was implemented to improve transparency and 10 
communication on post-marketing drug safety information.  11 
The FDA launched the FDA’s Transparency Initiative in June 2009 and three phases have 12 
since been implemented to increase the transparency on decision-making processes of 13 
the agency (FDA 2011). Since then more reports on the FDA’s assessments and semi-raw 14 
data from the AERS were released online. However, these early signal postings were 15 
opposed by physicians due to the concern that patients would stop taking these medicines 16 
without adequate causality being ascribed to the signal (Lofstedt et al. 2013).  17 
Safety communications from the FDA 18 
The FDA communicates new safety information through a combination of methods under 19 
‘Alerts’/‘Safety Alerts’ and ‘Drug Safety Communications’. ‘Public Health advisory’ aims to 20 
inform the general public on new risks associated with a medical product and to advise 21 
consumers on the medicines concerned. More targeted communication such as 22 
‘Information for Healthcare Professional’ sheet or ‘Dear Healthcare Provider’ letters are 23 
directed to the main prescribers of concerned products including details on scientific 24 
evidence and specific strategies for the treatment of conditions (FDA). The FDA is known 25 
for their timely response to emerging concerns and their reinforcement of messages over 26 
time; Early Communications, Follow-up Early Communications, and Reminders are often 27 
released by the FDA. 28 
The FDA has opened several channels to enhance the communication of safety 29 
information to health professionals and consumers. The “Drug Safety and Availability” 30 
page on FDA’s website provides Drug Safety Communications including new drug 31 
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warnings, drug recalls and drug label changes; moreover, there are easy ways to access 1 
the information via an email subscription for Recalls, Mobile Apps for Recalls, FDA on 2 
Facebook, FDA Drug Info on Twitter, FDA on Flickr, Drug Safety Podcasts and FDA 3 
Patient Safety News Video Broadcasts (FDA). The FDA’s announcements also often 4 
appear in both medical and non-medical media. 5 
The impacts of risk communication issued by the FDA on drug use have been frequently 6 
investigated. Although the FDA communication is generally rapid and more detailed, the 7 
inconsistent effects of box warnings from the FDA have been highlighted in several studies 8 
(Matlock et al. 2011; Dusetzina et al. 2012). The adherence to warnings or 9 
recommendations issued by the FDA depends on several factors. For example, the 10 
content of warnings must be summarised and focused directly on the risk and its 11 
management, including alternative treatment options to receive a targeted and widespread 12 
response (Dusetzina et al. 2012).  13 
2.1.2 European Medicines Agency 14 
The European Medicines Agency (EMA) is the European Union body responsible for: 1) 15 
inspecting good manufacturing practice, good laboratory practice and pharmacovigilance 16 
(pre- and post-marketing) of a new product; 2) coordinating the European Union’s 17 
pharmacovigilance system in monitoring the safety of medicines; and 3) conducting 18 
scientific assessment of a particular medicine on behalf of the European Union (EMA). The 19 
EMA is located in London and formed in 1995 in an attempt to harmonise the existing 20 
regulatory bodies in European nations. The EMA has a different approach to that of the 21 
centralised methodology of the FDA, as it incorporates a network of expertise and 22 
resources throughout the European Union for scientific assessment of medicines (EMA 23 
2005).  24 
The Committee for Medicinal Products for Human Use (CHMP) was established to prepare 25 
the Agency’s opinions on all questions concerning medicines. It is composed of 27 voting 26 
members of the EMA (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, 27 
Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 28 
Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 29 
Sweden, United Kingdom) and non-voting members (Norway, Iceland and Liechtenstein) 30 
chosen for their expertise regarding medicine evaluation. A Pharmacovigilance Working 31 
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Party (PhVWP) has the responsibility of evaluating the potential adverse drug reactions 1 
and reporting these to CHMP. CHMP initiates internal peer-review for the assessment of 2 
adverse events based on scientific evidence, necessary quality, safety, efficacy, and 3 
benefit/risk-balance model for making recommendations for changes, suspension, or 4 
withdrawal of the drug (EMA 2009). A panel within the CHMP known as the Scientific 5 
Advisory Group (SAG) provides independent recommendations on scientific or technical 6 
issues relevant to that product, such as, SAG on Diabetes/Endocrinology or SAG on 7 
Cardiovascular issue (EMA 2014). After the evaluation of each concern, a full report and 8 
recommendation called a European public assessment report (EPAR) is published on the 9 
Agency’s website (EMA). 10 
In 2010, the EMA was under pressure to increase the transparency and accessibility of 11 
information to the public (Lancet 2010). Risks associated with Vioxx, Avandia and 12 
Mediator were examples of public criticism on a lack of disclosure of information from the 13 
regulator and the regulatory relationship with industry (Bouder 2011). Strategies to 14 
improve the transparency of the regulatory environment on risk communication were 15 
discussed by the EMA and were included on the ‘Road map to 2015’ as a guideline 16 
document (EMA 2010). The establishment of an independent risk communication advisory 17 
board, a strategic view on transparency, the involvement of the public on risk 18 
communication and the evaluation of communication messages are suggested strategies 19 
for the EMA (Bouder 2011).  20 
Safety communications from the EMA 21 
Numerous safety communications are utilised by the EMA. European Public Assessment 22 
Reports (EPAR) contain a full risk and benefit assessment of the product and an update 23 
summary of product characteristics that is published on the EMA’s website. The Press 24 
Office under CHMP makes announcements with media representatives called a ‘Press 25 
release’ or ‘Public advisory’ related to an emerging risk and recommendation from the 26 
EMA. These communications contain the review process and time, up-to-date information, 27 
and recommendations related to the products concerned. With a similar purpose to the 28 
‘Press release’, Questions and Answers (Q&As) documents also provide risk and benefit 29 
assessments of the drug concerned on the EMA website. Specific communications to 30 
healthcare professionals by the EMA are termed ‘Direct Health Professional 31 
Communications’ (DHPC) or a ‘Dear Doctor letter’ (EMA).  32 
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All risk communications are published on the EMA’s website. The subscription of RSS 1 
(Rich Site Summary) feeds, monthly e-mail newsletter, audio and YouTube video are also 2 
available for healthcare professionals and consumers. National regulators in the European 3 
Union also adapt and combine the EMA communication with their own (EMA).  4 
Each of the EMA risk communications aims to describe the possible risk and benefit in 5 
using the concerned drug for targeted audiences but often tend to repeat standardised 6 
messages (Bouder 2011). However, these communications were observed to be unclear 7 
with regards to the expected benefits, magnitude and certainty of the risk communication. 8 
Inadequate information on the seriousness, baseline risk and recommendation on what 9 
action to take have also been a public concern (EMA 2009; Suvarna 2011). Suggested 10 
solutions are: improving templates of risk communication, targeted communication tools 11 
for various audiences/purposes, and better-informed benefit/risk decisions (e.g. risk 12 
stratification for healthcare professionals) and improving methods of message distribution 13 
(Suvarna 2011).  14 
2.2 The Australian regulatory authority 15 
2.2.1 Therapeutic Goods Administration 16 
The Therapeutic Goods Administration (TGA) is a division of the Australian Government 17 
Department of Health. The TGA ensures the safety, efficacy, and manufacturing quality of 18 
prescription medicines, vaccines, biological, blood and tissue products, medical devices, in 19 
vitro diagnostic devices, over-the-counter medicines, and complementary medicines (TGA 20 
2014). The establishment of the TGA was to integrate the Therapeutic Goods 21 
Administration Laboratories into the 1989 legislation of Therapeutic Goods for the full 22 
authority control of premarketing assessment, licensing, and post-marketing assessment 23 
of pharmaceutical products. The TGA is a major component of Australia’s National 24 
Medicines Policy and is developing the national regulatory framework to align with 25 
international regulatory systems (WHO 2004). 26 
The TGA structure comprises of three major groups: marketing authorisation, monitoring & 27 
compliance, and regulatory support. The marketing authorisation group is responsible for 28 
the approval of new therapeutic products for sale in Australia. The monitoring and 29 
compliance group ensures that approved products meet the mandatory standards 30 
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throughout their lifecycle. The regulatory support group supplies the legal, financial, 1 
technology & management information, parliamentary, and human resource services for all 2 
regulatory processes (TGA). 3 
Drug safety warnings, including monitoring and reviewing the concerns, falls to the 4 
monitoring and compliance group. When there is an emerging risk of a medical product, an 5 
Advisory Committee on the Safety of Medicines (ACSOM) is formed by the TGA. The 6 
members of ACSOM are selected for their knowledge and skills relevant to the drug of 7 
concern such as clinical pharmacology, biostatistics, and clinical expertise. The ACSOM 8 
assesses the evidence on the adverse events and provides the risk management plans for 9 
the TGA (TGA 2014). Unlike the EMA and FDA, the TGA does not conduct any new 10 
analyses. The TGA’s decision is based on the conclusion by advisory committee who 11 
assesses safety issued from adverse event notification, published articles, and 12 
manufacturer’s information.  13 
The range of TGA regulatory actions in response to a safety concern include: 14 
withdrawing/suspending/recalling a drug from the market, requesting an investigation from 15 
the manufacturers and requesting changes to product information (PI). The TGA is unable 16 
to make any change on the PI as it is the property of the manufacturer. The TGA can 17 
request that the drug sponsor updates the safety information on the PI; however, the 18 
process of discussion and agreement between authority and supplier may take time. If an 19 
emerging adverse effect needs an urgent response, other regulatory actions would be 20 
required for preventing further harm (Cook et al. 2009). Therefore, risk communications 21 
are necessary in order to alert health care professionals and consumers of an emerging 22 
risk (TGA).  23 
A previous review found that the PI for thyroid-related medicines failed to reflect an 24 
updated contraindication and dose recommendation from the medical literature and 25 
international guidelines (Stockigt 2007). This review also recommended that the process of 26 
updating the PI needed to be modified and required more of a proactive approach from the 27 
TGA in collaboration with suppliers and specialist clinicians. The “Box warning” on the 28 
product information was rarely used by the TGA. The TGA reserved it for the possible side 29 
effect, which is considered to be extremely necessary to alert the public. The content of 30 
Australian box warnings were shown to be succinct compared to the U.S. box warnings 31 
which are 10 times longer with a large amount of clinical evidence and practical 32 
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recommendations while only a few sentences of the negative effects were provided on the 1 
warning section in Australia (Buckley et al. 2011).  2 
In comparison with other industrialised countries, an attempt to improve the transparency 3 
of the TGA regulatory process has been delayed (Lancet 2010; FDA 2011; 4 
Health_Canada 2013). In November 2010, a review panel was formed to improve the 5 
transparency and understanding of TGA’s regulatory processes and decisions due to the 6 
perception that the TGA did not provide sufficient information to the public regarding TGA 7 
activities. In July 2011, the TGA transparency review was published under the 8 
Parliamentary Secretary for Health and Ageing. One topic from the TGA transparency 9 
review highlighted the difficulties in getting information about suspect products to 10 
consumers and health providers (TGA 2011). This review reflected community concern on 11 
two separate recent safety issues of poly-implant prosthetic breast implants and joint 12 
replacements. It indicated that a lack of effectiveness of the TGA’s regulatory 13 
communication had caused potential harm to the public (McGee et al. 2012; Bonython 14 
2014). The review also attacked the internal processes of the TGA in their delayed 15 
regulatory response to emerging safety information and following up on the issues 16 
concerned. It was suggested that the TGA develop an effective warning system to alert the 17 
public and to provide appropriate information on either the products under investigation or 18 
product recalls. The safety alerts needed timely distribution to health practitioners through 19 
jurisdictional and prescribing association networks (TGA review-recommendation 15–18) 20 
(TGA 2011).  21 
Since then, the TGA has been focusing on improving the transparency of regulatory 22 
decision-making processes as a part of the TGA reforms (TGA_reforms 2012). The early 23 
warning system is established as part of TGA's proactive approach to monitoring the 24 
safety of medicines. It was implemented in 2013 as a joint project between the TGA and 25 
the New Zealand Medicines and Medical Devices Safety Authority (Medsafe–the 26 
regulatory authority in New Zealand) to include current and historical information on safety 27 
concerns for medical products. Information on the decision criteria used, content of 28 
communication, publications and the update process of communication are available on 29 
the Trans-Tasman Early Warning System: Processes in Australia and New Zealand. 30 
Although this is a joint project on adverse event reports and regulatory processes, the 31 
communications themselves are separated between the two countries (TGA 2013).  32 
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Safety communications from the TGA 1 
Safety communications issued by the TGA are divided into monitoring communication and 2 
alerts communication. The monitoring communication underlines the potential safety 3 
concerns that the TGA has detected, even if they are in the early stages of investigation 4 
and little information is known. The monitoring communication aims to encourage 5 
practitioners, patients, and researchers to provide more data and clinical experiences 6 
related to these concerns (TGA 2013).  7 
The alert communications alert healthcare professionals and consumers to new safety 8 
information following the outcome of the TGA’s investigation. An alert communication on a 9 
concerned medicine is under ‘Alerts’, ‘Recalls’, and ‘Safety information’. ‘Alerts’ and 10 
‘Safety information’ may not necessarily indicate that the medicine is unsafe to use. The 11 
TGA expects healthcare professionals to use their clinical judgment in applying the safety 12 
communication to individual patients.  13 
The TGA issues a safety advisory message under ‘Alerts’ published on the TGA’s website, 14 
which includes information on the emerging event, any changes to product information or 15 
labelling and recommended use of the medicine to health professionals and consumers. 16 
Healthcare professionals and consumers can also subscribe to the ‘TGA-SAFETYINFO’ 17 
list to receive a notification email for any new TGA safety alerts (TGA_Alerts). 18 
The Medicine Safety Update is an article providing practical information and advice on 19 
emerging drug safety for health professionals. It is published every 2 months on the TGA’s 20 
website and appears in each edition of the Australian Prescriber Journal. The Medicine 21 
Safety Update replaced the Australian Adverse Drug Reactions Bulletin in 2010 (TGA). 22 
There is a difference in the timing of issued warnings between the FDA, EMA and TGA. 23 
For example, the FDA sent a warning letter to health professionals on the ischemic heart 24 
disease related to Vioxx in May 2002 (FDA 2002) but it was not until October 2003 when 25 
the first TGA Alert was issued. During that gap, the dispensing of rofecoxib continually 26 
increased in Australia. Some of the reasons behind the delay might be due to the fact that 27 
the spontaneous reporting signal on cardiovascular adverse events was not detected in 28 
Australia until the end of 2002 and there were no medical publications on the 29 
cardiovascular risk or stroke until 2005 (Armstrong 2006; Wahab et al. 2014). 30 
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As the majority of prescription medicines are subsidised by the Australian Government, the 1 
risk management strategy is extended to limiting access to the Pharmaceutical Benefits 2 
Scheme (PBS). The restriction of authorised prescribers and changes to restriction criteria 3 
on the PBS are also applied in response to safety concerns. However, changes to the PBS 4 
subsidy may be delayed until a series of warnings have been issued or the evidence is 5 
conclusive. For example, a change to flucloxacillin prescribing was observed after the 6 
issuing of warnings and multiple initiatives on the PBS subsidy to improve drug use 7 
(Roughead et al. 1999). 8 
There are several other ways to improve prescribing behaviour of concerned drugs. The 9 
TGA cooperates with the Quality Use of Medicines Policy arm of the national medicines 10 
policy through organisations such as the National Prescribing Service, which helps to 11 
distribute updated safety information. The NPS also provides educational programmes and 12 
resources to enhance the understanding and appropriate use of medicines to healthcare 13 
professionals and consumers (Gadzhanova et al. 2013). Examples of these programmes 14 
are the printed/online Australian Prescriber publication for health care professionals and 15 
the NPS RADAR mail-out on new drugs (NPS 2014). Updated safety information on the PI 16 
endorsed by the TGA is also published in other sources such as MIMS (monthly index of 17 
medical specialties), Australian Medicines Handbook, Therapeutic Guidelines, and 18 
NHMRC Clinical Practice Guidelines Portal. 19 
3. Evaluation of the impact of drug safety warnings 20 
Drug safety communications are utilised as intervention tools of the risk minimisation plan 21 
to raise awareness of the risk and to minimise the occurrence of risks associated with 22 
drugs in real-world settings. Regulatory agencies employ several methods to inform 23 
healthcare professionals of drug-related problems as stated above. Each communication 24 
method is chosen for different target audiences and various responses depending on the 25 
safety issue. This project focuses on the impacts of drug safety warnings on clinical 26 
practice. As there is no established design to evaluate the impact of drug safety warnings, 27 
several study designs and statistical analyses have been employed to examine these 28 
influences. Reviews of common types of safety warnings, expected outcomes, outcome 29 
measurements, study designs and statistical analyses are provided below. 30 
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3.1 Types of safety warnings 1 
Previous research investigated the impacts of several types of safety warnings such as 2 
Black box warning, Public health advisory, Dear Healthcare Provider letter issued by the 3 
FDA; Press release, Public advisory, Dear Healthcare Professional Communication by the 4 
EMA or European regulators; Safety Alerts by other national regulators on different 5 
outcomes of clinical practice (Piening et al. 2012). A number of articles have evaluated 6 
more than one warning in the range of one to eight per article. The most frequently 7 
assessed warnings are the Black box warning in the US. While Dear Healthcare 8 
Professional Communications are more frequently evaluated in other places, followed by 9 
Public Health Advisories and Safety Alerts (Dusetzina et al. 2012; Piening et al. 2012). 10 
3.2 Content and expected outcome of drug safety warnings 11 
The contents of a warning usually contain results of a regulatory evaluation on the risk-12 
benefit profile and recommendations on the use of the drug concerned. For warnings 13 
targeted at healthcare professionals, two main purposes are to raise their awareness of 14 
the safety issue and (if required) to change clinical practice. The expected outcomes of 15 
regulatory warnings on the changes to clinical practice are usually indicated in the 16 
recommendations.  17 
In addition to raising awareness, other expected outcomes of drug safety warnings are to 18 
encourage risk reporting, to prevent prescribing in specific groups of patients, to prevent 19 
concomitant use of drugs with their potential interaction, to encourage baseline and follow-20 
up laboratory tests, and to prevent serious adverse events from drug use (Dusetzina et al. 21 
2012; Piening et al. 2012). The following section provides a review of the expected 22 
outcomes related to the warning’s content.  23 
3.2.1 Warning on drug use in subpopulations 24 
Examples of safety warnings issued for preventing the use of drug in certain populations 25 
are: the Black box warnings regarding the risks of atypical antipsychotic use among elderly 26 
with dementia, the warning on the use of selective serotonin reuptake inhibitors (SSRIs) 27 
related to increased suicidal rate in children and adolescents, and the warning on 28 
thiazolidinedione drug class in patients with congestive heart failure (FDA 2007). Specific 29 
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subpopulation warnings usually include recommendations to avoid the concerned drug in 1 
high-risk patients and providing alternative treatment options.  2 
An expected outcome should be a decrease in the use of the concerned drug among the 3 
high-risk subpopulations and unchanged use among other groups of patients who may 4 
benefit from this drug. An increased use of alternative treatments and a reduction of 5 
adverse events in high-risk patients are also expected (Dusetzina et al. 2012).  6 
3.2.2 Warnings on drug-drug interactions 7 
To prevent concomitant use in the case of a drug-drug interaction or contraindication, the 8 
warnings usually list potential combinations and suggest a substitute if needed. Examples 9 
are the ‘Dear Doctor’ letters sent by the FDA to professionals listing drugs contraindicated 10 
for use with cisapride due to an increased risk of cardiac arrhythmias (Guo et al. 2003) and 11 
the warning on the concurrent use of terfenadine and some macrolides (e.g. erythromycin, 12 
ketoconazole) (Thompson et al. 1996). Recently, the warnings on the potential drug 13 
interaction between clopidogrel and drugs with CYP2C19 enzyme inhibitory effects were 14 
issued by the FDA and EMA (EMA 2009; FDA 2009). Similar to the previous warning, a 15 
decreased concurrent use of the drug-drug interaction is an expected outcome as well as 16 
substitution for the contraindicated medicine. Many studies indicate that a change in co-17 
prescribing in response to drug interaction warnings often takes months or years 18 
(Weatherby et al. 2002; Guo et al. 2003). For instance, an obvious decline in the 19 
contraindicated use of cisapride was not seen until after the third warning by the FDA 20 
(Weatherby et al. 2002; Guo et al. 2003). Despite serious cardiac warnings on the drug 21 
interaction, a decline in the coprescribing of contraindicated macrolides with terfenadine 22 
occurred slowly with the largest effect observed eighteen months following the first 23 
warning (Thompson et al. 1996). 24 
3.2.3 Recommendation for increased monitoring 25 
If certain complications are associated with the concerned drug, clinical monitoring or 26 
laboratory tests are recommended. Prior to the market withdrawal of trosiglitazone 27 
regarding hepatotoxicity, ‘Dear Healthcare Professional’ letters recommended that the liver 28 
function should be monitored in patients taking trosiglitazone (Graham et al. 2001; Cluxton 29 
et al. 2005). Other laboratory tests suggested by regulators are metabolic screening (e.g. 30 
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glucose testing) in patients starting second-generation antipsychotic drugs (Morrato et al. 1 
2010) and a tuberculin skin testing among infliximab users for a complication of latent 2 
tuberculosis (Vaughn et al. 2012). Apart from an increase in laboratory orders, an increase 3 
in follow-up visits for patients taking antidepressants are also suggested. Nevertheless, 4 
these expected effects were found to vary and were not necessarily consistent with the 5 
warnings. Studies on laboratory monitoring show unchanged rates of glucose testing in 6 
antipsychotic users moreover, rates of liver enzyme monitoring were shown to be lower in 7 
a certain group of practitioners following the FDA advice (Graham et al. 2001). 8 
3.2.4 Warnings on adverse events of concerned drugs 9 
In general population warnings on adverse events associated with use of a concerned 10 
drug prescribers are required to be cautious when using these medicines in all patients. 11 
Examples of drugs with serious adverse effect warnings are: third generation oral 12 
contraceptives associated with venous thromboembolism, droperidol regarding the risk of 13 
a cardiac arrhythmia, and the thiazolidinedione drug class (rosiglitazone and pioglitazone) 14 
associated with an increased risk of congestive heart failure (de Vries et al. 1998; Habib et 15 
al. 2008). Expected outcomes are a reduction of drug use in general or in patients with the 16 
high risk of developing adverse events if other treatments are available. A retrospective 17 
analysis showed a significant decline in droperidol use and a significant increase in 18 
ondansetron use (similar treatment effect as droperidol) for postoperative nausea and 19 
vomiting prophylaxis as suggested on the Black box warning in 2001 (Wax et al. 2007).  20 
3.3 Consequences of drug safety warnings 21 
Previous studies have assessed the intended and unintended consequences of drug 22 
safety warnings. The intended effects are a reduction in the number of prescriptions in 23 
populations at risk or a decrease in adverse events related to the concerned drug. For 24 
example, a decline of atypical antipsychotic drug use was observed in elderly with 25 
dementia in the year following the FDA advisory on an increased mortality (Dorsey et al. 26 
2010) and the dispensing of contraindicated drugs among cisapride users decreased after 27 
the issuing of ‘Dear Doctor’ letters (Smalley et al. 2000).  28 
The unintended consequences of drug warnings were also observed, particularly from the 29 
warnings on SSRIs and third-generation oral contraceptives (Piening et al. 2012). 30 
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Decreased use of SSRIs was reported in adults—the group of patients who would benefit 1 
from this treatment. A sharp fall in the all prescribing of third generation contraceptive pills 2 
occurred in the UK immediately after a press release concerning the safety of certain 3 
drugs in the same class (Flett et al. 1998). These consequences were spill-over effects of 4 
warnings to other subpopulations or other members of the same drug class (Ceilley et al. 5 
2009). The UK primary care database showed decreased rates of depression diagnoses in 6 
adolescent, which implied that GPs were cautious when making diagnoses following the 7 
warning (Wijlaars et al. 2012). 8 
3.4 Measuring the outcomes of drug safety warnings 9 
Previous studies have measured the changes in clinical practice as the outcomes of drug 10 
safety warnings. Healthcare utilisation, clinical diagnoses, and health behaviours are often 11 
assessed to indicate the impact of drug safety warnings (Dusetzina et al. 2012; Piening et 12 
al. 2012). The outcomes of interest can vary from a simple change in the number of 13 
prescriptions to complex social behaviours.  14 
Outcomes of studies depend on the purposes of warnings and the availability and 15 
accessibility of health information (Piening et al. 2012). Changes in patterns of healthcare 16 
utilisation and health outcome can be investigated using quantitative analyses. Healthcare 17 
utilisation includes drug utilisation, indication of drug use, use of other health care services 18 
(e.g. healthcare visits (Morrato et al. 2008), laboratory testing), etc. Primary outcomes 19 
regarding health utilisation used in the measurement of impact of warnings are listed 20 
below. 21 
3.4.1 Drug utilisation of a concerned drug or therapeutic class 22 
Changes in the use of the concerned drug are the most common outcomes assessed to 23 
investigate the impact of drug safety warnings (Dusetzina et al. 2012). Previous studies 24 
applied drug utilisation methods to measure changes in drug volume and standard daily 25 
requirement of concerned drug as the outcomes. In North American and Europe, Drug Use 26 
Evaluation and Drug Utilisation Review are terms used in criteria-based evaluation of drug 27 
use to ensure the appropriate drug therapy according to the current guideline or 28 
recommendation (Ratanawijitrasin 2002). Volume of drug use and amount of standard 29 
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dose use (defined daily dose) in a population are frequently used to calculate trends of 1 
drug use overtime. 2 
Volumes of drug use 3 
A common measurement in drug utilisation studies is the volume of drugs recorded in 4 
health databases (NHS 2012). Number of prescriptions, number of items, number of 5 
patients prescribed/dispensed drugs are counted without taking strengths, formulations or 6 
doses into account. Therefore the comparison between different time periods, groups of 7 
drugs, individual drugs, or studied population are difficult. For example, a 8 
prescription/package that may have contained 14 tablets in 2008 may increase to 30 9 
tablets in 2012 plus changing doses. The trend of actual consumption would be misleading 10 
if only volumes of drug were compared over time (WHO 2003).  11 
When the population size is known (defined cohort) or prescriptions of all therapeutic 12 
drugs can be identified during the study period, the proportion/rate of prescriptions or 13 
patients can be compared over time periods as well as between individual drugs or drug 14 
class (Strom 2005).  15 
Numbers of prescriptions and items are often collected for administrative purposes and 16 
obtained from wholesale or retail pharmacy prescription/dispensing data. Whereas 17 
numbers of patients prescribed the concerned drugs are acquired from medical records 18 
and medical claims database (Strom 2005). 19 
WHO anatomical Therapeutic Chemical Defined Daily Dose (ATC/DDD) 20 
Comparative utilisation among different populations over time can be examined by the 21 
World Health Organization Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose 22 
(DDD) system (Magrini et al. 1997; WHO 2013). The ATC system comprises of 5 23 
classification levels, for example A10BG02 is the ATC code for rosiglitazone:  24 
1st level indicates an anatomical main group e.g. A—Alimentary tract and metabolism 25 
2nd level indicates a therapeutic subgroup e.g. A10—Drug used in diabetes 26 
3nd level indicates a pharmacological subgroup e.g. A10B—Blood glucose lowering drugs 27 
4th level indicates a chemical therapeutic subgroup e.g. A10BG—Thiazolidinediones 28 
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5th level indicates a chemical substance e.g. A10BG02—Rosiglitazone 1 
The defined daily dose (DDD) is a medical meaningful unit assigned for each ATC code 2 
and provides an assumed average daily maintenance dose for a drug in adults. The DDD 3 
designated for all drugs are available on the WHO’s website (WHO 2013). DDDs per 4 
population per day are usually calculated from national pharmacy claims databases to 5 
compare drug utilisation between these jurisdictions (Tett et al. 2013).  6 
Advantages of DDDs (Wertheimer 1986) 7 
§ Able to work with gross drug statistics at various levels of the health chain 8 
§ Allows comparisons between drugs in the same therapeutic class and between 9 
different health care settings or geographic areas 10 
§ Can evaluate trends over time 11 
§ Relatively easy and inexpensive 12 
Disadvantages of DDDs (Wertheimer 1986) 13 
§ DDD is a technical unit of comparison but not a recommended dose 14 
§ DDDs do not reflect actual prescribing patterns (Number of prescriptions of each 15 
dosage will vary) 16 
§ DDD varies with drugs that have >1 indication, various doses, are used in 17 
combination with other drugs, do not take into account compliance variation 18 
§ There is no designated DDD for children 19 
§ There is no designated DDD for topical preparations 20 
3.4.2 Discontinuation rates or substitutes for the concerned drug 21 
Discontinuation of a concerned drug following the warnings is often used as an outcome, 22 
especially when an alternative treatment has been suggested in the recommendation. 23 
Prevalence/incidence of discontinuation and the substituted drug are compared before and 24 
after the warnings. For example, a decline in the rate of co-prescribing contraindicated 25 
drugs with cisapride was observed after the warning (Smalley et al. 2000; Guo et al. 2003). 26 
Prevalence of switches from third to second generation oral contraceptives was higher 27 
after the warnings on deep vein thrombosis associated with third generation oral 28 
contraceptives (de Vries et al. 1998).  29 
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Discontinuation and switching data can be obtained from electronic medical records and 1 
large health-claims databases such as the UK health improvement network and Medicaid 2 
program in the USA.  3 
3.4.3 Diagnosis and clinical outcomes 4 
Some safety warnings encourage screening for complications associated with drug use, 5 
for example, an increased diagnosis of diabetes from blood glucose screening in patients 6 
initiating second-generation antipsychotic drugs (Morrato et al. 2010). Withdrawal of COX-7 
2 inhibitor were associated with a temporally decline of myocardial infarction admissions 8 
but reversed the previous decreases in gastrointestinal haemorrhage hospitalisations 9 
(Wheeler et al. 2009). More cases of thrombotic thrombocytopenic purpure were reported 10 
after the issue of a Dear Health Professional letter in Italy (Malgarini et al. 2000).  11 
Diagnosis data must be linked to prescribing records in order to investigate their 12 
relationship. Linked data are available in health claims databases, electronic medical 13 
databases, and medical records. Fully linked databases are difficult to obtain in a large 14 
population, especially in Australia.  15 
3.4.4 Other health care services 16 
Other healthcare services used as measurement outcomes of drug safety warnings are; 17 
numbers of practice visits, referral to specialists, and laboratory testing (Graham et al. 18 
2001).  19 
After the FDA’s recommendations on the close monitoring in patients who start 20 
antidepressants, the frequency of visits did not increase compared to before the warning 21 
(Morrato et al. 2008; Busch et al. 2010). A shift in care provided from primary care to 22 
psychiatrist was seen after the warning of antidepressant use (Valuck et al. 2009). The 23 
rate of liver function testing in troglitazone users and metabolic screening in patients who 24 
started antipsychotic drug was expected to increase following the safety warnings although 25 
compliance could not be achieved (Graham et al. 2001; Morrato et al. 2010). 26 
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3.5 Analytic methods 1 
After outcomes of interest are defined, the next step is a method for data analysis. Several 2 
analyses have been used to evaluate the impact of drug safety warnings. They can be 3 
divided into quantitative and qualitative approach.  4 
Quantitative approach 5 
A quantitative approach aims to quantify the trends or time course of drug use at different 6 
levels of heath settings: national, urban, rural, or institutional. Study designs may be 7 
prospective, such as randomised control trials (RCTs) or retrospective. A RCT assesses 8 
the impact of a safety warning on expected outcome as an intervention by comparing the 9 
assigned intervention arm to a control arm. Both arms are subjected to the same biases 10 
and allow us to investigate the causal effect of a safety warning (Piening et al. 2012). 11 
However, it is often not feasible due to several factors such as ethical issues, time 12 
constraints, and high cost (Majumdar et al. 2003). Retrospective studies use previously 13 
collected data from existing databases or medical records. A before and after comparison 14 
of data over the warning period is used to measure the impact of the safety warning.  15 
Two categories of available data that are divided by the collective methods are cross 16 
sectional data and continuous data. The cross sectional data only provides the prevalence 17 
of interested outcomes at one point (or more) in time either before or after a safety 18 
warning. The post-intervention prevalence may not have the comparative baseline (pre-19 
intervention period). Examples include information from surveys and prescribing audits. 20 
Continuous data are routinely collected for administrative purposes such as electronic 21 
medical databases and health or pharmacy claims databases. These data provide an 22 
advantage in detecting the underlying secular trends before the intervention period. 23 
Statistical analyses are chosen according to the availability of the data. Examples of 24 
designs used in previous studies are provided below (Lunde PKM 1987; Piening et al. 25 
2012). 26 
3.5.1 Interrupted time series designs 27 
The interrupted time series design is a powerful quasi-experimental approach to provide 28 
an estimate of the impact of safety warnings (intervention). Data are collected at multiple 29 
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time points before and after an intervention to detect whether the intervention has a 1 
significantly greater effect than any underlying secular trend. This design accounts for the 2 
long-term non-periodic variation of observation before the warning, which is expected to 3 
continue after the warning. It is considered to be the best available study design for 4 
evaluating the impact of a new regulatory warning, policy, or guideline (Wagner et al. 5 
2002; Piening et al. 2012). The intervention effect is estimated by comparing the trend 6 
after the intervention to the trend in pre-intervention period. There are a wide variety of 7 
techniques that can be used based upon the characteristics of the data, number of 8 
observations and the existence of autocorrelation. The most frequent analyses are the 9 
auto regressive moving average model and segmental time series regression.  10 
1) The auto regressive moving average model (ARIMA) 11 
The auto regressive moving average (ARIMA) model has been used to investigate the 12 
trend of time-series data and the impact of health care interventions on trends of drug use 13 
(Ferrand et al. 2011; Langley et al. 2011; Ruiter et al. 2012). The impact of the intervention 14 
on subsequent observations can be detected as permanent abrupt, permanent gradual, or 15 
abrupt temporary. The ARIMA model incorporates the past values and directions over a 16 
period of time to better describe the trend of data. Apart from detecting the secular trend, 17 
the ARIMA detects the higher degree of correlation such as seasonal trend. However 18 
confounding effects on data are assumed to be similar both before and after the 19 
intervention periods. The ARIMA (p,d,q) model is an applied time-series model developed 20 
by Box-Jenkins (Box 1976; Griffiths et al. 2000) to forecast future observations that occur 21 
at equal time intervals and determine the effect of an intervention in time series data. 22 
Firstly, the integration process is differenced (d) to make stationary data. The Dickey-Fuller 23 
test can also be used to confirm the stationary data (Dickey 1979). The autoregressive 24 
model of order p explains the accumulated effect of the preceding data and moving 25 
average model of order q indicates the most recent random shock carried over from one 26 
period to the next. The appropriate model (p, q) is obtained from the visibility to the plots of 27 
autocorrelation functions (ACF) and partial autocorrelation functions (PACF) of time-series 28 
values (McDowall 1980). The best fitted model for analysis is examined using the 29 
Bayesian Information Criteria (Schwarz 1978).  30 
The fact that the ARIMA model is not supported by any theoretical model or structural 31 
relationship raises questions on its reliability. It can be challenging to achieve a high level 32 
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of accuracy for a chosen model ARIMA (p,d,q) as it depends on selecting appropriate 1 
values for variables p, d and q. The results may vary from one researcher to another due 2 
to different levels of skill and experience of each researcher. However, other modeling 3 
approaches also share this type of criticism. The utilisation of the ARIMA model has been 4 
widespread since the method was incorporated into a number of commonly used statistical 5 
software such as STATA, SAS and R. The major advantage of the ARIMA method is that it 6 
is based on autocorrelation; thus, the data can be fitted into either a linear model, an 7 
exponential smoothing model or both (Griffiths et al. 2000).  8 
2) Segmented time series regression  9 
Segmented time series regression is used to estimate changes in the proportion of events 10 
by comparing post-intervention trends to pre-intervention trends (baseline slope) (Wagner 11 
et al. 2002). This analysis controls for the autocorrelation (first order correlation) or secular 12 
trend. Common segmented regression models estimate coefficients, which correspond to 13 
the trends of pre-implementation and post-implementation periods. Typically, at least 12 14 
data points before and after the intervention are recommended to evaluate seasonal 15 
variation. For example, a significant association between the FDA advisory and a change 16 
in the trend of patients seen by psychiatrist as a declining trend at 1.8% per year before 17 
the warnings is significantly different from a declining trend at 3.5% per year after the 18 
warnings using a t test analysis (Morrato et al. 2008; Dorsey et al. 2010; Wijlaars et al. 19 
2012).  20 
3.5.2 Poisson regression 21 
Poisson regression analysis is the association between count data/rate data and the 22 
intervention (exposure). Count data are the count of events occurring and rate data are the 23 
count of events occurring to a particular unit of observation, divided by the unit’s exposure. 24 
Examples are co-dispensing/co-prescribing rate occurring among cisapride users before 25 
and after the warnings (Guo et al. 2003). Poisson regression is used to determine the 26 
overall association between antidepressant prescription rates and suicide rates, adjusted 27 
for sex and age, during the periods preceding and immediately following the public health 28 
warnings (Wijlaars et al. 2012). 29 
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3.5.3 Logistic regression 1 
This analysis categorises the outcomes that occurred during the period before and after 2 
the warning as a binary response. Predicted outcomes during the post-warning period are 3 
compared with the baseline (pre-warning) using logistic regression. Logistic regression 4 
measures the relationship between outcomes and the period of warnings. For example, 5 
there was no increase in the recommended outpatient visits among children starting 6 
antidepressants following the warning (Guo et al. 2003; Busch et al. 2010). The use of 7 
droperidol for postoperative nausea and vomiting prophylaxis significantly decreased after 8 
the Black box warning (Wax et al. 2007). 9 
All analyses need to consider adjusting for other influences such as scientific reports, 10 
media coverage, and industry promotion. This can be multifaceted and difficult to achieve, 11 
therefore additional qualitative research can help to interpret quantitative data and explain 12 
the complex reality of a given situation.  13 
Qualitative approach 14 
Qualitative research generally provides an understanding of a problem or issue from the 15 
perspective of the particular population it involves. It is an effective way of obtaining 16 
information on the opinions, behaviours, and social contexts of target populations. 17 
Previous research evaluated the impact of drug safety warnings by assessing 18 
practitioners’ knowledge, attitudes, beliefs, or experiences regarding safety 19 
communications. The measurement outcomes are: the degree of awareness of the risk 20 
associated with medicine (or recent updated labelling) and awareness of the specific 21 
recommendation; the agreement and satisfaction with the content provided in 22 
communication messages; and the impact of warnings on alterations to clinical practice. 23 
Studies in clinicians suggested high levels of awareness for a Black box warning on 24 
antidepressants but low levels of awareness of the recommended strategies (Richardson 25 
et al. 2007; Bhatia et al. 2008). An online survey reported that specialists had higher 26 
awareness regarding the Black box warning on long-acting beta-agonists (LABAs) 27 
compared to primary care physicians; however, a smaller proportion of specialists agreed 28 
with the warning (Karpel et al. 2009). About half of survey participants considered 29 
changing their practice after the FDA alert regarding suicidality and antiepileptic drugs 30 
(Shneker et al. 2009).  31 
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To date, there have been little or no studies on the impact of the safety warnings among 1 
Australian prescribers therefore qualitative research will help to provide a more in-depth 2 
understanding of prescribing behaviour and the structure of the drug warning system used 3 
by practitioners. Several methods of obtaining data are available for different types of 4 
questions . 5 
3.5.4 Questionnaire and Survey Methods 6 
Questionnaires or a survey-based design is the most common method for qualitative 7 
studies assessing prescribers’ knowledge, attitudes and beliefs regarding safety warnings 8 
(Feldman et al. 2011). Selected populations are primarily general practitioners or primary 9 
care physicians and the main prescribers of drugs. The selected population in previous 10 
studies are often convenience samples such as attendees of the conference or members 11 
of a medical association (Paschall et al. 2008; Phipps et al. 2011).  12 
In person, mail or telephone surveys are the best form when high response rates are 13 
needed; however, they are more time consuming, higher cost, and more difficult to code 14 
data (Bonevski et al. 2011). Web-based surveys are versatile and widely dispersed in 15 
social settings. Participants are autonomous on a web-based survey therefore it allows 16 
researchers to control for bias both from investigators and responders (Wright 2005). This 17 
type of survey is suitable when there is a limited budget and/or time; however, low 18 
response rates are the main concern. The increasing challenge of survey-based studies is 19 
the low response rate especially in general practitioners, which have been as low as 5% in 20 
previous papers (Karpel et al. 2009). Non-responders may cause selection bias (or 21 
socially-desirable response bias) and have an effect on generalisability and potential 22 
validity of the findings (Paschall et al. 2008). Systemic reviews of strategies to improve 23 
survey responses suggested that incentives, shorter questionnaires, pre-notification, 24 
follow-up contact with a copy of questionnaires could increase survey response rates 25 
(Edwards et al. 2009).  26 
Combined qualitative and quantitative analysis was used to interpret the results from the 27 
survey study. The comments and free text answers were collected for further interpretation 28 
and discussion while the responses were collected in the form of categorical variables. 29 
These results were presented as numbers and percentages among responders and were 30 
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quantitatively analysed using statistical tests. Pearson chi-square and Fisher exact tests 1 
are often used to evaluate the relationships between variables (Lydersen et al. 2003).  2 
3.5.5 Interviews 3 
Interviews either face-to-face or by telephone are optimal for collecting data on individuals’ 4 
status, experience and perspectives. It can achieve higher response rates compared to 5 
other designs (Bowling 2005). However, interviews involve social interactions that may 6 
result in decreased confidentiality and anonymity in answering, especially when sensitive 7 
issue are being assessed (Bowling 2005). Interviews are a more appropriate forum for 8 
open-ended questions to gauge the idea of participants of that topic and invite more in-9 
depth opinions. Interview data can be a useful mechanism for developing closed questions 10 
for a survey of the larger participants (Fowler et al. 2002). 11 
3.5.6 Focus groups 12 
Focus groups are efficient in generating broad overviews of issues among groups 13 
represented. Participants are free to discuss their opinions, attitudes towards the topic of 14 
interest and can often bounce ideas and opinions off each other. Focus groups can create 15 
the external validity when using participants from similar backgrounds or with shared 16 
interests. However, focus groups do have disadvantages, they can evoke social 17 
desirability bias and are often difficult to organise/coordinate with multiple participants. 18 
Often a few people can dominate the discussion leading to limited exploration of 19 
everyone’s viewpoints. Only a few focus groups have been used to examine the effect of 20 
drug warnings, one of those was to assess the influence of a Black box warning on the 21 
changes in providers’ practice on adolescent depression (Richardson et al. 2007). 22 
4. Australian healthcare system 23 
The healthcare system in Australia is primarily provided and funded by the Federal 24 
Government, Department of Health; however elements of system such as public hospitals 25 
are operated by State Governments. The National health policy aims to provide all 26 
Australians with accessible and affordable health care, additionally, all individuals have a 27 
choice of private health insurance (e.g. Life Health Cover, Medicare Levy Surcharge). 28 
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Medicare and the Pharmaceutical Benefits Scheme (PBS) are the two main healthcare 1 
funding systems operated by the Australian Government (Medicare). 2 
4.1 Medicare 3 
Medicare is a universal public health insurance scheme instituted in 1984 to provide free 4 
or subsidised health care treatment under the Medical Benefits Scheme (MBS). Medicare 5 
covers 100% of treatment and accommodation costs if you are a public patient in a public 6 
hospital. For medical services outside the hospital, 100% of MBS fee for a general 7 
practitioner, 85% for the specialist, optometrists, and dentists (in specific circumstances) 8 
can be reimbursed although these reimbursements are capped and therefore patient co-9 
payments vary at the discretion of the provider (Medicare).  10 
4.2 Pharmaceutical Benefits Scheme 11 
The Pharmaceutical Benefits Scheme (PBS) is the national formulary that provides 12 
affordable access to necessary medicines covering most medical conditions. Most of 13 
medicines listed on the PBS are prescribed by community medical practitioners and 14 
dispensed by community pharmacists. The government reimburses products listed on the 15 
PBS for all Australian citizens by paying a portion of the cost of medicines. The cost of the 16 
full scheme is financed from consolidated revenue, which is from the taxpayer (PBS 2012). 17 
In order to be available on the PBS, a medicine must be approved for sale in Australia by 18 
the TGA based on medicine’s safety, efficacy, and manufacturing quality. Then most 19 
pharmaceutical suppliers products will apply for a PBS listing for their product. The 20 
Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert committee, 21 
evaluates medicines using a cost-effectiveness analysis to determine whether its benefit is 22 
better or comparable to the available subsidised medicines at an acceptable price. If it is 23 
deemed acceptable the PBAC will recommend the subsidised conditions and price listing 24 
to the Government for funding on the PBS (Figure 1). PBS listing conditions correspond to 25 
clinical indications approved by the TGA when products are registered for marketing (PBS 26 
2012).  27 
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 1 
Figure 1. Processes of drug approval and the PBS subsidised listing 2 
Drugs listed on the PBS are categorised into three levels of restriction (PBS): 3 
§ Unrestricted benefits—The drug has no restrictions on its therapeutic uses. It may 4 
be used for whichever therapeutic condition that is considered appropriated by 5 
prescribers 6 
§ Restricted benefits—The drug is only subsidised for specific therapeutic conditions 7 
listed 8 
§ Authority required benefits—The drug is subsidised if prescribing reasons comply 9 
with the listed restrictions according to the efficacy, safety, and economic analyses. 10 
Authority required benefits are divided into two categories: 11 
• ‘Authority required’—The dispensing needs a telephone or written approval 12 
from the Department of Human Services or Department of Veterans’ Affairs. 13 
• ‘Authority required (STREAMLINED)’—Items do not require approval. 14 
Instead, a four digit streamlined authority code has to be included on the 15 
prescription according to the PBS restriction criteria. 16 
New drug 
Pre-marketing assessment 
quality, safety and efficacy  
TGA 
Market approval 
with clinical indications 
Product information 
Process application for PBS listing 
      Recommendation from PBAC 
            - Price listing 
            - Condition listing 
Product appears on the PBS Schedule 
Minister (or Cabinet) 
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Usually, new-entry medicines are listed as Authority Required Benefits due to the limited 1 
experience with the drug. The PBS listings may be reclassified depending on extended 2 
evidence of benefits and risks. This process closely reflects the updated data from the 3 
TGA and the product information (PBS). 4 
All Australian residents and those who qualify for a Medicare card are eligible for PBS 5 
subsidised medicines. There are two types of PBS beneficiaries: general and concession. 6 
Concession beneficiaries are Australian social security recipients and most aged 7 
pensioners (aged above 65 years) and the remainder are general beneficiaries (Centrelink 8 
2014). Patient contributions for the PBS are updated annually. When dispensed a 9 
medicine, patients pay the lowest value of either; the total cost of the medicine or a fixed 10 
co-payment. As of 1 January 2014, general beneficiaries contributed a co-payment of up 11 
to AU$36.90 for each dispensing with the general safety net threshold (maximum co-12 
payment) of AU$1421.20 per year, when they then pay concession beneficiary co-13 
payment amounts) compared to a considerably lower AUD$6.00 (maximum AU$360) for 14 
concession beneficiaries. The Government absorbs the remaining drug costs (PBS 2014). 15 
Besides the PBS, the Repatriation Pharmaceutical Benefits Scheme (RPBS) is a separate 16 
scheme administered and subsidised by the Department of Veteran’s Affairs (DVA). The 17 
RPBS provides pharmaceutical supplies for veterans and their dependants at a 18 
concessional rate. Those who are eligible for a DVA card can be reimbursed for all 19 
medicines listed on both the PBS and RPBS (DVA).  20 
5. Available sources of data in Australia 21 
5.1 PBS database 22 
The PBS database is a national administrative database that records reimbursed 23 
medicines by the Australian Government. Products subsidised by the PBS are assigned 24 
PBS codes, which are specific for each formulation. The PBS codes indicate; chemical 25 
name, strength, maximum quantities (e.g. tablets), maximum numbers of repeats, and 26 
dispensed price. These data are regularly updated in the Schedule of Pharmaceutical 27 
Benefits (PBS 2014).  28 
Available data on the PBS database are; amount of dispensing, cost of dispensing, and 29 
period of drug dispensed. All dispensings are recorded as aggregated, de-identified data 30 
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using the PBS codes (Medicare). Drug dispensing data on the PBS database are publicly 1 
available (Medicare) and are frequently used in research studies to investigate the 2 
utilisation trends in Australia such as antidepressants and antisecretory drugs 3 
(Hollingworth et al. 2010; Islam et al. 2014).  4 
Only subsidised drugs that cost more than the co-payment of each beneficiary are 5 
available in the database. At the time of writing the dispensing costs of all drugs listed on 6 
the PBS are higher than $6 in 2014 therefore all dispensings for concession beneficiaries 7 
are captured in the database. If the dispensing cost is under the general co-payment for 8 
example, pantoprazole, which cost $18.40 in 2014, then there is no record of any 9 
dispensings to general beneficiaries. Whereas ‘expensive’ medicines such as 10 
esomeprazole, which cost $38.32 in 2014, all dispensings will be recorded for both 11 
concession and general beneficiaries (PBS 2014). 12 
Similar to other pharmacy claims databases, the PBS was designed for pharmacy 13 
reimbursements. It does not link to clinical data at a patient level to provide information 14 
such as; patient characteristics, reason for dispensing, and other co-prescribed medicines. 15 
The dispensing data may not represent the actual prescribing trend in clinical practice 16 
because patients may choose not to fill the prescription (primary non-compliance) 17 
(Beardon et al. 1993; Shrank et al. 2010). Another limitation is that the dispensing data do 18 
not guarantee the actual consumption by patients (secondary non-compliance) (Roughead 19 
et al. 2007). 20 
5.2 AsteRx database 21 
The AsteRx database has collected clinical data from more than one hundred medical 22 
practices in all states of Australia since 2003. As of May 2012, demographic data of over 23 
half a million patients and 1,121 doctors were recorded as de-identified information. There 24 
are a total of seven million prescriptions including details on prescribing date, chemical 25 
name, strength, quantity, and drug codes (WHO Anatomical Therapeutic Chemical 26 
Classification (ATC) system codes and PBS codes). Other information such as diagnoses, 27 
consultations, and laboratory results are recorded in free text (Gilard et al. 2008). 28 
There are a total of 13 files in the AsteRx database. 29 
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§ The “Consult” file includes three variables: the “consultID”—a unique identification 1 
number of consultation, “consultDate”—date of consultation and 2 
“consultreasonDetail”—a free text of the details on the “consultID”. 3 
§ The “Diagnosis” file includes the “diagnosisID”, “diagnosisdate” and “diagnosis”—a 4 
free text. 5 
§ The “DoctorCD” file indicates the details of doctors in the AsteRx. This file 6 
composes of “DoctorID”, “state”—practicing state, “gender”, “YearofGrad”—year of 7 
graduation and “Qualifications”. 8 
§ The “Practice” file includes the details of practice sites: “PracticeID”, number of 9 
doctors, postal code and state. 10 
§ The “ReferralsCDM” file records the information on the category of referral doctors 11 
such as general practitioners and specialist type. 12 
§ The “ServiceRequestCDM” file records any service the practice site gave to the 13 
patients in free text. 14 
§ The “ScriptCDM” file indicates the details on the prescription. It composes of 15 
“ScriptID”—a unique identification number of the prescription”, “DoctorID”, 16 
“Scriptdate”—date of prescription, “Drugname”—generic or trade name of the drug, 17 
strength, dose, frequency, instructions, quantity, repeats, “scriptreason”—reason of 18 
this prescription, “pbstype”—PBS subscription according to the PBS website, 19 
“atccode”—Anatomical Therapeutic Chemical (ATC) code as recommended by the 20 
World Health Organization (WHO), “DrugID”—a unique identification number of the 21 
drug that links to the AsteRx drug reference, and “pbscode”—an identification 22 
number of the formulation as listed on the PBS website. 23 
§ The “ScriptRxCDM” file includes “reasonDeletion”—the reasons of a cessation of 24 
drug and “ceasedDate”—date of drug deletion/drug cessation. 25 
§ The “ImmunisationCDM” file indicates the details of immunisation of the patients. 26 
§ The “MeasureCDM” file includes other measurements that were recorded in the 27 
AsteRx. 28 
§ The “Pathology” file records the details of pathology sites, doctor who sent the 29 
tissue and date of sent tissue in free text.  30 
§ The “PathologyAtom” file indicates the pathology result. 31 
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§ The “Patient” file includes “PatientID”—a unique identification number of patient, 1 
gender, “yearofbirth”—year of birth, “monthofbirth”—month of birth, “pensionstatus” 2 
—status of patients’ pension and “Smoker”—smoking status of the patient (ex-3 
smoking or non-smoking) and number of years of smoking. 4 
The AsteRx clinical database provides prescribing data which links to patients’ 5 
demographics, prescribers’ characteristic, clinical diagnoses, and other co-prescribed 6 
medicines. These data can be used to investigate the prescribing or co-prescribing trends, 7 
more specific details on switching choices and other clinical factors associated with 8 
prescribing decisions (AsteRx 2012). 9 
5.3 DVA database 10 
The Australian Government Department of Veterans’ Affairs (DVA) administrative health 11 
claims database collects health services that are provided for all veterans and their eligible 12 
dependants (e.g. spouses, widows or widowers, and children) (DVA). The DVA database 13 
is assessed for research conducted by the University of South Australia and their 14 
collaborators (Wahab et al. 2014).  15 
According to statistics in 2011, the database contains an estimated eighty million 16 
pharmacy records, two hundred million medical service records, and six million hospital 17 
admissions for three hundred thousand patients. Data include patient characteristics such 18 
as age, sex, date of birth, date of death and residential status. DVA populations are 60% 19 
male and predominately elderly aged between 80 and 85 years. Medical consultations, 20 
pathology, hospital admissions, and diagnoses associated with the hospitalisation 21 
subsidised by DVA are also available. Hospitalisations are recorded using the WHO 22 
international Classification of disease, 10th revision (ICD-10). Prescriptions dispensed and 23 
subsidised by the PBS and RPBS for the DVA clients are recorded on the pharmacy 24 
claims information using WHO Anatomical Therapeutic Chemical (ATC) classification 25 
codes (DVA 2011; Pratt et al. 2013).  26 
Apart from veterans’ health studies, research conducted using DVA data include medical 27 
problems, medicines use in geriatrics and other pharmacoepidemiology studies (Pratt et 28 
al. 2013).  29 
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5.4 BEACH program 1 
The Bettering the Evaluation and Care of Health (BEACH) program is a general practice 2 
activity database that has been collected since 1998. It aims to provide accurate and 3 
timely data to various users including government, pharmaceutical industry, external 4 
organisation, and researchers for investigating GP/patient encounter information.  5 
A cross-sectional, paper based data collection system developed and validated by the 6 
University of Sydney is used to compile the data. The collection process is performed by 7 
randomly sampling one thousand general practitioners (GPs) annually across Australia 8 
and then recording one hundred consecutive consultations from each GP. As of July 2012, 9 
there were approximately 1,400,000 GP-patient encounter records in the BEACH 10 
database (BEACH 2012).  11 
The BEACH database contains the interrelationships of data variables including:  12 
§ Encounter characteristics 13 
§ Characteristics of GPs (e.g. age, gender, years in practice, size of practices, 14 
computer use, location of practice) 15 
§ Characteristics of patients seen by GPs (e.g. age, gender, healthcare coverage, 16 
status to the practice (new/seen)) 17 
§ Up to three visiting reasons 18 
§ Up to four problems managed at the consultation 19 
§ Treatment provided for each problem managed 20 
§ Drugs prescribed, drug supplied by the GP, dosage regimen, over the counter drug 21 
advised, clinical procedures 22 
§ Referrals to specialists and allied health services 23 
§ Test orders including pathology and radiology 24 
Other supplementary data is often nominated for collection by BEACH stakeholders e.g. 25 
smoking status, alcohol consumption, and body mass index. External organisations can 26 
also specify topics for data collection and data analysis (BEACH 2012).  27 
The BEACH collects data from random sample all over Australia, thus it provides general 28 
information on the prevalence of diseases and the clinical activities taking place in 29 
Australian general practice. Examples of studies utilising these data are common sexual 30 
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transmitted infections and their management (Johnston et al. 2004), musculoskeletal 1 
problems seen in adolescents seen by GPs (Henschke et al. 2014), and presentations that 2 
led to long consultations in children (Cooke et al. 2013; Freed et al. 2013). Other kinds of 3 
research that use the BEACH database are reliability and validity of GP records and 4 
development of tools for improving management.  5 
Since the information captured on the BEACH database is cross-sectional data, it can not 6 
be used to examine the trend or the changes over time. Not all prescribing drugs are 7 
recorded for each visit therefore a complete pattern of medicine use cannot be assessed.  8 
6. Chapter conclusion 9 
Given the public attention to the TGA’s safety communication and the necessary of drug 10 
safety warnings, this research aims to gain the comprehensive impacts of current drug 11 
safety warnings on clinical practice in Australia. Both quantitative and qualitative studies 12 
were conducted using recent drug safety warnings as case studies.  13 
Quantitative studies presented the impact size and direction of each drug safety warning 14 
on patterns of actual drug use using an interrupted time series analysis. Rates of events 15 
(e.g. switch and stop) before and after the warnings are also assessed using regression 16 
models (Piening et al. 2012). Currently, available databases for the patterns of drug use in 17 
Australia are the PBS database and AsteRx database. The publically available online PBS 18 
data records all prescriptions dispensed to Australian residents therefore the patterns of 19 
national drug consumption can be calculated using DDD/inhabitant/day during the period 20 
of interest. This data source lacks information on individual-linked drug use and diagnosis-21 
linked data that are captured in the clinical database, AsteRx. The AsteRx database can 22 
be used to examine concomitant drugs in individual patients, incidence/prevalence of 23 
events, duration of treatment, prescribers, and prescribing correlation. The AsteRx 24 
database is currently accessible for research conducted in the School of Pharmacy, the 25 
University of Queensland. 26 
A qualitative study assessed prescribers’ perspective on the overall drug warning system 27 
and towards recent drug safety warnings. Findings from a combined interview and survey 28 
study among Australian prescribers has been used to improve the understanding of the 29 
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impacts of drug safety warnings on prescribing decisions and better explain the changes in 1 
the quantitative studies. 2 
The next chapter will describe the recent drug safety warnings that may have significant 3 
impacts on the trends of drug use in Australia. 4 
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Chapter 2. Recent drug safety warnings 
Overview 
Diabetes mellitus and cardiovascular disease are two high-burden diseases in developed 
countries (Squires 2011). Prevalence of diabetes has increased in Australia from 2.4% in 
1995 to 4.2% in 2011. The data from the Australian Health Survey showed that 
approximately 1 million Australians had diabetes in 2011–2012 and 84.9% of those had 
type 2 diabetes (ABS 2012). Good glycemic control can prevent chronic complications of 
diabetes such as nephropathy, retinopathy, peripheral vascular disease, and 
cardiovascular/cerebrovascular diseases, which contribute greatly to the burden of disease 
and health care expenditure (UKPDS 1998; Bach et al. 2014). Cardiovascular disease is 
the primary cause of death in patients with type 2 diabetes as well as the leading cause of 
death among Australians since 2000 (Statistics 2012).  
Significant resources have been invested to develop new drugs for better controlling and 
preventing complications of diabetes and cardiovascular disease; however new treatments 
may come with unpredictable complications. 
Case study 1. Thiazolidinediones 
In the US, the number of patients treated with antidiabetic drugs increased by 42.9% from 
2003–2012 with much of this growth consisting of prescriptions for thiazolidinediones 
(rosiglitazone and pioglitazone) and dipeptidyl peptidase 4 inhibitors (DPP-4) (Hampp et 
al. 2014). Other antidiabetic treatments such as sulfonylureas, metformin, alpha 
glucosidase inhibitors and insulin have been extensively used with acceptable safety.  
During the expanding use of thiazolidinediones, a meta-analysis from Nissen et al. 
suggested an increased risk of myocardial infarction (MI) related to rosiglitazone treatment 
in May 2007 (Nissen et al. 2007). Pioglitazone, on the other hand, showed no evidence of 
an increase in ischemic heart events and seemed to be a better alternative to rosiglitazone 
(Lincoff et al. 2007). However, in 2011 the long-term use of pioglitazone was found to be 
associated with an increased risk of bladder cancer (Lewis et al. 2011). Regulatory bodies 
from around the world have announced a series of safety warnings related to the use of 
thiazolidinediones.  
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Case study 2. Clopidogrel and proton pump inhibitor interaction 
Since the availability of clopidogrel in 1997, this effective antiplatelet agent became the 
fastest growing pharmaceutical product across the globe (Committee 1996; ims 2011). A 
combination of clopidogrel and aspirin or ‘dual antiplatelet therapy’ is well recognised as 
the standard treatment and prevention for acute coronary syndrome. However, an 
increased risk of gastrointestinal bleeding, especially in patients with a history of 
gastrointestinal conditions and the elderly, is associated with this dual antiplatelet therapy 
(Yusuf et al. 2001; Steinhubl et al. 2002; Ng et al. 2008). Antisecretory agents such as 
proton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are usually 
coprescribed with antiplatelet agents to prevent these gastrointestinal complications 
(Kushner et al. 2009). For the last decade, clopidogrel (Plavix®) and proton pump 
inhibitors, particularly esomeprazole (Nexium®) were in the top five pharmaceutical product 
sales and highest expenditure worldwide (Chevarley 2010; ims 2011).  
In 2006, in vitro studies indicated a decrease in platelet inhibitory effect of clopidogrel 
related to PPI treatment (Gilard et al. 2006). Literature had been extensively published on 
the pharmacodynamic evidence of this interaction but clinical studies could not provide 
consistent outcomes (Kwok et al. 2013). The key international regulators issued several 
warnings on the drug interaction between clopidogrel and PPIs. However, the contents in 
the warnings have been modified over time with conflicting messages across nations.  
Studies in the US and Europe have investigated the impact of their regulatory warnings on 
the use of thiazolidinediones and the coprescribing of proton pump inhibitors with 
clopidogrel but the patterns of use in Australian were unknown. Chapter 3–6 will present 
studies conducted using Australian data, this chapter will provide background information 
on the details of the medicines involved and their safety warnings. 
1. Thiazolidinediones 
Thiazolidinediones (TZDs) were approved based on their efficacy in decreasing HbA1c in 
patients with type 2 diabetes without long-term data on safety and clinical outcomes 
(Aronoff et al. 2000; Phillips et al. 2001). Troglitazone (Rezulin®) was the first TZD 
approved by the FDA in 1997; however, shortly after its launch into the market severe 
hepatotoxicity effects were reported (Gitlin et al. 1998; FDA 2000). Regulatory warnings 
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were issued on this side effect including liver function monitoring, subsequently, 
troglitazone was withdrawn from the market in March 2000 (FDA 2000). In 1999, the FDA 
approved rosiglitazone (Avandia®) and pioglitazone (Actos®), which did not share 
troglitazone’s risk of hepatotoxicity (FDA 1999; FDA 2000). TZDs were considered as a 
third-line choice for type 2 diabetes treatment when metformin or a sulfonylurea were 
contraindicated or intolerable (NICE 2003). Although, pioglitazone and rosiglitazone 
showed similar glycaemic effects in their suggested therapeutic doses, pioglitazone was 
associated with better improvements in lipid profiles compared to rosiglitazone (Diamant et 
al. 2003; Goldberg et al. 2005). 
Mechanism of action 
Thiazolidinediones (TZDs) have a different mechanism of action to pre-existing 
antidiabetic agents. They improve insulin sensitivity by acting as modifiers of peroxisome 
proliferator-activated receptor gamma (PPAR–γ) or PPAR–γ agonists, regulating selective 
ligands of the nuclear transcription factor. PPAR receptors are found at the key sites of 
insulin resistance tissues including adipose tissue, skeletal muscle, and liver (Spiegelman 
1998; Olefsky 2000).  
Activation of the PPAR–γ responsive gene improves the regulation of glucose production, 
transport, and utilisation as well as the regulation of fatty acid metabolism. They promote 
endogenous and exogenous insulin sensitivity in muscle, fat, and liver. In in-vitro studies, 
pioglitazone acts like a partial PPAR-α agonist, while rosiglitazone has a pure PPAR–γ 
agonist effect (Yki-Jarvinen 2004).  
Glycaemic control 
The effect of TZDs on blood sugar control is progressive, and typically results in a decline 
of HbA1c in the region of 0.5–1.5% over one to three months. Rosiglitazone and 
pioglitazone have been used as an oral monotherapy or in combination with metformin, 
sulfonylureas, or insulin, which lead to further decreases in the level of HbA1c.  
Adverse effects  
The main side effects of TZDs are weight gain, fluid retention, oedema, and dilutional 
anaemia, which result from the PPAR–γ activities on various tissues. Weight gain after six 
months of treatment may be due to increased peripheral fat mass and fluid retention. The 
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fluid retention and oedema may cause by increased endothelial cell permeability as well as 
a renal effect of PPAR–γ. Because of fluid accumulation, the TZDs treatment is 
significantly associated with an exacerbation of congestive heart failure (Benbow et al. 
2001). Therefore congestive heart failure is a contraindication of TZDs. In 2002, TZDs 
were not recommended in patients with New York Heart Association (NYHA) functional 
classification stages III and IV (Nesto et al. 2003).  
Macular oedema has been associated with TZDs and typically resolves rapidly after drug 
cessation (Ryan et al. 2006; Liazos et al. 2008). TZDs also appear to be associated with a 
higher risk of peripheral fracture in women and bone loss in elderly women (Kahn et al. 
2006; Schwartz et al. 2006; Grey et al. 2007). 
1.1 Rosiglitazone 
1.1.1 Availability of rosiglitazone in Australia 
Rosiglitazone (Avandia®) was approved by the TGA in 2000 for type 2 diabetes treatment 
in patients with inadequate glycaemic control through lifestyle measures, sulfonylureas or 
metformin. It was first listed on the PBS in November 2003 and subsidised as a dual oral 
therapy with either metformin or a sulfonylurea. Patients must have a contraindication or 
intolerance to either metformin or a sulfonylurea and inadequate control of blood glucose 
(HbA1c>7% with metformin or sulfonylureas) to qualify for PBS subsidised treatment. 
Rosiglitazone’s PBS listing extended to triple therapy with metformin and a sulfonylurea in 
April 2005 and for use in combination with insulin in August 2005. Fixed dose combination 
tablets of rosiglitazone with metformin were listed on the PBS in July 2006 (PBS 2006; 
PBS 2008).  
In late 2008, the PBS revoked the subsidised conditions of rosiglitazone for the triple oral 
therapy and the use in combination with insulin (PBS 2008). Subsequently in March 2011, 
the PBS changed the restriction criteria for rosiglitazone from Authority Required 
(STEAMLINE) to Authority Required for dual oral therapy, which requires telephone 
approval prior to the dispensing of rosiglitazone.  
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1.1.2 Rosiglitazone and cardiovascular events 
On 21 May 2007, a meta-analysis was published concerning a significantly elevated risk of 
MI and cardiovascular mortality related to rosiglitazone therapy (Nissen et al. 2007). Two 
further meta-analyses were published in 2007: one observed an increased risk of 
cardiovascular events with rosiglitazone, and one was inconclusive (Diamond et al. 2007; 
Singh et al. 2007).  
An interim analyses of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation 
of Glycaemia in Diabetes (RECORD) trial, prospectively designed to evaluate the risk of 
cardiovascular outcomes between rosiglitazone in combination with metformin or 
sulphonylurea and dual therapy of metformin and sulphonylurea, had inconclusive findings 
with regards to cardiovascular events and rosiglitazone (Home et al. 2007). 
A FDA briefing document published their evaluation of three meta-analyses on myocardial 
ischemic events related to rosiglitazone, which concluded that there was an increased risk 
of MI and mortality associated with rosiglitazone use, particularly in patients exposed to 
long term nitrate treatment and insulin (FDA 2007). 
A retrospective evaluation from GSK, the manufacturer of rosiglitazone, on cardiovascular 
events of short-term, double blind, randomised studies of rosiglitazone found an increased 
incidence of congestive heart failure in patients prescribed rosiglitazone with sulfonylureas 
or insulin. This evaluation also observed greater events of myocardial ischemia in 
rosiglitazone treatment compared to placebo or other diabetes drugs (Cobitz et al. 2008). 
The RECORD study could not confirm the risk of myocardial infarction and overall 
cardiovascular morbidity or mortality of rosiglitazone; however, most of the studied patients 
had an incomplete follow-up status for the primary endpoint—first cardiovascular 
hospitalisation or cardiovascular death (Home et al. 2009). 
On 28 June 2010, an updated meta-analysis from Nissen et al. and a retrospective 
observational study by Graham et al. were published which again raised the 
cardiovascular concerns of rosiglitazone (Graham et al. 2010; Nissen et al. 2010).  
1.1.3 Safety warnings on cardiovascular events 
U.S. Food and Drug Administration  
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The FDA issued an alert on the potential increased risk of myocardial ischemia on the 
same date as Nissen’s publication (21 May 2007) (FDA 2007). On 30 July 2007, the joint 
committee of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug 
Safety and Risk Management Advisory Committee of the FDA assembled to discuss the 
cardiovascular risk of rosiglitazone. The FDA concluded that there was an increased risk 
of congestive heart failure and MI using three meta-analyses. Analysis of these results 
suggested that rosiglitazone users with long-term nitrate treatment and concomitant insulin 
therapy were at higher risk of myocardial infarction and cardiovascular mortality (Rosen 
2007). On 14 August 2007, the FDA issued a Black box warning to emphasise the 
exacerbation of heart failure related to rosiglitazone treatment (FDA 2007). In November 
2007, the precautions section for concomitant use of nitrate or insulin on the rosiglitazone 
label was updated. 
In September 2010, the joint committee evaluated the recently updated data available on 
the cardiovascular risk of rosiglitazone and voted to allow rosiglitazone to stay on the 
market while the EMA suspended rosiglitazone throughout Europe. The restriction 
program took full effect in November 2011. The FDA requested GSK to convene an 
independent expert panel to re-investigate the RECORD study and evaluate the integrity 
of the study findings. In June 2013, the re-adjudicated results of RECORD were 
unchanged from the findings in 2008 and the FDA joint committee reassured the accuracy 
of these results. Following the discussion and recommendations from the joint committee, 
the FDA eased the restrictions of rosiglitazone in the USA (FDA 2013). 
European Medicines Agency  
A few days after the publication by Nissen et al. and the warning by the FDA, the 
European Medicines Agency (EMA) announced a press release on the cardiac safety of 
rosiglitazone (EMA 2007). The updated product information and warning stated that 
rosiglitazone may be associated with an increased risk of ischemic events and should not 
be used in patients with myocardial ischemic symptoms. Another press release was issued 
to confirm the positive benefit-risk balance for rosiglitazone and pioglitazone in treatment 
of type 2 diabetes on 18 October 2007 (EMA 2007). During 2007–2008 the EMA re-
evaluated the benefits and risks of rosiglitazone using the data up to July 2008 and 
decided that the evidence regarding the link between rosiglitazone and ischemic heart 
disease was inconclusive.  
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In January 2008, a press release was issued by the EMA to recommend new warnings 
and contraindications for rosiglitazone in patients with ischemic heart disease and/or 
peripheral arterial disease (EMA 2008). On 9 July 2010, the EMA Diabetes/Endocrinology 
Scientific Advisory group (SAG) started to assess the updated available data and analysed 
the usage of rosiglitazone in the THIN database. The EMA concluded that the risk of 
rosiglitazone outweighed its benefits and recommended the suspension of all rosiglitazone 
containing products on 23 September 2010 (EMA 2010). 
Therapeutic Goods Administration 
The Therapeutic Goods Administration (TGA) approved the change on the product 
information that rosiglitazone should not be added to therapy in patients receiving insulin 
on 17 August 2007. The TGA considered the available data of three meta-analyses from 
Nissen et al., the FDA and the manufacturer as well as an interim analysis of the ongoing 
RECORD study when actioning the changed PI and Alerts. In December 2007, the TGA 
requested a box warning: "The use of AVANDIA/AVANDAMET is not recommended in 
patients with known ischaemic heart disease, particularly in those taking nitrates. 
AVANDIA/AVANDAMET has been shown to be associated with an increased risk of 
myocardial ischaemia (angina, infarction) in pooled short-term clinical studies, particularly 
in those who needed several antidiabetic drugs or nitrates. See Precautions" (TGA 2007). 
On 24 September 2010, the TGA published an advisory statement to reinforce the Box 
Warning (TGA 2010). 
1.2 Pioglitazone 
Pioglitazone seems to have a favourable effect on cardiovascular events. A PROspective 
pioglitAzone Clinical Trial In macroVascular Events (PROactive) randomised controlled 
trial focused on vascular outcomes of pioglitazone found a reduction in the composite of 
all-cause mortality, non-fatal MI, and stroke in patients with high risk of macrovascular 
events (Dormandy et al. 2005). A meta-analysis pooled individual patient data from 
pioglitazone clinical trials and found a reduction in composite outcomes of all-cause 
mortality, myocardial infarction and stroke (Lincoff et al. 2007). 
Chapter 2 
 49 
1.2.1 Availability of pioglitazone in Australia 
The TGA approved pioglitazone for use as a monotherapy and in combination with 
sulfonylureas, metformin or insulin on 6 February 2001. Pioglitazone was listed on the 
PBS in November 2003 with the same criteria as rosiglitazone, dual oral therapy with 
metformin or a sulfonylurea. Additionally, the pioglitazone listing was wider than 
rosiglitazone in 2004 allowing an initiation in combination with insulin in patients with 
inadequate control of blood glucose, despite concomitant use of insulin and oral 
hypoglycemic drugs. In November 2007, the PBS listing of pioglitazone was extended to 
triple therapy with metformin and a sulfonylurea under Authority Required 
(STREAMLINED) (PBS 2007). 
1.2.2 Pioglitazone and bladder cancer 
A small increase in the number of bladder cancer cases in patients taking pioglitazone 
compared to control was observed in the PROactive meta-analysis (0.15% compared to 
0.07% respectively), but it was concluded that these cases were unlikely related to drug 
(Dormandy et al. 2005). In March 2011, a French study reported a significantly increased 
risk of bladder cancer in patients exposed to pioglitazone compared to other antidiabetic 
medicines with higher risk in those exposed for more than twelve months, subsequently 
this study was published in June 2011 (Maladie 2011). Another retrospective cohort study 
showed a significant risk of developing bladder cancer among patients who took 
pioglitazone for more than two years (Lewis et al. 2011).  
1.2.3 Safety warnings on bladder cancer 
The EMA started a review on the risk of bladder cancer related to pioglitazone in March 
2011. On 9 June 2011, the French regulatory authority decided to suspend pioglitazone-
containing products in France (EMA 2011). On 21 July 2011, the EMA issued a warning 
for pioglitazone on the small increased risk of bladder cancer. EMA recommended that 
pioglitazone should not be used in patients with history of bladder cancer or with 
uninvestigated macroscopic haematuria (EMA 2011). 
The FDA also requested a retrospective cohort study among pioglitazone users in March 
2011 (Lewis et al. 2011). On 15 June 2011, the FDA announced that using pioglitazone for 
more than one year might be associated with an increased risk of bladder cancer. The 
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FDA recommended that pioglitazone should not be used in patients with active bladder 
cancer, and that practitioners should use pioglitazone with caution in patients with history 
of bladder cancer (FDA 2011).  
On 18 July 2011, the TGA issued a safety advisory on the increased risk of bladder cancer 
associated with the use of pioglitazone for more than one year (TGA 2011). Health 
professionals were advised: “Do not use pioglitazone in patients with bladder cancer or a 
history of bladder cancer. Consider the risk of bladder cancer in all patients treated with 
pioglitazone.” 
1.3 Impact of regulatory warnings on thiazolidinediones in other countries 
The usage of both rosiglitazone and pioglitazone were assessed after the emerging 
myocardial infarction risk of rosiglitazone. The EMA reported a decline in rosiglitazone in 
many countries from the assessment of drug usage during 2008–2010 (EMA 2010). 
Studies on the impact of EMA press releases and DHPCs showed a significant decrease 
in the dispensing of rosiglitazone after the 2007–2008 warnings in the Netherlands (Ruiter 
et al. 2012). Studies using the UK databases found a sharp decrease in rosiglitazone 
prescription numbers and an increase in switching to pioglitazone following the warnings 
on cardiac events of rosiglitazone (Hall et al. 2011; Leal et al. 2013). Most of the studied 
data depicted a transient increase in pioglitazone use during the intensive warnings of 
rosiglitazone in 2007–2008 as a result of an increase in the number of pioglitazone 
initiations and new users of pioglitazone (Shah et al. 2008). 
In the US, pharmacy claims databases were accessed to evaluate TZD after the FDA 
warnings. The average number of claims per day per million members for rosiglitazone 
decreased dramatically after May 2007 while pioglitazone remained flat through 2007–
2008. On the other hand, sitagliptin claims increased 5-fold during 2007 (Starner et al. 
2008). 
Some studies assessed the adverse events associated with rosiglitazone and found a 
decline in monthly rates of these events after November 2007. A study assessing the 
reason for switching found that switching from pioglitazone to other antidiabetic drugs was 
more common in patients with heart failure conditions and that switching from rosiglitazone 
was more likely in patients with ischemic heart disease, heart failure, insulin treatment, or 
a recent sulphonylurea prescription (Hall et al. 2011). 
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Various analytical models such as ARIMA model, Logistic regression and Poisson 
regression were used to examine the outcomes of interest, which include; number of 
users/prescriptions/dispensing, prevalence/incidence of prescriptions (e.g. person-years), 
proportion of all antidiabetic drug users, rate of switching, new users, number of initiations, 
and diagnoses/laboratory details related to the recommendations provided in the warnings 
(Ehrenstein et al. 2013). 
2. Clopidogrel and proton pump inhibitors interaction 
Overview 
In 2009, the FDA and EMA announced a possible interaction between clopidogrel and 
PPIs, later that year, the FDA recommended against the concomitant use of omeprazole 
and esomeprazole with clopidogrel. The TGA refrained from any specific comment aside 
from the following update on the Consumer Product Information “consult your doctor 
before using these two drugs” in October 2011. Most in vitro studies have shown that 
omeprazole and esomeprazole reduce measures of the antiplatelet efficacy of clopidogrel. 
The considerable diversity in evidence on the risk of cardiovascular outcomes of 
concomitant clopidogrel and PPI therapy in clinical studies has led to a debate regarding 
the clinical applicability of the interaction.  
2.1 Antiplatelet agents 
Antiplatelet therapy is used for secondary prevention of coronary artery diseases and 
thrombotic cerebrovascular by inhibition of platelet aggregation in arterial thrombosis 
(Steinhubl et al. 2002; Patrono et al. 2008). Antiplatelet drugs are grouped according to 
their mechanisms of platelet inhibition: irreversible cyclooxygenase inhibitors, adenosine 
diphosphate receptor inhibitors (thienopyridiens), phosphodiesterase inhibitors, 
glycoprotein IIb/IIIa receptor antagonists, reversible P2Y12 antagonists (Eikelboom et al. 
2012). Patients may benefit from different antiplatelet regimens; however, aspirin and 
clopidogrel are common oral antiplatelet therapies in patients with artherothrombosis with 
or without vascular intervention (Steinhubl et al. 2002; Kushner et al. 2009; Eikelboom et 
al. 2012). 
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2.1.1 Aspirin 
Aspirin is a non-steroidal anti-inflammatory drug often used as an analgesic, antipyretic 
and anti-inflammatory drug (Eikelboom et al. 2012). The antiplatelet activity of low-dose 
aspirin (75–375 mg daily) was acknowledged in the 1960s as prolonged bleeding time 
(Weiss et al. 1967). Aspirin 100 mg tablets and 300 mg effervescent tablets are subsidised 
on the PBS. 
Low dose aspirin inhibits platelet aggregation due to its irreversible inactivation of the 
cyclooxygenase (COX) -1 enzyme, which is a key enzyme in thromboxane A2 production. 
Thromboxane A2 induces platelet aggregation and vasoconstriction. In contrast, much 
larger daily doses of aspirin are required to inhibit the COX-2 dependent anti-inflammatory 
pathway rather than the antiplatelet pathway (Awtry et al. 2000). 
Roles in the prevention of atherothrombosis 
Daily dose of aspirin 75–100 mg is recommended for the long term prevention of serious 
atherothrombotic events (Collaboration. 2002). In primary prevention or prophylaxis of 
atherothrombosis, low dose aspirin yielded a 12% relative risk reduction in the incidence of 
major vascular events, particularly non-fatal myocardial infarction (MI). However, the 
benefits of aspirin in patients with a high risk of major thrombotic events need to be 
weighed against the risk of major bleeding (Baigent et al. 2009).  
For secondary prevention in patients with existing vascular conditions, the benefits of 
aspirin exceed the bleeding risk (Baigent et al. 2009). Long-term aspirin therapy is 
recommended for patients with acute coronary syndrome (ACS) unless aspirin is 
contraindicated (Aroney et al. 2008). Even so, aspirin is considered to have a weaker 
inhibitory effect on platelet aggregation compared to other antiplatelet drugs. Thus it is 
used in combination with other antiplatelet drugs (Yusuf et al. 2001).  
2.1.2 Clopidogrel 
Overview 
Clopidogrel is a second-generation thienopyridine. Clopidogrel is a prodrug that needs 
metabolic activation through the hepatic cytochrome (CYP) 450 system to generate active 
metabolites. Clopidogrel’s metabolic pathways can be interfered with by other drugs that 
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share the same CYP450 enzyme (e.g. CYP2C19 drug interaction with PPIs). The first-
generation agent, ticlopidine, was limited in use due to serious hematological toxicity and 
was replaced by clopidogrel. The antiplatelet effect of the newest thienopyridine, 
prasugrel, is more potent than clopidogrel and is not disturbed by polymorphisms in 
CYP2C19 or the concomitant use of PPIs (Brandt et al. 2007; Farid et al. 2008).  
Pharmacokinetics and pharmacodynamics 
Clopidogrel is an inactive prodrug therefore its therapeutic efficacy depends on its two-step 
oxidative process. First, hepatic CYP450 isoenzymes CYP1A2, CYP2B6, and CYP2C19 
transform clopidogrel into 2-oxo-clopidogrel. Subsequently CYP2B6, CYP2C9, CYP2C19, 
and CYP3A4 oxidise 2-oxo-clopidogrel into a highly labile active metabolite (Figure 2) 
(Savi et al. 1994; Savi et al. 1998; Savi et al. 2000). 
 
Figure 2. Clopidogrel metabolism 
The active metabolite of clopidogrel is a potent inhibitor of adenosine diphosphate (ADP)-
induced platelet aggregation (Defreyn et al. 1991). It reduces the amount of platelet ADP 
binding sites by selective and irreversible blockade of the platelet ADP P2Y12 receptor 
(Savi et al. 1992; Savi et al. 1998; Savi et al. 2000).  
At a maintenance dose of 75 mg daily, clopidogrel reaches steady state after 4–7 days 
and inhibits approximately 50–60% of platelet aggregation. A loading dose of 300–600 mg 
achieves the same levels of platelet aggregation within 4–24 hours (Gurbel et al. 2003; 
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Patrono et al. 2004; Gurbel et al. 2005; Lev et al. 2007; Kim et al. 2008; Kushner et al. 
2009; Patrono et al. 2011).  
Clopidogrel resistance 
Mechanisms underlying variable or insufficient responses to clopidogrel have been 
attributed to multiple factors (Gurbel et al. 2003; Muller et al. 2003; Gurbel et al. 2005). 
These include impaired gastric absorption of clopidogrel, increased reactivity of resting 
platelets, up-regulation of other platelet activation pathways, CYP450 isoenzymes activity, 
genetic polymorphisms of the CYP2C19 allele, and drug-drug interactions (Kim et al. 2008; 
Holmes et al. 2011; Shmulevich et al. 2011). Recently, CYP2C19 metabolic activity was 
shown to be the key to the pharmacodynamic response and clinical efficacy of clopidogrel 
(Angiolillo et al. 2007). The CYP2C19 loss-of-function allele (*2 to *8 CYP2C19 allele) is 
responsible for more than 90% of poor metabolisers (Cayla et al. 2011; Holmes et al. 
2011). Patients with genetic polymorphisms of the CYP2C19 allele could not convert 
clopidogrel to its active metabolites. Studies suggested that CYP2C19 loss-of-function 
allele is associated with the risk of cardiovascular events in clopidogrel-treated patients 
(Collet et al. 2009; Simon et al. 2009; Hulot et al. 2010; Simon et al. 2011). In vitro studies 
revealed impaired antiplatelet activity of clopidogrel by the concomitant use with CYP3A4- 
and CYP2C19-metabolised drugs (Zahno et al. 2010). Recent clinical studies have been 
trying to establish whether the interaction is clinically significant (Almadi et al. 2011; Ogilvie 
et al. 2011; Aihara et al. 2012). 
Side effects 
Clopidogrel is generally well tolerated with minor side effects such as stomach upset, 
diarrhoea and constipation (Committee 1996). Although clopidogrel can cause easy 
bleeding/bruising, the risk of upper gastrointestinal bleeding is less likely compared to low-
dose aspirin. Clopidogrel rarely causes serious hematologic reactions (e.g. thrombotic 
thrombocytopenic purpura, neutropenia), which are of major concern in the thienopyridine 
drug class (Pereillo et al. 2002). 
Roles in prevention of atherothrombosis 
The Clopidogrel vs Aspirin in Patients at risk for Ischemic Events (CAPRIE) trial compared 
the efficacy and safety of clopidogrel (75 mg/day) with aspirin (325 mg/day). Clopidogrel 
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treatment was more effective in reducing the risk of MI, ischemic stroke or vascular 
mortality than those in the aspirin treatment group with a similar overall incidence of 
haemorrhagic events (Committee 1996). Several randomised clinical trials have shown the 
comparative efficacy and safety profiles of clopidogrel in reducing cardiovascular events 
compared to aspirin or placebo (Committee 1996; Collaboration. 2002; Diener et al. 2004; 
Berger et al. 2009).  
Patients with coronary, cerebrovascular or peripheral arterial disease who cannot tolerate 
low-dose aspirin can use clopidogrel (75 mg daily) as an alternative antiplatelet. 
Frequently, clopidogrel is given with aspirin to reduce the risk of severe cardiovascular 
events in patients with acute coronary artery syndromes and after coronary intervention 
(Collaboration. 2002; Gurbel et al. 2005; Smith et al. 2006; Patrono et al. 2008; Patrono et 
al. 2011).  
As the distinct and complementary pathways of platelet activation and aggregation, a 
combination of aspirin and a thienopyridine the so-called “dual antiplatelet therapy” is 
shown to have clinical benefit in high-risk clinical settings (Yusuf et al. 2001; Steinhubl et 
al. 2002; Diener et al. 2004; Chen et al. 2005; Sabatine et al. 2005; Bhatt et al. 2006; 
Berger et al. 2009). The combination of aspirin and clopidogrel consistently reduces the 
risk of cardiovascular events in ACS patients undergoing percutaneous coronary 
intervention (PCI) (CURE) (Steinhubl et al. 2002), patients with unstable angina/non-ST-
segment-elevation myocardial infarction (CURE) (Yusuf et al. 2001), and acute myocardial 
infarction with ST-segment elevation (CLARITY, COMMIT) (Chen et al. 2005; Sabatine et 
al. 2005).  
National and international guidelines recommended the combination of low dose aspirin 
and clopidogrel (75mg daily) for at least 12 months in patients with ACS after undergoing 
percutaneous coronary intervention (PCI) with or without stent. Continuation of clopidogrel 
beyond 15 months maybe considered in patients undergoing PCI with drug-eluting stent 
placement (Aroney et al. 2008; Kushner et al. 2009; Chew et al. 2011).  
Studies have reported an increased risk in upper gastrointestinal bleeding complications 
due to dual therapy compared to the same dose of aspirin alone or clopidogrel alone 
(Diener et al. 2004; Hsu et al. 2011). Antiplatelet therapy is correlated with various 
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hemorrhagic complications, and upper gastrointestinal bleeding is the most frequent 
bleeding site (Trenk 2009).  
Availability of clopidogrel in Australia 
In November 1999, clopidogrel 75 mg tablet (Plavix® and Iscover®) was listed on the PBS 
subsidised formulary for the secondary prevention of ischemic cerebral stroke or transient 
cerebral ischemic events and the secondary prevention of myocardial information or 
unstable angina in patients with a history of cerebrovascular ischaemic episodes while on 
therapy with low-dose aspirin, or with contraindications to low-dose aspirin (such as 
gastrointestinal bleeding, allergy). In 2009, the listing of clopidogrel was extended to the 
treatment of acute coronary syndromes and the use following stent insertion in patients 
without a prior history of acute coronary syndrome in combination with aspirin (PBS 2009). 
In 2010, clopidogrel was listed as fifth-highest PBS drug by total cost to Australia (PBS 
2010).  
2.2 Antisecretory agents 
Only two classes of drugs, proton pump inhibitors (PPIs) and histamine 2 receptor 
antagonists (H2RAs), are available as antisecretory agents for treating gastric acid-related 
disorders. Both drug classes inhibit gastric acid secretion but have different modes-of-
action and metabolic pathways (Schafer et al. 2010). 
2.2.1 Proton pump inhibitors 
Overview 
PPIs are recognised as efficient acid suppressants for the treatment of acid related 
gastrointestinal disorders (Welage et al. 2000). PPIs are shown to be more effective in the 
treatment of complicated gastric/duodenal ulcers, Zollinger-Ellison syndrome, erosive 
esophagitis and gastroesophageal reflux disease (GORD) compared to H2RAs (Torguson 
R ; Welage et al. 2000).  
A duration of 4–8 weeks of PPI therapy is recommended in dyspepsia, GORD, peptic ulcer 
and mild to moderate esophagitis. Continuous PPI therapy is recommended for sever 
esophagitis and Barrett’s esophagus, Zollinger-Ellison syndrome, scleroderma, and 
strictures (NICE 2004). For the eradication of Helicobacter pylori (H. pylori), PPIs play a 
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key role in triple therapy with two antibiotics (clarithromycin and amoxicillin/metronidazole) 
for 1 week and continued PPI treatment for up to 8 weeks (Gillen et al. 2004). PPI therapy 
is also useful in healing and preventing stress- and NSAID-induced ulcerations until 
NSAID treatment is stopped (Singh et al. 2005). Patients with a high risk of gastrointestinal 
bleeding particularly the elderly and patients with multidrug therapy often require long-term 
PPI treatment. Thus, they have a higher possibility of PPIs interacting with other drugs 
(Singh et al. 2005; Blume et al. 2006).  
Availability in Australia 
Five proton pump inhibitors are subsidised on the PBS but are not funded for all 
indications. Omeprazole and lansoprazole were launched in 1994, followed by 
pantoprazole (1995), rabeprazole (Pariet®) (2001) and esomeprazole (Nexium®) in August 
2002. As at January 2014, all five PPIs are PBS subsidised as ‘Restricted Benefits’ for 
peptic ulcers and GORD. Esomeprazole 40 mg is listed as ‘Authority Required benefits’ on 
the PBS for Zollinger-Ellison syndrome and scleroderma. Only esomeprazole and 
omeprazole are subsidised for H. pylori eradication (PBS). As a class, PPIs are 
continuously among the top 10 most commonly subsidised medicines in Australia based 
on prescription numbers, daily dose and cost to the Government (PBS 2010).  
Pharmacodynamics and pharmacokinetics 
PPIs are designed to diffuse and inhibit gastric acid secretion at the surface of parietal 
cells in the stomach. PPIs irreversibly inactivate the gastric hydrogen, potassium-
adenosine triphosphate (H+, K+-ATPase) enzyme system, also called the proton pump, 
which is the end stage of acid production (Kahrilas et al. 2000). The suppressive effect of 
PPIs last for 24 to 72 hours with once daily dosing and increases with repeated once daily 
dosing to plateau after 4 days.  
PPIs are rapidly absorbed, highly protein bound, and extensively metabolised in the liver 
by cytochrome P450, particularly CYP2C19 and CYP3A4 (Blume et al. 2006). Each PPI 
has different substitutions on its pyridine and/or benzimidazole groups and some 
pharmacokinetic pathways. However, all PPIs are very similar in their pharmacological 
properties.  
Drug-drug interaction 
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Although PPIs are metabolised via cytochrome P450, the inhibitory potency of each PPI is 
dependent on different enzymes (Li et al. 2004; Ogawa et al. 2010). The most extensively 
studied PPI drug interactions are omeprazole and pantoprazole (Blume et al. 2006; 
Wedemeyer et al. 2014). Omeprazole is the most potent in vitro inhibitor of CYP2C19 and 
a moderate inhibitor of CYP3A4 (Li et al. 2004), while pantoprazole has a considerably 
lower potential for drug interactions (Singh et al. 2005; Blume et al. 2006). Omeprazole 
increases the plasma concentration of warfarin, diazepam, phenytoin, while pantoprazole 
is not likely to interact with these medicines. The interaction profiles of lansoprazole and 
rabeprazole were limited in studies; however, they appear to have a less potential than 
omeprazole (Wedemeyer et al. 2014). 
Side effects 
Although PPIs are largely well tolerated, incidence of rare but serious adverse effects has 
been described in research studies. Chronic treatment with PPIs has been associated with 
increased risks of bone fractures, especially at high doses (Yang et al. 2006; Gray et al. 
2010); the FDA requested these risks be added to the label in 2010 and the EMA in 2012. 
Meta-analyses and observational studies found an increased risk of community-acquired 
pneumonia in patients receiving PPIs and moreover, a recent meta-analysis shows an 
association with a higher dose PPI and short duration (<30 days) (Laheij et al. 2004; 
Johnstone et al. 2010; Eom et al. 2011; Giuliano et al. 2012). Patients using PPIs are 
reported to have an increased risk of a Clostridium difficile infection from meta-analysis 
studies (Dial et al. 2004; Leonard et al. 2007). The FDA issued a safety alert on Clostidium 
difficile—associated diarrhoea and the pneumonia associated with PPIs in 2012. 
Hypomagnesaemia, vitamin B12 deficiency, iron deficiency, thrombocytopenia, 
rhabdomyolysis and acute interstitial nephritis have also been associated with the long-
term use of PPIs (Ali et al. 2009; Wilhelm et al. 2013).  
2.2.2 Histamine 2 receptor antagonists 
The long availability of H2RA including known safety and efficacy profiles has led to 
accessibility of these medicines over the counter in many countries; however, proton pump 
inhibitors are replacing H2RA in clinical practice (Klinkenberg-Knol et al. 1995). H2RAs are 
considered to be less effective in decreasing gastric acid than PPIs, which shut down the 
final step of acid secretion (Lanas et al. 2007).  
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Availability in Australia 
Cimetidine, famotidine and ranitidine were made available on the PBS prior to 1992 
followed by nizatidine in 1993. Currently, only famotidine and ranitidine are available over-
the counter in Australia.  
Drug-drug interaction 
Cimetidine is the prototype H2RA; however, its clinical use is restricted by its adverse 
effects and drug-drug interactions. Cimetidine can increase a variety of drugs that 
metabolise via CYP1A2, CYP2C6, CYP2D9, and CYP3A4 enzymes. Ranitidine interferes 
minimally with hepatic metabolism of other drugs with an affinity of only 10% that of 
cimetidine. Famotidine and nizatidine have no significant drug interactions via CYPs 
therefore making them safe for use with other drugs (Sabesin 1993; Hatlebakk et al. 
1996).  
Side effects 
Side effects of H2RAs occur in a small proportion of patients with the most common being 
headache, dizziness, diarrhoea, constipation, and muscular pain. Using cimetidine is 
associated with reversible endocrine side effects including gynecomastia and galactorrhea 
due to its nonsteroidal antiandrogen properties. Ranitidine has minimal side effects and 
none of the antiandrogenic and prolactin-stimulating effects of cimetidine (Sabesin 1993; 
Lev et al. 2007). 
2.3 Concomitant use of clopidogrel and proton pump inhibitors 
Gastrointestinal bleeding has been examined as one of the most common causes of life-
threatening complications after acute coronary syndrome (ACS) (Liberopoulos et al. 2006). 
Gastrointestinal bleeding is usually precipitated by antithrombolytic, anticoagulation, or 
antiplatelet therapy and infrequently by colonic ischemia induced by hypo-perfusion. There 
are many other potential factors associated with an increased risk for upper GI bleeding in 
ACS patients including older age, previous GI events, and the use of other precipitating 
medicines such as NSAIDs (Ali et al. 2009). 
PPIs or H2RAs are often prescribed prophylactically to prevent gastrointestinal 
haemorrhage or complications in patients taking antiplatelet drugs (Lev et al. 2007; 
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Schafer et al. 2010). In the CURE study, major GI bleeding occurred in 1.33% of patients 
on dual therapy compared to 0.75% in aspirin alone during the 12-month follow-up. 
Studies have shown that the use of PPI prophylaxis significantly lowers the risk of clinical 
upper GI bleeding and is more effective compared to H2RAs (Mehta et al. 2001; Ali et al. 
2009; Pongprasobchai et al. 2009; Yasuda et al. 2009). One study showed that 
esomeprazole (PPI) is superior to famotidine (H2RA) in preventing upper GI complications 
related to aspirin, clopidogrel, enoxaparin, or thrombolytics (Ng et al. 2012). 
Studies suggest PPIs have benefit in patients who need a dual antiplatelet therapy, 
especially aspirin and clopidogrel to prevent the risk of gastric bleeding complications 
(Abraham et al. 2010; Barkun et al. 2010). The American College of Cardiology 
Foundation/American College of Gastroenterology/American Heart Association 
(ACCF/ACG/AHA) 2010 expert consensus recommended the use of a PPI to reduce GI 
bleeding among patients who require antiplatelet therapy with a history of upper GI 
bleeding and multiple risk factors for GI bleeding. They did not suggest the routine use of 
either a PPI or a H2RA for prophylaxis in patients with low risk of GI bleeding (Abraham et 
al. 2010). 
2.4 Interaction between clopidogrel and proton pump inhibitors 
The clopidogrel-PPI interaction was first demonstrated by Gilard and colleagues in 2006. 
They found an in vitro reduction of antiaggregatory platelet response of clopidogrel in PCI 
patients taking PPI treatment (Gilard et al. 2006). Since then, several pharmacodynamics 
studies have extensively analysed the clopidogrel-PPI interaction (Table 1). The clinical 
relevance of this interaction has been evaluated in observational studies and randomised 
trials but the clinical importance remains uncertain (Table 2).  
2.4.1 In vitro studies on clopidogrel-PPI interaction 
 In vitro or pharmacodynamic studies use surrogate markers such as of clopidogrel 
efficacy on platelet aggregation as outcomes. The Omeprazole Clopidogrel Aspirin (OCLA) 
trial randomised patients who had undergone elective PCI with stent and who received 75 
mg daily of aspirin and clopidogrel and either omeprazole 20 mg daily or placebo. The 
antiplatelet effect of clopidogrel was measured using the vasodilator-stimulated 
phosphoprotein (VASP) phosphorylation assay to provide a platelet reactivity index (PRI) 
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on day 1 and 7. The mean PRI was significantly higher in omeprazole treatment, 
demonstrating less effective antiplatelet aggregation of clopidogrel (less clopidogrel 
response) (Gilard et al. 2008). The potential interaction of the PPI class effect was 
investigated by the PPI And Clopidogrel Association (PACA) study. The PACA compared 
pantoprazole to omeprazole treatment in patients talking aspirin 75 mg and clopidogrel 
150 mg using VASP-PRI and adenosine diphosphate-induced aggregation (ADP-Ag) for 
platelet reactivity. Pantoprazole has significantly less effect on platelet responsiveness to 
clopidogrel than omeprazole but no significant difference in platelet reactivity (Cuisset et 
al. 2009). Researchers hypothesised that omeprazole may interact adversely with 
clopidogrel at the level of CYP2C19; thus, omeprazole inhibits the conversion of 
clopidogrel to the active anticoagulating form (Cuisset et al. 2009; Ho et al. 2009). A 
randomised placebo-controlled crossover study among healthy subjects tried to address 
the argument about whether this interaction was a PPI class effect or CYP2C19 inhibiting 
effect on clopidogrel. Results showed that active metabolites of clopidogrel and platelet 
response were significantly decreased in the omeprazole group when the clopidogrel 
dosage was increased or administered 12hr apart from omeprazole. The PRI did not 
significantly change in the pantoprazole group leading the authors to conclude that an 
interaction between clopidogrel and omeprazole exists but not pantoprazole (Angiolillo et 
al. 2011). Esomeprazole is the S-isomer omeprazole which is assumed to have similar 
metabolic pathways and effects as omeprazole (Richter et al. 2001; FDA 2009), although 
studies have not been able to provide consistent effects of esomeprazole treatment on 
clopidogrel’s antiplatelet efficacy (Siller-Matula et al. 2009; Neubauer et al. 2010; 
Fernando et al. 2011; Hsu et al. 2011).  
Table 1. In vitro studies of clopidogrel and PPIs 
Study Design Patients 
(n) 
Treatment Outcome Results 
Gilard 
(Gilard et 
al. 2008) 
Randomised, 
Double-Blind 
(OCLA) 
Elective 
PCI (124) 
Omeprazole 
vs. placebo 
VASP-PRI PRI: placebo 39.8%, 
omeprazole: 51.4%, 
p<0.0001 
Cuisset 
(Cuisset et 
al. 2009) 
Randomised 
(PACA) 
NSTE MI 
who 
Undergoing 
PCI (104) 
Omeprazole 
vs. 
pantoprazole 
VASP-PRI, 
ADP-Ag 
PRI: pantoprazole 36%, 
omeprazole 48%, p=0.007 
APD-Ag: pantoprazole 50 U+/-
18%, omeprazole 52 U+/- 
15%, p=0.29 
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Siller-
Matula 
(Siller-
Matula et 
al. 2009) 
Non-
randomised 
study design. 
CAD with 
undergoing 
PCI (300) 
Pantoprazole 
vs. 
esomeprazole 
vs. non-PPI 
VASP-PRI, 
ADP-Ag 
PRI&APD-Ag: pantoprazole 
50%&47U, esomeprazole 
54%&42U, non-PPI 
49%&41U, 
No significance 
Neubauer 
(Neubauer 
et al. 2010) 
Retrospective 48 hr after 
PCI with 
stent 
(336) 
Pantoprazole 
vs. 
omeprazole/ 
esomeprazole 
vs. without PPI 
Impedance 
aggregome-try 
(in Ohm), 
Clopidogrel 
low-response 
(%)  
Non-PPI 2.75 Ohm&21.9%, 
pantoprazole 
2.33Ohm&16.4%, 
omeprazole/esomeprazole 3 
Ohm&30.8%  
No significance  
Angiolillo 
(Angiolillo 
et al. 2011) 
Four-way 
crossover 
Healthy 
volunteers 
(282) 
 
Omeprazole 
vs. placebo 
0,12 h apart 
Pantoprazole 
vs. placebo 
MPA, VASP-
PRI, ADP-AG 
Metabolic drug-drug 
interaction between 
clopidogrel and omeprazole 
and but not pantoprazole 
Ferreiro JL 
(Ferreiro et 
al. 2011) 
Randomized 
crossover 
study 
Healthy 
volunteers 
(20) 
Pantoprazole 
vs. placebo 
Aggregometry, 
VerifyNow 
P2Y(12) 
system 
No significance 
Fernando 
(Fernando 
et al. 2011) 
Randomised 
to 
esomeprazole 
or placebo 
CAD (31) Esomeprazole 
vs. placebo 
VASP, PRI, 
PRU 
Esomeprazole attenuation 
antiplatelet effects (p< 0.01) 
 
Funch-
Brentano 
(Funck-
Brentano et 
al. 2013) 
Randomised 
three-period 
crossover 
Healthy 
subjects 
(36) 
Omeprazole 
Rabeprazole 
Placebo 
VASP-PRI No significance 
Hsu (Hsu 
et al. 2011) 
Randomised 
controlled 
CAD (165) Esomeprazole 
vs. no PPI 
ADP-induced 
platelet 
aggregation 
test 
No significance 
VASP-PRI: Vasodilator-stimulated phosphoprotein platelet reactivity index; PRI: Platelet reactivity index; 
NSTE MI: Non ST-elevated Myocardial infarction; ADP-Ag: Adenosine diphosphate induced platelet 
aggregation; CAD: Coronary artery disease; PCI: Percutaneous coronary artery intervention; CLR: 
Clopidogrel low-response; PRU: Platelet reactivity units; MPA: Mean platelet aggregation; PPI: proton pump 
inhibitor. 
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2.4.2 Clinical studies on the clopidogrel-PPI interaction 
Although pharmacodynamic studies show PPIs affecting platelet function, inconsistent 
findings from clinical studies mean it is difficult to establish the clinical importance of this 
clopidogrel-PPI interaction.  
In 2009, a retrospective cohort study in Veterans Affairs medical records investigated 
8,205 patients who were hospitalised for ACS. 63.9% of patients were coprescribed a PPI 
(mainly omeprazole and rabeprazole) at any time point during cloidogrel treatment. The 
concomitant use of a PPI and clopidogrel was associated with an increased risk of 
rehospitalisation for ACS and all-cause mortality (OR 1.25, 95% CI 1.11–1.41) (Ho et al. 
2009). Analyses of PPIs as a class from post hoc studies and retrospective studies found 
an increased risk of major adverse cardiovascular event (MACE) associated to PPI 
treatment in ACS patients with or without PCI (Dunn SP 2008; Charlot et al. 2010; 
Evanchan et al. 2010; Gupta et al. 2010; Kreutz et al. 2010; van Boxel et al. 2010; Dunn et 
al. 2013). A nationwide Danish cohort study observed an increased risk of adverse 
cardiovascular events associated with PPI use in ACS patients, regardless of clopidogrel 
use (Charlot et al. 2010). Whereas, a post hoc of TRITON-TIMI38 and other observational 
studies show no significant association of the clinical cardiovascular outcomes and PPI 
treatment in ACS patients taking clopidogrel (O'Donoghue et al. 2009; Rassen et al. 2009; 
Gaspar et al. 2010; Ray et al. 2010; Garcia Rodriguez et al. 2013). One study focused on 
pantoprazole, the less potent inhibitor of CYP2C19, and did not find a significantly 
increased risk of cardiovascular events as found in other PPIs (Juurlink et al. 2009). 
However, another study from Stockl et al. reported that pantoprazole was also associated 
with an increased risk of cardiovascular outcomes in patients with a stent implantation 
(Stockl et al. 2010). The COGENT trial, the only RCT to date, comparing clopidogrel alone 
and combination of clopidogrel and omeprazole, found no significant increase in the risk of 
cardiovascular outcomes in the combination group. However, upper GI bleeding was 
observed to significantly decrease in the omeprazole treatment group (HR 0.34, 95%CI 
0.18–0.63, p=0.001). Unfortunately, this RCT was terminated early due to bankruptcy of 
the sponsor therefore the number of subjects recruited and follow up times were less than 
expected (Bhatt et al. 2010). The use of retrospective observational studies may also be 
limited by confounding due to diverse baseline characteristics and limited compliance data. 
Moreover, sample sizes were insufficient or follow-up time was too limited in all 
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randomised clinical trials to confirm the clinical relevance of this interaction. Details of 
some of these studies are provided below (Table 2).  
Table 2. Clinical studies on the clopidogrel-PPI interaction 
Study Study 
design 
Patients 
(n) 
Treatment Outcome Results 
Bhatt 
(Bhatt et 
al. 2010) 
Randomized 
double-blind 
(COGENT)  
ACS or 
undergoing 
PCI (3873) 
Omeprazole vs. 
placebo 
MACE, 
UGIB 
106 days 
MACE-HR 0.99, 95% CI 0.68–
1.44 
UGIB-HR 0.34,95%CI 0.18–
0.63 
Underpowered, Ran out of 
finances 
Dunn 
(Dunn SP 
2008) 
(Abstract) 
Post hoc 
Randomized 
double blind 
(CREDO) 
Elective PCI 
(1053) 
PPIs MACE  
1 year 
OR 1.633, 95%CI 1.015–2.627 
Ho (Ho et 
al. 2009)  
Retrospective 
cohort 
ACS (8205) PPIs vs. 
without PPI 
Mortality or 
rehospitalis-
ation for 
ACS 
OR 1.25, 95%CI 1.11–1.41 
O`Donogh
ue 
(O'Donogh
ue et al. 
2009) 
Post hoc 
Randomized 
double blind 
(TRITON-
TIMI38) 
Undergoing 
PCI (6795) 
PPIs MACE No significance 
Juurlink 
(Juurlink 
et al. 
2009) 
Nested-case-
control  
MI (734 
cases, 
2057controls
) 
Omeprazole, 
pantoprazole, 
lansoprazole, 
rabeprazole 
Death; reMI 
Up to 3 
months 
OR 1.27, 95%CI 1.03–1.57 for 
OME-LANSO-RABE group 
OR 1.02, 95%CI 0.7–1.47 for 
PANTO group 
Rassen 
(Rassen 
et al. 
2009) 
Retrospective 
Cohort 
ACS or PCI 
(18565) 
PPIs MACE 
6 months 
MI or Death: RR 1.22, 95% CI 
0.99–1.51; for death, RR 1.20, 
95% CI 0.84–1.70; for 
revascularization, RR 0.97, 
95% CI 0.79–1.21 
Charlot 
(Charlot et 
al. 2010) 
Nationwide 
Danish cohort 
First MI 
(56406) 
Clopidogrel: 
PPIs vs. 
without PPI 
non-
MACE 
1 year 
HR 1.29, 95%CI 1.17–1.42 in 
clopidogrel 
HR 1.29, 95%CI, 1.21–1.37 in 
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clopidogrel: 
PPIs vs. 
without PPI 
non-clopidogrel 
Kreutz 
(Kreutz et 
al. 2010) 
Retrospective 
cohort 
Undergone 
PCI with 
stent 
(Medco 
16,690) 
PPI vs. 
clopidogrel 
alone 
(omeprazole, 
esomeprazole, 
pantoprazole, 
lansoprazole) 
Major 
cardiovascul
ar events 
within 1 yr. 
HR 1.51, 95%CI 1.39–1.64 
 
Zairis 
(Zairis et 
al. 2010) 
Retrospective 
Cohort 
Elective PCI 
(588) 
Omeprazole MACE 
1 year 
HR 1.1, 95% CI 0.6–1.8 
Gupta 
(Gupta et 
al. 2010) 
Retrospective 
Cohort 
PCI (315) Omeprazole, 
lansoprazole, 
rabeprazole 
MACE 
4 years 
OR 1.95, 95%CI 1.09–3.49 
Gaspar 
(Gaspar et 
al. 2010) 
Retrospective 
Cohort 
ACS (802) Omeprazole, 
lansoprazole, 
rabeprazole 
MACE 
6 months 
No significance 
Evanchan 
(Evanchan 
et al. 2010) 
Retrospective MI with PCI 
(5794) 
Omeprazole, 
esomeprazole, 
pantoprazole, 
lansoprazole 
MI 
1 year 
OR 1.78, 95% CI 1.55–2.07 
Ray (Ray 
et al. 
2010) 
Retrospective 
Cohort 
ACS with 
PCI (20596) 
PPIs MACE, 
UGIB 
1 year 
MACE-HR 0.99, 95%CI 0.82–
1.19 
UGIB-HR 0.50, 95%CI 0.39–
0.65 
Stockl 
(Stockl et 
al. 2010) 
Retrospective 
Cohort 
MI or stent 
implantation 
(2066) 
Pantoprazole 
vs. others 
MACE 
1 year 
PPIs: HR1.93; 95%CI, 1.05–
3.54; p=0.03 
Pantoprazole: HR 1.91; 
95%CI, 1.19–3.06; p=0.008 
Van Boxel 
(van Boxel 
et al. 
2010) 
Retrospective 
Cohort 
New 
clopidogrel 
users 
(18,139) 
PPIs MACE, 
peptic ulcer 
(PU) 
MACE-HR 1.75, 95% CI 1.58–
1.94 
Low incidence of PU but 
increase PU disease-HR 4.76, 
95%CI 1.18–19.17 
Harjai 
(Harjai et 
al. 2011) 
Retrospective 
Cohort 
PCI (1210) PPIs MACE 
6 months 
No significance 
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Simon 
(Simon et 
al. 2011) 
Retrospective 
cohort 
(FAST-MI) 
MI (3670) PPIs MACE OR 0.90, 95%CI 0.60–1.35 
Hsiao 
(Tsai et al. 
2011) 
Retrospective 
cohort study  
ACS taking 
clopidogrel 
and aspirin 
(9753) 
PPIs vs. no 
PPI 
 ACS re-
hospitalization  
1 year 
No significance 
Aihara 
(Aihara et 
al. 2012) 
Retrospective 
Propensity 
Score 
Matching 
Underwent 
PCI (1000) 
PPIs vs. 
without PPI 
MACE No significance 
Bhurke 
(Bhurke et 
al. 2012) 
Retrospective 
Cohort 
ACS 
(10,101) 
PPIs MI, PCI, 
ACS 
HR 1.44, 95%CI 1.24–1.67 
Schmidt 
(Schmidt 
et al. 
2012) 
Population-
based cohort 
PCI (12001) Clopidogrel 
users: PPIs vs. 
without PPI 
clopidogrel 
non-users: 
PPIs vs. 
without PPI 
MACE 
1 year 
HR 1.24, 95% CI 0.97–1.58 for 
clopidogrel users 
HR 1.26, 95% CI 0.97–1.63 for 
clopidogrel non-users 
Garcia 
Rodriguez 
(Garcia 
Rodriguez 
et al. 2013) 
Population-
based cohort 
study in 
THIN, GPRD 
Clopidogrel 
monotherapy 
and dual 
antiplatelet 
therapy 
(42,542) 
Clopidogrel: 
PPIs vs. 
without PPI 
Dual 
antiplatelet: 
PPIs vs. 
without PPI 
MI, coronary 
death 
Peptic ulcer 
bleeding 
(PUB) 
CV-PPI+mono clop: RR 1.06, 
95%CI 0.47–2.36 
CV-PPI+dual: RR 0.8, 95%CI 
0.47–1.37 
UGIB-PPI+dual-RR 0.66, 
95%CI 0.27–1.6 
Hsu (Hsu et 
al. 2011) 
Randomised 
controlled 
CAD (165) Esomeprazole 
vs. no PPI 
MACE, 
Recurrent 
peptic ulcer 
No significance in MACE 
Reduced recurrent of peptic 
ulcers 
ACS: Acute coronary syndrome; MACE: Major adverse cardiac event; UGIB: Upper gastrointestinal 
bleeding; HR: Hazard ratio; VASP-PRI: Vasodilator-stimulated phosphoprotein platelet reactivity index; PRI: 
Platelet reactivity index; NSTE MI: Non ST-elevated Myocardial infarction; ADP-Ag: Adenosine diphosphate 
induced platelet aggregation; CAD: Coronary artery disease; PCI: Percutaneous coronary artery intervention; 
CLR: Clopidogrel low-response; PRU: Platelet reactivity units; MPA: Mean platelet aggregation; PPI: proton 
pump inhibitor. 
Despite a concern on the antiplatelet effects of clopidogrel related to PPIs, several studies 
suggested that PPIs and H2RA are associated with a reduction in the risk of upper GI 
bleeding and recurrent peptic ulcer in CAD patients who are also taking clopidogrel and 
aspirin (Ng et al. 2008; Bhatt et al. 2010; Hsu et al. 2011; Kwok et al. 2011). A double-
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blind, randomised, controlled trial suggests that esomeprazole is better than famotidine in 
preventing GI complications in patients taking a combination of aspirin, clopidogrel, and 
either enoxaparin or thrombolytics (Ng et al. 2011). 
Meta-analyses also could not provide conclusive evidence on the cardiovascular events of 
concomitant use of clopidogrel and PPIs. Meta-analysis studies by Kwok et al concluded 
that both platelet function and clinical studies of the clopidogrel-PPI interaction were 
considerably heterogeneous in their study designs, baseline characteristics and drug 
exposure, thus no clear interaction could be determined (Kwok et al. 2011; Kwok et al. 
2013). Siller-Matula et al. also found heterogeneity in the overall analyses but after a 
sensitivity analysis assessment, concluded that concomitant PPI with clopidogrel may 
influence the risk of the cardiovascular events (Siller-Matula et al. 2010). Another meta-
analysis by Chen concluded that PPIs were associated with an attenuated antiplatelet 
effect of clopidogrel in in vitro studies but a lack of compatibility between clinical studies 
(Chen et al. 2011) (Table 3).  
Table 3. Meta-analysis studies on the clopidogrel-PPI interaction 
Study Study 
design 
Patients 
(n) 
Treatment Outcome Result 
Kwok 
(Kwok et 
al. 2010) 
Meta-
analysis 
Post-PCI 
23 studies 
(93,278) 
PPI vs. no 
PPI 
MACE No significant due to 
unmeasured confounders 
Siller-
Matula 
(Siller-
Matula et 
al. 2010) 
Meta-
analysis 
25 studies 
(159,138) 
PPIs vs. no 
PPI 
MACE, MI, 
Mortality, 
GI bleeding 
MACE-RR 1.29, 95%CI 
1.15–1.45 
MI-RR 1.31, 95%CI 1.12–
1.53 
Mortality-RR 1.04,95%CI 
0.93–1.16 
GI bleeding-RR 0.5, 95%CI 
0.37–0.69 
Chen 
(Chen et 
al. 2011) 
Meta-
analysis 
13 studies 
(31,073) 
PPIs vs. no 
PPI 
MACE RR 1.49, 95%CI 1.43–1.55 
fixed-effects model 
RR 1.40, 95%CI 1.15–1.70 
random-effects model 
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Pharmacodynamic studies on the interaction between clopidogrel and PPIs in 2008 led to 
the warnings of concomitant use of clopidogrel and all PPIs (Dunn SP 2008; Gilard et al. 
2008). Once studies suggested an effect of omeprazole but not pantoprazole on the 
platelet function of clopidogrel, the class effect of PPIs was reconsidered (Juurlink et al. 
2009; Sibbing et al. 2009; Siller-Matula et al. 2009). The possible explanation for this 
observation is that the metabolic activation of clopidogrel was interfered with via the 
CYP2C19 activities of the higher inhibitory potency of omeprazole. As the clinical impact of 
the clopidogrel-PPI interaction remains conflicting, the risk of PPIs on secondary 
prevention of cardiovascular events of clopidogrel must be balanced with the benefit in 
preventing GI bleeding. Several articles and guidelines suggest pantoprazole as a 
preferable choice if a PPI is required with clopidogrel. 
2.5 Regulatory warnings on the clopidogrel-PPI interaction 
Between the first in vitro study from Gilard to Angiolillo’s study (as shown in Table 1), 
studies were continuously being published on the clopidogrel-PPI interaction, it was during 
this time that a series of warnings were made from the FDA and EMA according to this 
updated information (Gilard et al. 2008; Angiolillo et al. 2011). Both the FDA and EMA 
went from the PPI drug class warnings to more specific warnings on omeprazole and 
esomeprazole. A lack of clinical evidence on this interaction may be the cause of 
hesitation from the TGA to take action.  
2.5.1 Warnings from the U.S. Food and Drug Administration 
In January 2009, the FDA issued an early communication warning recommending that 
healthcare providers should re-evaluate the initiation or continuation of PPI treatment in 
patients taking clopidogrel (FDA 2009). The FDA also mentioned that there was no 
evidence of any change in antiplatelet activity of clopidogrel by concomitant use with 
H2RAs (with an exception of cimetidine).  
In November 2009, the FDA issued a public health advisory on clopidogrel-omeprazole 
interaction and updated labelling for clopidogrel and omeprazole. This announcement 
recommended avoiding omeprazole and clopidogrel together at any time of the day. This 
recommendation was based on studies showing that omeprazole reduced clopidogrel’s 
anti-clotting effect through the CYP 2C19 enzyme and this inhibitory effect was present 
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even when taking 12 hours apart (Angiolillo et al. 2011). The FDA informed health 
professionals that they did not have enough information about the inhibitory effect of PPIs 
other than omeprazole; however, it was suggested that other potent CYP2C19 inhibitors 
should be avoided including esomeprazole. H2RAs, except cimetidine, were suggested if a 
drug to reduce acid was needed. The update of the clopidogrel drug label was processed 
by Sanofi-Aventis and Bristol-Myers Squibb (FDA 2009). The FDA also published details 
mentioning the Angiolillo et al. study and COGENT study as well as other alternatives for 
healthcare professionals.  
The FDA published three ‘Considerations for Healthcare Professionals’ and 
recommendations listed below in November 2009 (FDA 2009). 
• “The concomitant use of omeprazole and clopidogrel should be avoided because of the 
effect on clopidogrel's active metabolite levels and anti-clotting activity. Patients at risk 
for heart attacks or strokes, who are given clopidogrel to prevent blood clots, may not 
get the full protective anti-clotting effect if they also take prescription omeprazole or the 
OTC form (Prilosec OTC). 
• Separating the dose of clopidogrel and omeprazole in time will not reduce this drug 
interaction. 
• Other drugs that should be avoided in combination with clopidogrel because they may 
have a similar interaction include: esomeprazole (Nexium), cimetidine (which is 
available by prescription Tagamet and OTC as Tagamet HB), fluconazole (Diflucan), 
ketoconazole (Nizoral), voriconazole (VFEND), etravirine (Intelence), felbamate 
(Felbatol), fluoxetine (Prozac, Serafem, Symbyax), fluvoxamine (Luvox), and ticlopidine 
(Ticlid). 
• At this time FDA does not have sufficient information about drug interactions between 
clopidogrel and PPIs other than omeprazole and esomeprazole to make specific 
recommendations about their co-administration. Healthcare professionals and patients 
should consider all treatment options carefully before beginning therapy. 
• There is no evidence that other drugs that reduce stomach acid, such as most H2 
blockers ranitidine (Zantac), famotidine (Pepcid), nizatidine (Axid), except cimetidine 
(Tagamet and Tagamet HB—a CYP2C19 inhibitor) or antacids interfere with the anti-
clotting activity of clopidogrel. Ranitidine and famotidine are available by prescription 
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and OTC to relieve and prevent heartburn and antacids are available OTC to relieve 
heartburn. 
• Talk with your patients about the OTC medicines they take. Be aware that patients may 
be taking non prescription forms omeprazole and cimetidine.” 
In October 2010, after the COGENT study was published (Bhatt et al. 2010), the FDA 
issued a reminder for healthcare professionals to avoid concomitant use of clopidogrel and 
omeprazole. The FDA emphasised that the interaction between clopidogrel and PPIs was 
not a class effect. A weak inhibitor of CYP2C19 such as pantoprazole should be 
considered as an alternative PPI (FDA 2010). 
Several safety labelling changes of clopidogrel related to PPIs were approved by FDA 
Center for Drug Evaluation and Research (CDER) including; October 2009—add 
omeprazole as drug interactions of clopidogrel, August 2010—avoid omeprazole and 
suggest pantoprazole as alternative, and December 2011—avoid omeprazole and 
esomeprazole with clopidogrel (FDA 2013). 
In December 2011, the FDA updated labelling for clopidogrel and esomeprazole, which 
extended to avoid esomeprazole with clopidogrel due to the CYP2C19 interaction and that 
it is a component of omeprazole.  
2.5.2 Warnings from the European Medicines Agency 
In May 2009, the EMA issued a warning on the interaction between clopidogrel and PPIs, 
in which PPIs may reduce the antiplatelet effect of clopidogrel. The Committee for 
Medicinal Products for Human Use and the Pharmacovigilance Working Party 
recommended an amendment to the product information of clopidogrel  “Discourage 
concomitant use of PPIs unless absolutely necessary” (EMA 2009). In March 2010, EMA 
issued a public statement replacing the class warning of PPIs with a more specific PPI 
warning for concomitant use of omeprazole or esomeprazole with clopidogrel based on 
two studies, which were completed at the end of August 2009. They stated as “no solid 
grounds” were present or little evidence was available the class warning of PPIs was 
unjustified (EMA 2010). Both the FDA and EMA stated that there were no data indicating 
an interaction between H2RA and clopidogrel.  
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2.5.3 Warnings from the Therapeutic Goods Administration  
While the issue of the clopidogrel-PPI interaction had been extensively investigated and 
debated among researchers and drug authorities, the TGA refrained from any 
announcement. In October 2011 the TGA made its first recommendation regarding the 
interaction, stating “It would be misleading if consumers are only warned about this 
particular interaction and not other interactions and may assume that they do not need to 
check if they are not taking clopidogrel.” Therefore the TGA issued advisory statement 223 
“Ask your doctor or pharmacist before use if you are taking other medicines regularly”, 
which the TGA said it was adequate to cover all possible interactions between clopidogrel 
and PPIs (TGA 2011). 
The above releases demonstrate that the detail in EMA and FDA warnings are much more 
comprehensive than the Australian TGA warning, which is only two sentences long and 
lacks guidance about specific management strategies or alternative choices for healthcare 
professionals and consumers. It may be worthwhile alerting healthcare professionals and 
consumers, who are making a decision on the use of these medicines, to the emerging 
data on CYP2C19 activity related to the clopidogrel interaction and possible reduction of 
efficacy in antiplatelet aggregation. 
Due to the widespread use of proton pump inhibitors and clopidogrel, the mixed signals 
expressed by drug authorisations, and the inconclusive research around this co-
prescribing, it is unknown how this information has affected prescribing practices. 
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Objectives and hypotheses of this thesis 
Overview 
The purpose of this thesis was to expand the understanding of the impact of drug safety 
warnings on clinical practice in Australia. To date, there has been no study on the effects 
of drug safety warnings on drug use or prescribing decisions in Australia. We lack a 
comprehensive overview of the effectiveness of the Australian drug warning system in 
reducing the risks of new medicines. For these reasons, the aims of this PhD were: 1) to 
compare the timing and content of Australian regulatory warnings and warnings from major 
international drug authorities, 2) to investigate the impact of local and international 
regulatory warnings on the pattern of drug use in Australia, and 3) to evaluate prescribers’ 
awareness and response to drug safety warnings. 
Two recent drug safety warnings on adverse effects related to the thiazolidinedione drug 
class and on a drug interaction between clopidogrel and proton pump inhibitors (PPIs) 
provide excellent case studies to assess the impact of drug safety warnings on clinical 
practice in Australia. 
Firstly, the studies in Chapter 3&4 investigated a series of regulatory warnings on an 
increased risk of serious cardiovascular events related to rosiglitazone and regulatory 
warnings on a small increase risk of bladder cancer related to the long-term use of 
pioglitazone. The impact of warnings on drug use was analysed in two databases: 
Pharmaceutical Benefit Scheme (PBS) in Chapter 3—contains dispensing data from the 
national subsidised formulary and AsteRx in Chapter 4—a clinical database collected from 
medical practices. Several additional factors that may influence the pattern of drug use 
were also identified and included in analyses. 
To examine the impact of warnings with different degree of certainty, the second study in 
Chapter 5 investigated warnings on the clopidogrel-proton pump inhibitors interaction. This 
drug interaction warning was complicated by conflicting and inconclusive clinical evidence. 
We investigated changes to the pattern of antisecretory drugs co-prescribed with 
clopidogrel in the AsteRx database after the safety warnings. 
A qualitative approach was taken in Chapter 6 to assess prescribers’ perspective on drug 
safety warnings in Australia. This study used a combination of interviews and survey tools 
to assess the sources of drug safety information among practitioners. The outcome 
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expanded the understanding of drug warning systems and their influence on prescribers. 
To better explain the patterns of drug use and prescribing decisions, the degree of 
awareness of warnings and responses to warnings in Chapters 3&4 (thiazolidinediones) 
and Chapter 5 (clopidogrel-PPI) were examined.  
The primary and secondary outcomes of the impact of warnings on dispensing and 
prescribing patterns in Chapter 3–5 are explored by incorporating into findings from the 
survey. All results from this thesis are discussed in Chapter 7. 
1. Objectives 
The following objectives were proposed: 
I. To evaluate warnings on adverse effects of the thiazolidinedione drug class 
a. To compare the timing and content of warnings between local authority—the 
TGA and international authorities—the FDA and EMA 
b. To investigate the impact of warnings from the TGA, FDA and EMA on the 
changes in national dispensing patterns of the thiazolidinedione drug class in 
the PBS 
c. To investigate the impact of warnings from the TGA, FDA and EMA on the 
changes in prescribing details in patients using thiazolidinediones in the 
AsteRx database 
II. To evaluate warnings on drug interaction between clopidogrel and proton pump 
inhibitors  
a. To compare the timing and content of interaction warnings between local 
authority—the TGA and international authorities—the FDA and EMA 
b. To investigate the impact of interaction warnings from the TGA, FDA and 
EMA on the on patterns of antisecretory coprescribing with clopidogrel in the 
AsteRx database 
c. To identify other factors related to adverse effects that influenced patterns of 
the thiazolidinedione drug class use 
III. To assess prescribers’ perspectives toward drug safety warnings 
a. To determine sources of drug safety information among participants 
b. To obtain participants’ opinions on local drug safety warnings 
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c. To examine the awareness and response towards two recent drug warnings 
2. Hypotheses 
The following hypotheses were tested based on the above objectives:  
I. Warnings on adverse effects of the thiazolidinedione drug class 
a. Drug safety warnings from the FDA, EMA and TGA would be similar in timing 
and content.  
b. Patterns of thiazolidinedione use would significantly decrease after warnings 
from the FDA, EMA, and TGA. 
c. More patients would stop rosiglitazone after the FDA, EMA and TGA 
warnings. Patients who stop rosiglitazone after the warnings would switch to 
a non-thiazolidinedione antidiabetic medicine. 
II. Drug interaction warnings between clopidogrel and proton pump inhibitors 
a. Drug safety warnings from the FDA, EMA and TGA would be similar in timing 
and content.  
b. There would be a significant decrease in proton pump inhibitor coprescribing 
with clopidogrel after the first issue of interaction warnings from the FDA, 
EMA, and TGA and (maybe) specific reduction in omeprazole and 
esomeprazole due to differences in the content of the warnings. 
c. There would be other factors influencing coprescribing patterns such as a 
rapid growth of new products and other clinical conditions. 
III. Prescribers’ perspective 
a. Prescribers use multiple sources of drug safety information, including the 
TGA warnings. There would be multiple sources of drug safety information 
used by participants; however, the TGA would be the most assessable and 
reliable source. 
b. Prescribers regularly receive drug safety communications from the TGA via 
either the TGA’s subscription email or the TGA’s website. 
c. Prescribers have a high awareness on the thiazolidinedione and clopidogrel-
PPI warnings. Prescribers have changed their prescribing in response to the 
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safety warnings. Prescriber awareness and response will correlate with the 
changes in pattern of drug use in Chapters 3&4 and Chapter 5. 
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Chapter 3. The impact of thiazolidinedione warnings on the dispensing 1 
of PBS items 2 
1. Synopsis 3 
This study investigates the impact of warnings on adverse events of thiazolidinediones on 4 
the national patterns of drug use in the PBS database. Warnings on myocardial infarction 5 
events of rosiglitazone announced by the FDA and EMA in May 2007 were associated with 6 
a significant decrease in rosiglitazone utilisation in Australia. A decline in rosiglitazone use 7 
was observed prior to TGA warnings in December 2007. Findings in this chapter suggest 8 
that Australian prescribers may have acted in response to scientific evidence or 9 
international safety warnings (EMA, FDA), prior to the TGA warning. Minor effects on the 10 
pattern pioglitazone utilisation were observed following bladder cancer warnings in June–11 
July 2011. 12 
2. Overview 13 
As of 2014, there are seven classes of drugs used in Australia for the treatment of 14 
lowering blood sugar levels (PBS 2014). Current clinical guidelines recommend initiating 15 
metformin as first line therapy concurrent with lifestyle intervention and titrating to 16 
maximally effective dose over 1–2 months (Nathan et al. 2006; NICE 2011). There is no 17 
consensus on which drug should be used if metformin fails to achieve glycaemic goals. 18 
Usually, oral hypoglycaemic drugs will be added and followed by insulin to maintain HbA1c 19 
below the recommendation for each condition. Table 4 summarises the currently available 20 
agents and subsidy restrictions on the PBS for the treatment of type 2 diabetes (PBS 21 
2014). 22 
Table 4. Available drugs for treatment of type 2 diabetes in Australia 23 
Drug class Generic name PBS listing 
Biguanides Metformin No restriction  
Sulfonylureas Glibenclamide No restriction 
Gliclazide, gliclazide MR 
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Glimepiride 
Glipizide 
Alpha glucosidase 
inhibitors 
Acarbose No restriction 
Thiazolidinediones Rosiglitazone November 2003—Dual oral 
therapy with metformin or a 
sulfonylurea 
April 2005—Triple oral therapy 
with metformin and a 
sulfonylurea 
August 2005—In combination 
with insulin 
November 2008—Revoked 
triple therapy and in 
combination with insulin 
March 2011—Authority 
Required for dual oral therapy 
Pioglitazone November 2003—Dual oral 
therapy with metformin or a 
sulfonylurea 
2004—In combination with 
insulin 
November 2007— Authority 
Required (STREAMLINED) for 
triple therapy with metformin 
and a sulfonylurea 
Dipeptidyl peptidase 
4 (DPP-4) inhibitors 
Vildagliptin 1 November 2011—Authority 
Required (STREAMLINED) for 
triple oral combination with 
metformin and a sulfonylurea  
1 April 2014—Authority 
Required (STREAMLINED) for 
dual oral therapy with 
metformin or a sulfonylurea 
Saxagliptin 
Sitagliptin 
Linagliptin 
 Allogliptin 1 December 2013—Authority 
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Required (STREAMLINED) for 
triple or dual oral therapy with 
metformin or a sulfonylurea 
Combination tablets Metformin/glibenclamide No restriction 
Metformin/rosiglitazone Listed in July 2006 
Metformin/sitagliptin 
Merformin/vildagliptin 
Listed in August 2009 
Insulin  No restriction 
Incretin mimetics Exenatide 
Liraglutide 
Authority required 
(streamlined): in combination 
with metformin and/or a 
sulfonylurea 
Sodium-glucose 
transporter inhibitors 
(SGLT2) 
Canagliflozin 
Dapagliflozin 
- 
Previous research showed that biguanides had the highest rate of oral anti-diabetic drug 1 
consumption using the PBS/RPBS data in 2011, comprising 43.6% of all oral antidiabetic 2 
drugs (a total of 12.6 DDD/1000inhibitants/day). Sulfonylureas were the second most 3 
dispensed oral drugs contributing to 41% of all dispensing (11.9 DDD/1000inhibitants/day) 4 
followed by thiazolidinediones at 5.9% of all oral antidiabetic drugs (1.7 5 
DDD/1000inhibitants/day) (Sylvain Pichetti 2013).  6 
2.1 Warnings on cardiovascular risk related to rosiglitazone 7 
Since a meta-analysis by Nissen suggested an elevated risk of myocardial infarction and 8 
cardiovascular deaths associated with rosiglitazone therapy on 21 May 2007 (Nissen et al. 9 
2007), a series of warnings on cardiac events were issued by the FDA, EMA and TGA as 10 
listed in a chronological order below. 11 
21 May 2007—The FDA issued an alert on rosiglitazone. This alert included an ongoing 12 
FDA review of clinical data. The FDA suggested that healthcare professionals should 13 
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consider this and other available data when making individual treatment decisions for their 1 
patients with type 2 diabetes. 2 
23 May 2007—The EMA press release stated that the risk of cardiac ischaemic events 3 
was included in the EU product information in September 2006. Prescribers were 4 
reminded to adhere to the restrictions for use in patients with cardiac disease. Patients 5 
were suggested not to stop rosiglitazone and discuss with their doctor at their next regular 6 
visit. 7 
14 August 2007—The FDA requested the manufacture revise the rosiglitazone label 8 
highlighting an increased risk of congestive heart failure.  9 
18 October 2007—The EMA press release confirmed the positive benefit-risk balance for 10 
rosiglitazone treatment in patients with type 2 diabetes. 11 
14 November 2007—The FDA updated the WARNING SECTION of the rosiglitazone label 12 
to include myocardial ischemic events. 13 
December 2007—The TGA requested a Box Warning on the product information stating 14 
that rosiglitazone was not recommended in patients with known ischemic heart disease 15 
particularly in those who need several antidiabetic drugs or nitrates. 16 
24 January 2008—The EMA press release recommends a new warning stating that “the 17 
use of rosiglitazone in patients with ischemic heart disease and/or peripheral arterial 18 
disease is not recommended”. 19 
23 September 2010—The FDA restricted access and distribution of rosiglitazone. 20 
23 September 2010—The EMA suspended all rosiglitazone-containing products 21 
throughout Europe. 22 
24 September 2010—The TGA published an advisory statement to reinforce the Box 23 
Warning in the previous approved product information. 24 
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2.2 Warnings on the risk of bladder cancer related to pioglitazone 1 
9 June 2011—The EMA press release announced ongoing review on a small increased 2 
risk of bladder cancer related to pioglitazone that had caused the suspension of 3 
pioglitazone in France.  4 
15 June 2011—The FDA suggested that pioglitazone should not be used in patients with 5 
active bladder cancer and to use with caution in patients with history of bladder cancer. 6 
18 July 2011—The TGA stated that “Do not use pioglitazone in patients with bladder 7 
cancer or a history of bladder cancer.” Healthcare providers should consider the risk of 8 
bladder cancer in all patients treated with pioglitazone. 9 
21 July 2011—The EMA advised healthcare professionals to avoid pioglitazone in patients 10 
with history of bladder cancer or with uninvestigated macroscopic haematuria. 11 
In the present study, the Defined Daily Dose (DDD), a unit of drug utilisation 12 
recommended by the WHO is used to represent the assumed maintenance dose per day 13 
for rosiglitazone and pioglitazone in adults and to compare drug usage between different 14 
drugs and different periods (Wertheimer 1986; WHO 2013). The analysis of 15 
thiazolidinediones (TZDs) consumption structures is presented as monthly DDDs per 16 
1000inhabitants per day of rosiglitazone and pioglitazone over the study period. DDDs for 17 
rosiglitazone is 6 mg (ATC code: A10BG02) and pioglitazone is 30 mg (ATC code: 18 
A10BG03) according to the WHO ATC/DDD system (WHO 2013). Table 5 lists 19 
thiazolidinedione-containing products, PBS codes assigned to each item, pack size, and 20 
dispensed price available on the PBS (PBS 2014). The dispensed prices of all 21 
thiazolidinedione-containing products were over both the concession and general co-22 
payment thresholds during the study period therefore all dispensing data were captured in 23 
the PBS database. 24 
Table 5. Details of rosiglitazone and pioglitazone listed on the PBS in 2011  25 
Name and strength PBS code Pack size Dispensed price 
Rosiglitazone 4 mg 8689H 28 $61.52 
Rosiglitazone 8 mg 8690J 28 $91.19 
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Rosiglitazone 2 mg with 500 mg 
metformin 
9059T 56 $64.32 
Rosiglitazone 2 mg with 1000 mg 
metformin 
9060W 56 $66.96 
Rosiglitazone 4 mg with 500 mg 
metformin 
9061X 56 $93.99 
Rosiglitazone 4 mg with 1000 mg 
metformin 
9062Y 56 $96.63 
Pioglitazone 15 mg 8694N 28 $53.00 
Pioglitazone 30 mg 8695P 28 $77.62 
Pioglitazone 45 mg 8696Q 28 $99.01 
3. Chapter aims 1 
This chapter aims to evaluate the warnings of adverse effects related to the 2 
thiazolidinedione drug class  3 
Specific aim 1: To compare the timing and content of warnings between local authority—4 
the TGA and international authorities—the FDA and EMA. 5 
Specific aim 2: To investigate the impact of warnings from the TGA, FDA and EMA on the 6 
changes in national dispensing patterns of the thiazolidinedione drug 7 
class in the PBS. 8 
4. Published Manuscript entitled “Utilisation trends of rosiglitazone 9 
and pioglitazone in Australia before and after safety warnings” 10 
The manuscript entitled “Utilisation trends of rosiglitazone and pioglitazone in Australia 11 
before and after safety warnings” is published in the BMC Health Services Research, 12 
14:151 (2014) (Appendix 1).  13 
The co-authors contributed to the manuscript as follows: PhD candidate, Suvimol 14 
Niyomnaitham, designed the study under the supervision of Dr Alesha Smith, Dr Adam La 15 
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Caze, and Dr Karen Whitfield. The PhD candidate performed all data collection and data 1 
analysis with biostatistics help from Dr Andrew Page. Suvimol Niyomnaitham took the lead 2 
role in manuscript preparation and writing. All co-authors revised the manuscript for 3 
intellectual content and approved the final manuscript. The manuscript presented in this 4 
chapter has been adjusted to fit the overall style of the thesis. 5 
  6 
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Utilisation trends of rosiglitazone and pioglitazone in Australia 1 
before and after safety warnings 2 
Suvimol Niyomnaitham1,2*, Andrew Page3, Adam La Caze1, Karen Whitfield1, Alesha J. 3 
Smith1,4 4 
1School of Pharmacy, University of Queensland, Australia, 2Faculty of Medicine Siriraj 5 
Hospital, Mahidol University, Thailand, 3School of Pharmacy, University of Otago, New 6 
Zealand 7 
ABSTRACT 8 
Background  9 
A series of drug safety warnings have recently been made by drug authorities relating to 10 
adverse effects of rosiglitazone and pioglitazone on cardiovascular diseases and bladder 11 
cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in 12 
Australia following the timing of these various health authority warnings such as the 13 
Australian Therapeutic Good Administration (TGA), European Medicines Agency (EMA) 14 
press releases or U.S. Food and Drug Administration (FDA) is unknown. This study 15 
investigated the utilisation patterns of rosiglitazone and pioglitazone in Australia before 16 
and after warnings of major drug authorities. 17 
Methods  18 
We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit 19 
Scheme (PBS) subsidised drug dispensing data for the Australian population from 20 
February 2004 to July 2012. The World Health Organisation Anatomic Therapeutic 21 
Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the drug 22 
utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, 23 
which first occurred in May 2007. The DDD/1000population/day were examined in a series 24 
of time-series regression analysis with the drug safety warnings specified as interventions. 25 
Results  26 
Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 27 
1.96/1000population/day in January 2007. Then rosiglitazone use decreased significantly 28 
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after the initial EMA press release and FDA warning on cardiovascular risk in May 2007 1 
(with a 15.04% average monthly decline, p-value<0.001), however use did not significantly 2 
decrease after the TGA warning or subsequent EMA and FDA warning. Pioglitazone 3 
utilisation proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day 4 
during 2009–2010. However, pioglitazone utilisation has slightly declined after the FDA, 5 
EMA, and TGA warnings related to bladder cancer.  6 
Conclusions  7 
Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone 8 
utilisation in Australia. Rosiglitazone began to decline prior to TGA warnings in December 9 
2007, which suggests that Australian prescribers may have acted in response to scientific 10 
evidence or international safety warnings (EMA, FDA), prior to the response of the TGA. 11 
Minor effects were observed after bladder cancer warnings on pioglitazone utilisation. 12 
Background 13 
Thiazolidinediones (TZDs) were approved for type 2 diabetes mellitus treatment based on 14 
efficacy studies, which showed a decrease in HbA1c, by 0.8–1.5% and improved insulin 15 
sensitivity (Aronoff et al. 2000; Phillips et al. 2001). Both TZDs, rosiglitazone and 16 
pioglitazone, were listed on the Australian Pharmaceutical Benefit Scheme (PBS) as 17 
subsidised second line therapy with either metformin or a sulfonylurea in November 2003 18 
and later extended to triple oral therapy with metformin and a sulfonylurea and in 19 
combination with insulin. 20 
In May 2007, a meta-analysis by Nissen and Wolski found a small increased risk in 21 
myocardial infarction and a borderline increase in cardiovascular death in patients treated 22 
with rosiglitazone (Nissen et al. 2007); however, another ongoing clinical trial evaluating 23 
cardiovascular outcomes of rosiglitazone showed cardiovascular events associated with 24 
rosiglitazone (Home et al. 2007) to be inconclusive. Because cardiovascular disease can 25 
be a lethal complication in patients with diabetes mellitus, several studies have tried to 26 
establish the adverse cardiovascular effect associated with rosiglitazone treatment (Gerrits 27 
et al. 2007; Bilik et al. 2010).  28 
Since then, drug regulatory authorities have investigated these cardiovascular effects and 29 
issued several warnings on the use of rosiglitazone (Weatherby et al. 2002; FDA 2010). 30 
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The Australian regulatory authority, the Therapeutic Goods Administration (TGA) is 1 
responsible for ensuring the safety of medical products within Australia. The TGA 2 
distributes safety information to healthcare professionals through the “Safety Advisory” on 3 
the TGA’s website, similar to that of the U.S. Food and Drug Administration (FDA) drug 4 
safety communication and European Medicines Agency (EMA) press releases.  5 
Since late 2008, the PBS steadily limited the subsidisation of rosiglitazone use in 6 
combination with insulin and triple oral therapy. On 1 July 2011, the PBS restricted 7 
prescription of rosiglitazone by requiring prior telephone approval. 8 
While the meta-analysis raised a concern around the cardiovascular risk of rosiglitazone, a 9 
study of pioglitazone showed that in comparison it was a safe alternative with an 10 
insignificant increase in mortality, myocardial infarction and stroke (Lincoff et al. 2007). 11 
Pioglitazone also reduced the risk of hospitalisation for acute myocardial infarction in 12 
patients with type 2 diabetes in comparison with rosiglitazone (Lincoff et al. 2007; 13 
Erdmann et al. 2010). In June 2011, a French study suggested an increased risk of 14 
bladder cancer in patients who were treated with pioglitazone for more than one year 15 
leading to a temporary withdrawal of pioglitazone by the French Agency. Another study in 16 
the US also indicated a possible increase in bladder cancer risk in patients on pioglitazone 17 
for more than 2 years, compared with diabetes patients who were not receiving 18 
pioglitazone (Lewis et al. 2011; Mamtani et al. 2012). The TGA, as well as FDA and EMA, 19 
announced safety warnings outlining a possible risk of bladder cancer related to 20 
pioglitazone use in June–July 2011; however, there have been no further updates on this 21 
issue. 22 
The increasing risk of cardiovascular disease with rosiglitazone led to a decrease in the 23 
utilisation patterns, in the US (Starner et al. 2008; Cohen et al. 2010) and some countries 24 
in Europe (Stewart et al. 2009; Ruiter et al. 2012). It is expected that after the bladder 25 
cancer warnings, pioglitazone will follow a similar utilisation trend to that of rosiglitazone. 26 
However, it is plausible that pioglitazone use may have slightly changed as a result of 27 
prescribers weighing up the benefit in blood sugar control and prevention of cardiovascular 28 
events versus the possible increased risk of bladder cancer, which has a very low 29 
incidence (3 cases per 1000 pioglitazone users) (Lewis et al. 2011; Mamtani et al. 2012). 30 
The dispensing patterns of rosiglitazone and pioglitazone following the emerging 31 
cardiovascular event and safety warnings have not been described in Australia, although it 32 
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is hypothesised that the trends will follow that of the US and Europe. This study aims to 1 
describe the patterns of rosiglitazone and pioglitazone use, and investigate the influential 2 
factors on changes of utilisation in Australia, with special focus on the safety warnings by 3 
TGA, FDA and EMA. 4 
Methods 5 
Data sources 6 
Drug utilisation among populations over time can be examined using the World Health 7 
Organization Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system. 8 
Data on monthly dispensing were obtained from the PBS database, a national 9 
administrative scheme which records drugs subsidised by the Government for Australian 10 
citizens. The PBS database captures all subsidised drug formulations, cost and amount of 11 
dispensing and period of drug dispensed by pharmacists for patients used at home. Drug 12 
dispensed data on the PBS database were used in research studied and shown to 13 
represent trends of drug utilisation in Australia (Hollingworth et al. 2010; Islam et al. 2014). 14 
Rosiglitazone and pioglitazone are listed as subsidised drugs for all Australians therefore a 15 
complete record of dispensed medicines was obtained. Denominator populations from 16 
Centrelink and the Australian Bureau of Statistics were used to calculate the DDD per 17 
1000 population per day (the proportion of the population receiving a DDD of this drug per 18 
day). All the data for this study were aggregated, routinely collected and publically 19 
available via government sources, therefore ethics approval was not required.  20 
Australian drug safety warnings for rosiglitazone and pioglitazone were acquired from 21 
safety alerts and safety information for health professionals on the TGA website. We 22 
accessed the EMA’s safety announcements, called “press releases”, and the FDA drug 23 
safety communication from their official websites. Since mid-2007, major drug authorities 24 
have issued safety warnings related to rosiglitazone and pioglitazone. The first TGA 25 
announcement which highlighted the increased risk of ischemic heart disease associated 26 
with rosiglitazone was issued in December 2007 (TGA1), followed by a second warning to 27 
avoid using rosiglitazone in patients with ischemic heart disease in September 2010 28 
(TGA2). The FDA had three announcements related to cardiovascular risk of rosiglitazone; 29 
firstly, a safety alert in May 2007 (FDA1), a label update on heart-related risks in August 30 
2007 (FDA2), and then restrictions on rosiglitazone use in September 2010 (FDA3). There 31 
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were four EMA press releases on risk of ischemic heart disease in May 2007 (EMA1), 1 
October 2007 (EMA2), January 2008 (EMA3) and September 2010 (EMA4). While the 2 
TGA and FDA still allowed rosiglitazone on the market, the EMA suspended all medical 3 
products containing rosiglitazone across Europe in September 2010. 4 
For pioglitazone, the FDA issued a warning on a possible increased risk of bladder cancer 5 
in patients who used pioglitazone for longer than one year in June 2011, followed by the 6 
same warnings in the EMA press release and the TGA safety advisory in July 2011. 7 
Whilst there were other plausible types of information sent to prescribers with regards to 8 
the drug safety, it is recognised that the warnings from the FDA, EMA and TGA have a 9 
large influence on drug safety communication. For example, the pharmaceutical 10 
companies marketing these medicines did not implement changes to the Product 11 
Information until after the TGA announcement. In Australia, medical media picked up this 12 
side effect once it came out from the FDA as well as medical associations issued the FDA 13 
warning on their articles. 14 
Analyses 15 
Monthly dispensing data of rosiglitazone and pioglitazone from January 2004 to July 2012 16 
were converted to DDD/1000population/day. Descriptive trends in rosiglitazone and 17 
pioglitazone utilisation were examined in the time series of DDD/1000pop/day. The auto-18 
regressive, integrated, moving average model (ARIMA) integrates the temporal size and 19 
direction dependency (autocorrelation) inherent in time-series data to better characterise 20 
changes in data over a period of time (Box GEP 1975). Autocorrelation functions (ACF) 21 
and partial autocorrelation functions (PACF) was used to obtain the best fitted model for 22 
analysis as well as the Bayesian Information Criteria. The percentage change in 23 
DDD/1000pop/day was used to remove the month to month trend component of the time 24 
series before fitting into ARIMA models. The separate and combined effects of the 25 
announcement of the EMA, FDA, and TGA warnings on trends in rosiglitazone and 26 
pioglitazone utilisation were also investigated by fitting into ARIMA models. Impacts of 27 
drug safety warnings (interventions) on the subsequent observations were then 28 
investigated using the ARIMA model as a step-function (having a permanent and 29 
immediate impact on any subsequent trends). All statistical analyses were performed with 30 
a 5% statistical significance level using STATA 12.1 (StataCorp, College Station, TX). 31 
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Results 1 
A total of 1,686,087 rosiglitazone prescriptions and 2,405,881 pioglitazone prescriptions 2 
were dispensed during January 2004–July 2012. We calculated the monthly utilisation 3 
(DDD/1000population/day) using Australian population data, which was in the range of 4 
20.1 million in 2004 to 22.9 million in 2012. As shown in Figure 3, the rosiglitazone 5 
utilisation increased steadily from 2004 and reached the peak in January 2007 with a 6 
defined daily dose of 1.96 per 1000 people per day. However, in May 2007, the trend of 7 
rosiglitazone utilisation started decreasing and remaining lower than 0.50 8 
DDD/1000pop/day in May 2009 and 0.15 DDD/1000pop/day in July 2011. Pioglitazone 9 
utilisation has exceeded rosiglitazone use since September 2008 and remained stable 10 
during 2009–2010 (1.5–1.7 DDD/1000pop/day). Nevertheless, the trend of pioglitazone 11 
utilisation appeared to decrease in September 2011. 12 
 13 
Figure 3. Utilisation of rosiglitazone and pioglitazone by the Australian population 14 
between 2004–2012.  15 
The drop-down lines indicate months of drug safety warnings issued. 16 
Rosiglitazone warnings 17 
EMA1 Reminded the risk of rosiglitazone in patients with cardiac failure and other cardiac disorders 18 
including myocardial infarction.  19 
FDA1 Advised to evaluate the antidiabetic treatment options other than rosiglitazone in patients who have 20 
underlying heart disease and high risk of heart attack. 21 
FDA2 Adds box warnings for heart-related risks of rosiglitazone. 22 
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EMA2 Suggested that rosiglitazone should only be used after careful evaluation of ischemic heart 1 
disease. 2 
TGA1 Advised that rosiglitazone should not be prescribed for patients with known ischemic heart disease 3 
or at high risk for ischemic heart disease. 4 
EMA3 Suggested that rosiglitazone must not be used in patients with an acute coronary disease. 5 
EMA4 Recommended suspension of all rosiglitazone-containing products. 6 
FDA3 Restricts access to rosiglitazone due to an elevated risk of cardiovascular events. 7 
TGA3  Reinforced that rosiglitazone should not be used in patients with known ischemic heart disease. 8 
Pioglitazone warnings 9 
FDA  Announced the warnings on a possibly increased risk of bladder cancer in patients who used 10 
rosiglitazone for longer than one year. 11 
TGA  Advised the prescribers that use of pioglitazone for more than a year may be associated with an 12 
increased risk of bladder cancer. 13 
EMA  Recommends new contraindications and warnings for pioglitazone to reduce small increased risk 14 
of bladder cancer. 15 
 16 
There are no seasonal autocorrelation detected for both rosiglitazone and pioglitazone 17 
utilisations. Based on visual inspection of PACF and ACF plots, an ARIMA (1,0,2) model 18 
best characterised for rosiglitazone data and pioglitazone data was best characterised as 19 
an ARIMA (1,0,1). Findings from ARIMA models indicated that the utilisation of 20 
rosiglitazone decreased significantly after the EMA1 and FDA1 warnings by 15.04%. This 21 
decline was seen after the intervention in June 2007 compared to before the warnings 22 
(p<0.001) (Table 6). Additionally, the utilisation of rosiglitazone also significantly 23 
decreased following warnings from FDA2, EMA2, TGA1, and EMA3. However, after 24 
adjustment for FDA2, EMA2, TGA1, and EMA3 for preceding warnings, effects were 25 
attenuated and were no longer statistically significant (Table 6). Later warnings relating to 26 
EMA4, FDA3, and TGA2 were not significantly associated with decreases in rosiglitazone 27 
use (Table 6). 28 
Table 6. Effects of drug warnings on the utilisation of rosiglitazone and 29 
pioglitazone 30 
Drug 
authorities 
Month-
year 
Warnings Adjusted 
for 
Coefficienta 95%CIb p-value 
Rosiglitazone: ARIMA (1,0,2) model 
EMA1_FDA1  May 2007 Ischemic heart  -15.04 [-21.86, -8.22] <0.001 
FDA2 Aug 2007 Label update EMA1_FDA1 -2.61 [-40.41, 35.20] 0.893 
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aCoefficient=Percentage change in magnitude and direction after the intervention; bCI=confidence interval; 1 
TGA=Therapeutic Good Administration; EMA=European Medicines Agency; FDA=U.S. Food and Drug 2 
Administration; EU=European Union; US=United States of America 3 
 4 
For pioglitazone, although we can see a decline after the FDA, TGA, and EMA warnings 5 
on bladder cancer in June–July 2011, there is no statistically significant effect on 6 
subsequent pioglitazone use after fitting this into ARIMA model (Table 6).  7 
Discussion 8 
The changes of rosiglitazone and pioglitazone utilisation were observed between 2004 and 9 
2012 in Australia. It is always difficult to attribute cause to utilisation trends, however it is 10 
likely that increased marketing of TZDs may have contributed to the increasing trend of 11 
rosiglitazone during 2004–2006 or that fewer alternatives to metformin, sulfonylurea, and 12 
insulin were available at this time. Our results show a decreasing trend in rosiglitazone 13 
utilisation in the period after the drug authorities’ warnings in 2007–2008. Although the 14 
numbers of rosiglitazone prescriptions in Australia are relatively low in comparison to the 15 
UK, and North America, the overall trends are consistent with those shown in Europe and 16 
North America (Starner et al. 2008; Stewart et al. 2009; Shah et al. 2010; Ruiter et al. 17 
2012). There are two possible explanations for the dip seen in April 2007. It might be a 18 
heart related 
EMA2 Oct 2007 Ischemic heart EMA1_FDA1, 
FDA2 
1.94 [-95.49, 99.36] 0.969 
TGA1 Dec 2007 Ischemic heart EMA1_FDA1, 
FDA2, EMA2 
-5.25 [-38.01, 27.51] 0.837 
EMA3 Jan 2008 Ischemic heart EMA1_FDA1, 
FDA2, EMA2, 
TGA1 
-0.39 [-80.06, 79.28] 0.992 
FDA3, TGA2, 
EMA4 
Sep 2010 EU suspended, 
US restriction 
EMA1_FDA, 
FDA2, EMA2, 
TGA1, EMA3 
1.25 [-8.99, 11.49] 0.811 
Pioglitazone: ARIMA (1,0,1) model 
FDA June 2011 Bladder cancer  -5.76 [-13.91, 2.39] 0.166 
EMA, TGA July 2011 Bladder cancer  -6.57 [-14.80, 1.65] 0.117 
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seasonal trend as the same fluctuation was noted in March–April 2006; however, this was 1 
not sensitive enough to be detected by the ARIMA model. Secondly, the dip is an artifact 2 
of the data, this is actually the utilisation on its way up which is demonstrated by the higher 3 
use again in May 2007. 4 
The sharply decreasing utilisation trend is significantly attributable to the safety alert from 5 
meta-analysis study and the initial warnings from the EMA and FDA in May 2007. For the 6 
reason that the FDA issued the cardiovascular alert of rosiglitazone on the same day as 7 
publication by Nissen et al. (Nissen et al. 2007), we could not distinguish the effects 8 
between the authority warnings and the publication. Furthermore, the effects of these 9 
warnings and associated literature are likely to be cumulative rather than a discrete effect 10 
on the following utilisation. Several restrictions in rosiglitazone subsidies from the PBS 11 
during October 2008–February 2009 were also examined; however, these impacts are not 12 
significant after adjustment for previous warnings. As a result of the consecutive series of 13 
cardiovascular warnings on rosiglitazone since 2007 and the limited access on PBS, the 14 
numbers of rosiglitazone prescriptions have remained lower than 5,000 per month since 15 
2010. 16 
Australian utilisation of pioglitazone was less than half of rosiglitazone during 2005–2007 17 
and the increasing trend in use was moderate compared to the Netherlands and the US 18 
(Cohen et al. 2010; Ruiter et al. 2012). From 2008–2010, when peak levels were reached, 19 
the increase in pioglitazone nearly mirrors the decline in rosiglitazone. The findings 20 
suggest that prescribers might have replaced rosiglitazone with the same drug class 21 
pioglitazone (Starner et al. 2008; Hurren et al. 2011), due to the reported cardiovascular 22 
benefits of pioglitazone, and no clinical outcome associated with an increase risk of 23 
ischemic heart disease that was seen with rosiglitazone (Gerrits et al. 2007; Erdmann et 24 
al. 2010). While the decreasing trend of pioglitazone was observed in the US and Europe 25 
in 2008 (Hurren et al. 2011; Ruiter et al. 2012), Australian pioglitazone utilisation plateaued 26 
until 2011. The delay in decreasing trend compared to that of other countries may be 27 
attribute to limited availability of second-line and third-line therapy alternatives such as 28 
sitagliptin (was not PBS subsidised until August 2008) or exenatide (was not PBS 29 
subsidised until August 2010). The US and UK data (Hurren et al. 2011; Leal et al. 2013) 30 
show that the number of other new drugs, which were available in their markets since 31 
2007 such as sitagliptin and exenatide, increased after the cardiovascular alerts of TZD. 32 
Nevertheless, Figure 3 shows the decline in the utilisation of pioglitazone after July 2011. 33 
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This decreasing trend may have been caused by more alternative treatments on the PBS 1 
or the safety concern of increased risk of bladder cancer in long-term users of 2 
pioglitazone. Although, this decline was of a lesser magnitude than for rosiglitazone, 3 
prescribers may consider the risk/benefit ratio, where the benefits of pioglitazone in 4 
lowering blood sugar outweigh the possible risk of bladder cancer (Kostapanos et al. 5 
2012). However, more data points following this bladder cancer risk might be needed to 6 
examine the true effect of this warning.  7 
Since TGA safety warnings are considered by the Australian Department of Health and 8 
Aging to be first-line alerts to healthcare providers, we would expect to see a significant 9 
effect on these utilisations. However, the fact that a) the decline in rosiglitazone use 10 
occurred prior to the first TGA warning, and b) after we adjusted for the preceding EMA, 11 
FDA warnings, we could not see a significant effect of the TGA warning on utilisation 12 
trends suggests that Australian prescribers were aware of the international warnings as 13 
well as the safety information from the literature. This might be associated with the way 14 
that information was delivered, since Australian warnings were delayed, less frequently 15 
communicated, and accessed compared to the FDA and European warnings (Buckley et 16 
al. 2011). Australian practitioners may receive safety information from medical articles or 17 
media that referred to the US or European warnings. A further qualitative study is being 18 
conduct to gain the insight into sources of drug safety information among Australian 19 
prescribers. 20 
Since time series model prediction is based on the pattern of drug use in the past 21 
confounding influences on data may be difficult to disentangle. Although trends can be 22 
impacted by temporal changes in drug supply or the way data are recorded, we did not 23 
find those problems during study period. Furthermore, the Australia PBS data is 24 
aggregated data collected for administrative purposes, which does not link utilisation to the 25 
prescribing data in clinical settings. Therefore, clinical reasons for the decrease in 26 
dispensing cannot be fully investigated, nor primary non-compliance in patients be 27 
established. 28 
The strength of this study is that it captures almost all prescriptions dispensed over 2004–29 
2012 in total Australian population (private prescriptions represent a very small percentage 30 
of all prescriptions). This is achieved because rosiglitazone and pioglitazone are ‘high’ cost 31 
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drugs that are government subsidised in Australia. This allowed us to investigate the 1 
patterns of population based thiazolidinedione utilisation. 2 
Conclusions 3 
The utilisation of rosiglitazone significantly decreased following the authorities’ safety 4 
warnings on ischemic heart disease. The pattern of rosiglitazone utilisation started 5 
declining significantly prior to the TGA warning in December 2007; therefore it appears 6 
that Australian prescribers were alerted by the literature and international warnings such 7 
as EMA and FDA. In contrast, pioglitazone utilisation increased during the rosiglitazone 8 
warning period during 2007–2010. In comparison to the US and Europe, the decline in the 9 
trend of pioglitazone use maybe due to a lack of second and third line therapies in 10 
Australia. Despite concerns surrounding the possible risk of bladder cancer with long term 11 
use of pioglitazone, this study showed weaker effects of safety warnings on bladder 12 
cancer and pioglitazone utilisation. A number of publications have studied the effect of 13 
authorities’ warnings in the US and Europe to improve their warning systems (Esterly et al. 14 
2011; Sen et al. 2011; Ruiter et al. 2012). This is one of the first studies to date that has 15 
investigated utilisation patterns in relation to drug safety warnings in Australia and 16 
suggests that TGA warnings may not affect prescribing in cases such as this where 17 
prescribers may be attuned to particular medicine safety issues described in earlier 18 
international warnings or literature. Further research is needed to understand how and 19 
when prescribers obtain drug safety information in Australia. This is particularly pertinent 20 
as Australia and New Zealand look to combine their drug safety warning systems. 21 
5. Additional analyses 22 
Sensitivity analyses of rosiglitazone and pioglitazone utilisation were performed using 23 
segmented regression modelling. 24 
5.1 Sensitivity analysis of rosiglitazone utilisation 25 
The segmented regression model was fitted to a least squared regression line for each 26 
segment of DDD/1000population/day of rosiglitazone before and after the EMA and FDA 27 
warning in June 2007. Parameter estimates, standard errors and p-values from segmented 28 
regression models predicting the DDD of rosiglitazone have been included in Table 7. 29 
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The times series regression equation for this analysis is  1 
ŷt =β0 + β1 × Time + β2 × Intervention+ β3 × Time_post_intervention + et 2 
; ŷt is the independent outcome variable (DDD/1000population/day). Time is the number of 3 
months, starting from February 2004 as 1, and then increasing by 1 for every month. 4 
Intervention is a variable with the value 0 for the segment before the FDA_EMA warning 5 
and 1 for the segment after the FDA_EMA warning. Time_post_intervention is the number 6 
of months after the EMA_FDA warning, starting from June 2007, with the value 0 for the 7 
segment before the warning. et is the random variation at time t not explained by the 8 
model. 9 
The coefficient β0 estimates the baseline level of the rates at which DDD/1000pop/day of 10 
rosiglitazone was at the beginning of the observation; β1 estimates the base rate trend 11 
before the EMA_FDA warning; β2 estimates the change in rate level after the EMA_FDA 12 
warning. It is the measurement of rate change from the last time point before the warning 13 
to the first time point after the warning; β3 estimates the change in rate slope after the 14 
warning. 15 
 16 
Figure 4. Monthly daily drug dose of rosiglitazone per 1000 population per day in 17 
the PBS database from February 2004 to July 2012 18 
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The results indicated that before the EMA_FDA warning, there was a significant month-to-1 
month increase in the trend of rosiglitazone by 0.053 DDD/1000pop/day (p-value for pre-2 
intervention trend <0.001). Right after the warning in June 2007, there was a slight 3 
decrease in the DDD of rosiglitazone from the month before (β2=0.1, from 1.88 in May 4 
2007 to 1.78 in June 2007) but this decrease was not significant.  5 
There was a significant decrease in the month-to-month trend of rosiglitazone by 0.027 6 
DDD/1000pop/day after the EMA and FDA warning (p-value for post-intervention trend 7 
<0.001). The visual inspection of Figure 4 and results of segmented regression modelling 8 
suggested that the post-intervention trend was in a different direction to the pre-9 
intervention trend. The effect of the warning in June 2007 resulted in a decrease of 10 
rosiglitazone dispensing. For example, at 12 months after the warning, the utilisation of 11 
rosiglitazone was 1.05 DDD/1000pop/day while the predicted utilisation calculated from 12 
the baseline trend (β1) was 2.579 DDD/1000pop/day. 13 
Table 7. Parameters from segmented regression model of 14 
DDD/1000population/day of rosiglitazone in the PBS database 15 
 Coefficient Standard 
error 
t-statistic p-value 
Intercept (β0) -0.2 7 0.041 -5.27 <0.001 
Baseline trend (β1) 0.0528 0.002 26.77 <0.001 
Level change after 
warning (β2) 
-0.100 0.016 -0.11 0.99 
Trend change after 
warning (β3) 
-0.0274 0.002 -16.62 <0.001 
5.2 Sensitivity analysis of pioglitazone utilisation 16 
Firstly, the spike of pioglitazone utilisation in June 2012 was balanced by using the mean 17 
difference of the point before (May 2012) and the point after (July 2012). In this study, two 18 
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models of segmented regressing modelling were performed as sensitivity analyses: two-1 
segmented regression and three-segmented regression models.  2 
In two-segmented regressing model, the pioglitazone utilisation was divided into two 3 
segments before and after the FDA warning in June 2011. Subsequently, a least squared 4 
regressing line to each segment was fitted into the model.  5 
The two-segmented regression equation for this analysis is  6 
ŷt =β0 + β1 × Time + β2 × Intervention+ β3 × Time_post_intervention + et 7 
; ŷt is the independent outcome variable (DDD/1000population/day). Time is the number of 8 
months, starting from February 2004 as 1, and then increasing by 1 for every month. 9 
Intervention is a variable with the value 0 for the segment before the FDA warning and 1 10 
for the segment after the FDA warning. Time_post_intervention is the number of months 11 
after the FDA warning, starting from July 2011, with the value 0 for the segment before the 12 
warning. et is the random variation at time t not explained by the model. 13 
The coefficient β0 estimates the baseline level of the rates at which DDD/1000pop/day of 14 
pioglitazone was at the beginning of the observation; β1 estimates the base rate trend 15 
before the FDA warning; β2 estimates the change in rate level after the FDA warning. It is 16 
the measurement of rate change from the last time point before the warning to the first 17 
time point after the warning; β3 estimates the change in rate slope after the warning.  18 
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 1 
Figure 5. Monthly daily drug dose of pioglitazone per 1000 population per day and 2 
predicted lines of segments before and after the FDA warning in the PBS 3 
database from February 2004 to July 2012 4 
Figure 5 depicts the pioglitazone utilisation in the PBS database and the predicted trends 5 
of segments before and after the warning based on the least square regression. The 6 
results indicated that before the FDA warning, there was a significant month-to-month 7 
increase in the trend of pioglitazone by 0.021 DDD/1000population/day (p-value for pre-8 
intervention trend <0.001). There was a slight increase in the pioglitazone utilisation from 9 
the month before the FDA warning but this increase was not significant (Table 8).  10 
The change in trends of the two predicted lines in Figure 5 suggested a significant impact 11 
by the warning on the trend of pioglitazone utilisation. There was a decrease in the month-12 
to-month trend of pioglitazone by 0.026 DDD/1000population/day after the FDA warning; 13 
however, this decrease was not statistically significant (p-value for post-intervention trend 14 
0.054).  15 
Table 8. Parameters from two-segmented regression model of 16 
DDD/1000population/day of pioglitazone in the PBS database 17 
 Coefficient Standard 
error 
t-statistic p-value 
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Intercept (β0) 0.009 0.026 0.34 0.732 
Baseline trend (β1) 0.021 0.001 30.86 <0.001 
Level change after 
warning (β2) 
-0.100 0.016 -0.11 0.99 
Trend change after 
warning (β3) 
-0.026 0.012 -2.15 0.054 
Although slopes of segments before and after the warning are different in the two-1 
segmented regression model, a plateau was observed from January 2010 to June 2011 2 
(before the warning). Therefore, the three-segmented regression model was fitted by 3 
dividing the period before the warning into two segments: the segment between February 4 
2004 - December 2009 and the segment between January 2010 - June 2011. Figure 6 5 
depicts the pioglitazone utilisation in the PBS database and three predicted lines from the 6 
three-segmented regression model.  7 
 8 
Figure 6. Monthly daily drug dose of pioglitazone per 1000 population per day and 9 
predicted lines of three segments in the PBS database from February 10 
2004 to July 2012 11 
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The visual inspection of Figure 6 and results from the three-segmented regression model 1 
(Table 9) suggested a slight decrease of month-to-month pioglitazone utilisation by 0.006 2 
DDD/1000population/day from January 2010 - June 2011, although this decrease is not 3 
statistically significant (p-value 0.347). 4 
There was a month-to-month decrease in the post-intervention trend by 0.026 5 
DDD/1000population/day but this decrease was not statistically significant. In comparison 6 
to the segment (January 2010 - June 2011) before the warning, the impact of the FDA 7 
warning resulted in a more decrease in the trend of pioglitazone utilisation. 8 
Table 9. Parameters from two-segmented regression model of 9 
DDD/1000population/day of pioglitazone in the PBS database 10 
 Coefficient Standard 
error 
t-statistic p-value 
Intercept (β0) -0.012 0.027 -0.43 0.671 
Baseline trend (β1) 
(February 2004 -
December 2009) 
0.022 0.001 24.25 <0.001 
Level change (β2) 
from December 2009 
to January 2010  
0.35 0.016 1.23 0.709 
Trend (β3) 
(December 2009-
January 2010) 
-0.006 0.007 -0.97 0.347 
Level change after 
warning (β4) 
0.217 0.020 0.98 0.199 
Trend after warning 
(β5) 
-0.026 0.012 -2.15 0.054 
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6. Chapter conclusion 1 
This chapter described the utilisation of rosiglitazone and pioglitazone in the national PBS 2 
database and the impact of warnings issued by the TGA, FDA, and EMA on the patterns of 3 
drug use. The first warning issued by the TGA on the risk of cardiovascular events of 4 
rosiglitazone (in December 2007) was 6 months behind the warnings from the FDA and 5 
EMA (in May 2007). There were two safety communications on cardiac events related to 6 
rosiglitazone by the TGA, which seemed to be less frequent compared to the FDA and 7 
EMA communications (Buckley et al. 2011). The prevalence of dispensing rosiglitazone 8 
was highest in early 2007 when the first warnings from the FDA and EMA came out. The 9 
results in this chapter suggest that a decrease in dispensing trend of rosiglitazone was 10 
significantly associated with the warnings issued by the FDA and EMA. The impact of the 11 
TGA warning in December 2007 insignificantly changed the amplitude of the declining 12 
trend of rosiglitazone following previous warnings from the FDA and EMA. Findings from 13 
this study imply that prescribers stopped using rosiglitazone but how prescribers changed 14 
the management in patients taking rosiglitazone cannot be examined in this PBS 15 
database. 16 
Conversely to the decrease in rosiglitazone use following the cardiovascular warning, the 17 
prevalence of dispensing pioglitazone continuously increased and reached its plateau in 18 
late 2009. Since there was no evidence on an increased risk of myocardial infarction 19 
related to pioglitazone, prescribers may have switched from rosiglitazone to pioglitazone. 20 
In chapter 4, changes in antidiabetic prescriptions following warnings on rosiglitazone will 21 
be investigated using the AsteRx clinical data.  22 
The TGA warning on the bladder cancer risk related to pioglitazone was issued in the 23 
same period as other major regulatory warnings. However, there was no significant 24 
change to the pattern of pioglitazone use following these warnings. Further investigation 25 
into why different impacts of warnings on changes in patterns of rosiglitazone and 26 
pioglitazone were observed will be conducted using a combined interview and survey 27 
study in Chapter 6. 28 
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Chapter 4. The impact of thiazolidinedione warnings on the prescribing 1 
of drugs in the AsteRx database 2 
1. Synopsis 3 
The previous chapter investigated the impact of adverse events warnings on the national 4 
dispensing trends of rosiglitazone and pioglitazone. In this chapter, the AsteRx data 5 
provides further details on changes of prescribing rosiglitazone and pioglitazone following 6 
their warnings. Using the AsteRx data the prescribing trend of rosiglitazone significantly 7 
decreased after the warnings from the FDA and EMA in May 2007 similar to the 8 
dispensing trend seen in the PBS database. There were increases in the number of 9 
switches from rosiglitazone to pioglitazone and pioglitazone initiations after the 10 
cardiovascular warnings of rosiglitazone. The trend in the prescribing of pioglitazone 11 
insignificantly changed after the bladder cancer warning in June–July 2011. This is likely to 12 
be due to the availability of the new antidiabetic drug, dipeptidyl peptidase-4 inhibitors. 13 
2. Chapter aims 14 
The chapter aims to evaluate the impact of warnings from the TGA, FDA and EMA on the 15 
changes in prescribing details of patients using thiazolidinediones in the AsteRx database. 16 
3. Submitted Manuscript entitled “Impact of regulatory warnings on 17 
the prescribing rosiglitazone and pioglitazone in Australia” 18 
The manuscript entitled “Impact of regulatory warnings on the prescribing rosiglitazone 19 
and pioglitazone in Australia” is submitted to Research in Social & Administrative 20 
Pharmacy 2014.  21 
The co-authors contributed to the manuscript as follows: PhD candidate, Suvimol 22 
Niyomnaitham, designed the study under the supervision of Dr Alesha Smith, Dr Adam La 23 
Caze, and Dr Karen Whitfield. The PhD candidate performed all data collection and data 24 
analysis. Suvimol Niyomnaitham took the lead role in manuscript preparation and writing. 25 
All co-authors revised the manuscript for intellectual content and approved the final 26 
manuscript.  27 
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Purpose 1 
This study describes Australian prescribing patterns of rosiglitazone, following the 2 
warnings regarding myocardial infarction in 2007, and pioglitazone, following the warnings 3 
on the risk of bladder cancer in 2011. 4 
Methods 5 
Rosiglitazone and pioglitazone were described using the AsteRx database as proportions 6 
of total antidiabetic prescriptions from January 2005–April 2012. The database contains 7 
prescribing and other clinical details collected from 100 practices in Australia. Changes in 8 
prescribing trends after warnings from the Australian Therapeutic Goods Administration 9 
(TGA), US Food and Drug Administration (FDA), and European Medicines Agency (EMA) 10 
were investigated using the auto-regressive, integrated, moving average (ARIMA) model.  11 
Results 12 
The trend of rosiglitazone significantly declined after the warnings from FDA and EMA in 13 
May 2007 (p=0.001) using the ARIMA model. Within one year from May 2007, 14 
rosiglitazone fell from 7.2% to 3.1% of total antidiabetic prescriptions. The TGA warning in 15 
December 2007 had no significant effect on the declining trend of rosiglitazone prescribing 16 
after adjustment for the previous FDA and EMA warnings. Pioglitazone was the most 17 
popular switching choice from rosiglitazone after May 2007. That explained the upward 18 
trend of pioglitazone until its decline was observed in 2009. Warnings on the risk of 19 
bladder cancer in June–July 2011 did not have any significant effect on the ongoing 20 
decline of pioglitazone prescriptions. 21 
Conclusions 22 
Prescribing of rosiglitazone significantly decreased due to a series of warnings on cardiac 23 
risk. The 2011 warnings regarding the risk of bladder cancer were not significantly 24 
associated with changes in the pioglitazone prescribing. 25 
Introduction 26 
Recently, drug authorities issued several warnings on thiazolidinediones (TZDs) related to 27 
their risks on cardiovascular disease and bladder cancer. Rosiglitazone and pioglitazone 28 
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belong to the TZD drug class. Their efficacy in increasing insulin sensitivity helps improve 1 
glycemic control (e.g. HbA1c) in patients with type 2 diabetes (Bolen et al. 2007). 2 
However, long-term outcomes of TZDs were not known. In November 2003, TZDs were 3 
first listed on the Pharmaceutical Benefit Scheme (PBS), a national subsidised program for 4 
Australian citizens, for dual oral therapy with metformin or a sulfonylurea. Subsequently, 5 
the TZDs listing was extended to include in combination with insulin. Rosiglitazone was 6 
subsidised for triple oral therapy with metformin and a sulfonylurea in 2005 (PBAC 2007). 7 
During 2005-2006, studies suggested an increased risk of macular oedema and proximal 8 
fractures related to TZDs (Colucciello 2005; Bonds et al. 2006). However, the emerging 9 
risk of myocardial infarction among rosiglitazone users from a meta-analysis in May 2007 10 
raised the public awareness of potential harms of rosiglitazone treatment (Nissen et al. 11 
2007). Evidence for an increased risk of myocardial infarction in patients taking 12 
rosiglitazone was inconclusive from two large clinical studies (Gerstein et al. 2006; Kahn et 13 
al. 2006) and an interim analysis of cardiovascular outcomes of rosiglitazone (Home et al. 14 
2007). Major drug authorities promptly responded to the evidence of an increased risk of 15 
myocardial ischemia of rosiglitazone. Firstly, the FDA announced a safety concern on the 16 
same day as the meta-analysis was published on 21 May 2007 and then placed a Box 17 
warning on rosiglitazone in August 2007. In September 2010, the FDA restricted 18 
rosiglitazone via a registration program (Beermann et al. 2005; Berger et al. 2009; Bennett 19 
et al. 2010). The EMA issued three press releases on the cardiac risk related to 20 
rosiglitazone in May 2007, October 2007 and January 2008, followed by the suspension of 21 
all rosiglitazone products in September 2010 (Bhatt et al. 2006; Bhatia et al. 2008; Bhatt et 22 
al. 2010; Boisvert 2010). 23 
The Therapeutic Goods Administration (TGA) is a regulatory authority in Australia 24 
responsible for the safety of medicines. The TGA communicates new drug safety 25 
information to healthcare professionals by publishing ‘Alerts’ (as required) and every two 26 
months a ‘Medicines safety update’ on their website, similar to that of the US Food and 27 
Drug Administration (FDA) drug safety communication and the European Medicines 28 
Agency (EMA) press release. The TGA issued its first official warning on the myocardial 29 
infarction risk of rosiglitazone in December 2007 (Gaarder et al. 1961).  The TGA’s second 30 
warning released in September 2010 recommended avoiding rosiglitazone use in patients 31 
with cardiac conditions (TGA 2011). Although the EMA had suspended rosiglitazone 32 
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across Europe, the FDA and TGA still allowed rosiglitazone marketing in the US and 1 
Australia. 2 
In November 2008, rosiglitazone was no longer PBS subsidised for treatment in 3 
combination with insulin and triple oral therapy, as a result of the increased risk of 4 
congestive heart failure and myocardial infarction (2005; Cobitz et al. 2008). Subsequently, 5 
the PBS required telephone approval for rosiglitazone prescriptions from 1 July 2011. 6 
Studies suggest that pioglitazone is a safer alternative without evidence of an increase in 7 
myocardial infarction, stroke and mortality (Dormandy et al. 2005; Lipscombe et al. 2007). 8 
However, findings from a French study in 2011 showed an increased risk of bladder 9 
cancer related to long term treatment of pioglitazone which led to a temporary suspension 10 
of pioglitazone in France and Germany (Gaspar et al. 2010). A retrospective study from 11 
the US supported a possible risk of bladder cancer in patients using pioglitazone for more 12 
than two years compared to those who were not taking pioglitazone (Lewis et al. 2011). 13 
Safety warnings from the FDA in June 2011 and the EMA and TGA in July 2011 outlined 14 
the possible risk of developing bladder cancer when used more than 1 year (2005; 2007; 15 
Gaspar et al. 2010). 16 
Declining trends of thiazolidinedione utilisation after the safety warnings were found in a 17 
previous study using the national dispensing data (Niyomnaitham et al. 2014). To date 18 
there has not been an analysis of changes in thiazolidinedione use focusing on patient-19 
level data, such as that provided by the AsteRx database. To better understand the impact 20 
of drug safety warnings, we conducted a retrospective analysis investigating the changes 21 
to the prescribing of antidiabetic drugs in patients using rosiglitazone and pioglitazone after 22 
the safety warnings. 23 
Aims 24 
The goals of this study are to investigate the use of rosiglitazone and pioglitazone over the 25 
period 2005–2012 using the AsteRx clinical database and to describe the change in 26 
prescribing patterns after drug safety warnings. 27 
Materials and methods 28 
Data sources 29 
Chapter 4 
 106 
The AsteRx database contains clinical data from more than 100 medical practices in all 1 
states of Australia since 2003. De-identified demographic data of over half a million 2 
patients and six hundred doctors are collected. There are a total of seven million 3 
prescriptions including prescribing date, chemical name, strength, quantity, and drug code 4 
(WHO Anatomical Therapeutic Chemical Classification (ATC) system codes and 5 
Australian Pharmaceutical Benefits Scheme (PBS) item codes). PBS codes are unique for 6 
each drug formulation and strength and are used for dispensing and government 7 
reimbursement in Australia.  Diagnoses, consultations, and laboratory results are recorded 8 
in plain text (Gilard et al. 2008). 9 
1. Rosiglitazone and pioglitazone utilisation 10 
All antidiabetic prescriptions from 1 January 2005–30 April 2012 were extracted from the 11 
AsteRx database using ATC drug codes and PBS drug codes. ATC codes of oral 12 
antidiabetic drugs (biguanides, sulfonamides, alpha glucosidase inhibitors, dipeptidyl 13 
peptidase-4 inhibitors (DPP-4), thiazolidinediones, and combinations of oral antidiabetic 14 
drugs) including insulin and analogues were used to extract and identify classes of 15 
antidiabetic drugs. Each antidiabetic drug in a multiple anti-diabetes regimen contributed to 16 
each antidiabetic prescription where the premixed formulation, for example, Avandamet 17 
(rosiglitazone combined with metformin) was counted twice – one in rosiglitazone and one 18 
in metformin. We also used PBS codes to confirm the completeness of antidiabetic data 19 
capture. 20 
2. Discontinuation among patients using TZD 21 
All patients who were prescribed rosiglitazone or pioglitazone from January 2005–April 22 
2012 were identified using ATC codes and PBS codes. We only included patients who had 23 
at least two prescriptions of any kind of antidiabetic drug to confirm that the patients had 24 
diabetes. The use of the diagnostic data recorded as plain text entries into AsteRx was 25 
explored, but this data was found to be unreliable. 26 
All prescriptions of diabetes medicines after the first TZD prescription of each patient were 27 
investigated until the earliest of the following: a) 30 April 2012; b) termination of patient’s 28 
medical record; or c) discontinuation of the TZD treatment. 29 
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Dates at which patients discontinued their TZD were divided into: i) date of discontinuation 1 
of TZD in the treatment regimen without addition of any antidiabetic agent to an existing 2 
regimen after 60 days of the end of last TZD supply date (“stop” TZD date); ii) date of 3 
replacement of TZD by another antidiabetic agent in an existing regimen within 60 days of 4 
the end of last TZD supply date (“switch” TZD date). An antidiabetic agent that was 5 
prescribed to replace TZD in an existing regimen was defined as the “switching choice”. 6 
Drug safety warnings (interventions) 7 
Drug safety warnings in Australia were obtained from the TGA website under ‘Safety 8 
alerts’ and ‘Safety information for health professionals’ (Almadi et al. 2011). The safety 9 
announcement called ‘Press release’ from the EMA and the FDA drug safety 10 
communication were acquired from their official websites (Angiolillo et al. 2007; Almadi et 11 
al. 2011). In this study, we assessed the effects of the first safety announcements from 12 
each of the regulatory authorities on cardiac risk of rosiglitazone in May 2007 (EMA and 13 
FDA) and December 2007 (TGA). 14 
The effects of warnings on an increased bladder cancer risk related to long-term use of 15 
pioglitazone were investigated after June 2011 (FDA) and July 2011 (EMA and TGA). 16 
Analyses 17 
1. Changes in rosiglitazone and pioglitazone prescriptions 18 
Numbers of prescriptions for each antidiabetic drug were converted to a percentage of 19 
total monthly antidiabetic prescriptions. The combined formulation of rosiglitazone and 20 
metformin was attributed to thiazolidinedione drug class and rosiglitazone prescriptions. To 21 
investigate the prescribing trend, the percentage of rosiglitazone and pioglitazone 22 
prescriptions were assessed using the time series analysis called auto-regressive, 23 
integrated, moving average model (ARIMA). The ARIMA model has been used to 24 
investigate the impact of health care interventions on trends of drug use (Ferrand et al. 25 
2011; Langley et al. 2011; Ruiter et al. 2012). The ARIMA (p,d,q) model is an applied time-26 
series model developed by Box-Jenkins (Griffiths et al. 2000) to forecast future 27 
observations that occur at equal intervals and determine the effect of an intervention in 28 
time series data. p refers to accumulated effect of the preceding data and q is the most 29 
recent random shock carried over from one period to the next. d indicates number of 30 
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differences to achieve stationary of the trend. Firstly, the integration process is differenced 1 
(d) to make stationary data. Then autocorrelation functions (ACF) and partial 2 
autocorrelation functions (PACF) were plotted and visually observed to obtain the 3 
appropriate model (p, q) for analysis (McDowall 1980). The best fitted model for analysis 4 
was obtained using the Bayesian Information Criteria (Schwarz 1978). The coefficient (ω) 5 
represents the effect of warnings from the EMA, FDA, and TGA, which were tested for 6 
statistical significance on subsequent prescribing trends and were assumed as an abrupt 7 
and permanent effect in this study (McDowall 1980; Griffiths et al. 2000).  8 
2. Discontinuation among patients using TZD 9 
The proportion of patients who discontinued (stop/switch) rosiglitazone before and after: 10 
May 2007 (first EMA and FDA warnings on myocardial ischemia) and December 2007 (the 11 
first TGA warning) were investigated. The rate of discontinuations per patient using 12 
rosiglitazone during periods before/after warnings or incidence rate ratio (IRR) was 13 
analysed using Poisson regression (Cameron et al. 2013). We also limited the comparison 14 
period to two years before and after the warnings to further investigate the chance of 15 
discontinuation. STATA 12.1 (StataCorp, College Station, TX) was used to perform all 16 
statistical analyses with a 5% significance level. 17 
Results 18 
Diabetes diagnoses and prescriptions were examined in the AsteRx database to estimate 19 
diabetes prevalence. Among patients who were active in the AsteRx database (had at 20 
least one prescription of any medicines), 6.19% had a diabetes diagnosis or antidiabetic 21 
prescription. There was a total of 101,874 prescriptions for all antidiabetic drugs among 22 
29,125 patients from 1 January 2005–30 April 2012. Figure 4 shows the percentage of 23 
each antidiabetic drug class that was prescribed in the AsteRx database. A biguanide 24 
(metformin) was the most commonly prescribed antidiabetic drug class during the study 25 
period, followed by sulfonamide and insulin. Overall use of thiazolidinediones peaked at 26 
12.26% in May 2007 after that the number of prescriptions gradually decreased to 1.76% 27 
in December 2011. After DPP-4 became available in August 2008 and DPP-4 plus 28 
metformin in 2009, the combination of these DPP-4 prescriptions surpassed 29 
thiazolidinediones in May 2010. 30 
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 1 
Figure 7. Percentage of each antidiabetic drug in the AsteRx database from 2 
January 2005–April 2012 3 
The market share of rosiglitazone (including both rosiglitazone and 4 
rosiglitazone+metformin) progressively increased and reached its peak in May 2007 with a 5 
9.28% share of total antidiabetic prescriptions. After May 2007, the use of rosiglitazone 6 
declined substantially until the end of 2008 where prescriptions made up less than 2% of 7 
all antidiabetic prescriptions.  Pioglitazone rose over 3% during 2008 and overtook 8 
rosiglitazone prescriptions in September 2008. Pioglitazone started decreasing in October 9 
2008 and remained steady at approximately 2% of total use at the end of study period 10 
(Figure 5). 11 
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 1 
Figure 8. Percentage of rosiglitazone and pioglitazone from January 2005–April 2 
2012 in the AsteRx database. The dashed lines indicate released months 3 
of safety warnings.  4 
There were no seasonal autocorrelation detected for rosiglitazone or pioglitazone 5 
prescriptions in this database. Both rosiglitazone and pioglitazone data were stationary 6 
after one difference (d =1). The visual observation of PACF and ACF plots suggested an 7 
ARIMA (1,1,0) model to best characterize the rosiglitazone data and ARIMA (0,1,1) for 8 
pioglitazone data. The monthly percentage of rosiglitazone prescriptions was fitted into the 9 
ARIMA (1,1,0) model to investigate the effects of 1) the FDA and EMA warnings in May 10 
2007 and 2) TGA in December 2007 (Table 10). The proportion of rosiglitazone 11 
prescriptions decreased significantly after the FDA and EMA warnings (p=0.001). The 12 
declining trend of rosiglitazone was not significantly associated with the TGA warning 13 
(p=0.062). Although the p-value was significant in the ARIMA model after adjusting for the 14 
previous EMA and FDA warnings, the positive number of adjusted coefficient (ω=0.37) 15 
indicates the upward trend of the rosiglitazone from the TGA warning. Therefore, the TGA 16 
warning was also not significantly associated with the subsequent trend of rosiglitazone 17 
prescriptions after adjusting for the EMA and FDA warnings. For pioglitazone, a decline 18 
was observed after the FDA, EMA, and TGA warnings related to the risk of bladder 19 
cancer; however, this was not significant according to the ARIMA model. 20 
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Table 10. Effects of drug warnings on the trend of rosiglitazone and pioglitazone 1 
prescriptions in ARIMA models 2 
Drug 
authorities 
Month-
year Warnings 
Adjusted 
for 
Coefficient
a (ω) 95%CI
b p-valuec 
Rosiglitazone  ARIMA (1,1,0) 
EMA, FDA  May 2007 Myocardial infarction - -0.37 [-0.60, -0.15] 0.001 
TGA December 
2007 
Myocardial infarction - -0.19 [-0.40, 0.01] 0.062 
  EMA, FDA 0.37 [0.09, 0.65] 0.010 
Pioglitazone ARIMA (0,1,1) 
FDA June 
2011 
Bladder cancer - -0.13 [-0.32, 0.06] 0.191 
EMA, TGA July 
2011 
Bladder cancer - -0.10 [-0.32, 0.12] 0.374 
a Coefficient (ω) =Coefficients were transformed to percentage change in magnitude and direction after the 3 
intervention; bCI=confidence interval; cStatistical significance at p-value<0.05 is presented in bold; 4 
TGA=Therapeutic Good Administration; EMA=European Medicines Agency; FDA=US Food and Drug 5 
Administration 6 
 7 
We examined other factors that might have impacted on the trend of rosiglitazone and 8 
pioglitazone prescriptions. After adjustment for the first warning from the FDA and EMA, 9 
the PBS’s subsidy change and restriction in November 2008 and 2011 had insignificant 10 
associations with the decreasing trend of rosiglitazone. The introduction of DPP4 in late 11 
2008 was also not significantly associated with either rosiglitazone or pioglitazone 12 
prescriptions in the ARIMA models. 13 
Nine hundred and seven patients were prescribed rosiglitazone before May 2007 and 14 
twelve hundred and ninety five patients after May 2007. Approximately 20% of patients 15 
had evidence of rosiglitazone discontinuation (termination of rosiglitazone before the 16 
ending of their prescribing records) with 17.97% switching to another antidiabetic drug 17 
before the warning in May 2007 (Table 11). It is estimated that 35% of patients 18 
discontinued rosiglitazone after May 2007. The rate of rosiglitazone discontinuation (both 19 
switching and stopping) after May 2007 was 7.33 [95%CI 6.46–8.33] times the rate before 20 
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the FDA and EMA warnings in May 2007. When the comparison period is limited to two 1 
years before and after May 2007, the rate of rosiglitazone discontinuation during June 2 
2007–May 2009 is 5.70 [95%CI 4.79–6.79] times the incidence rate during June 2005–3 
May 2007. 4 
Table 11. Number of patients who discontinued rosiglitazone before and after the 5 
FDA and EMA warnings in May 2007 6 
Discontinuation January 2005–May 2007 June 2007–April 2012 
Switch 163 (17.97%)   414 (31.97%) 
Stop 19 (2.09%) 44 (3.4%) 
Total patients 907 1295 
For those who switched from rosiglitazone to another antidiabetic drug before May 2007, 7 
insulin was the most common switching choice (27%) along with 25% metformin, 24% 8 
sulfonamide, and 18% pioglitazone. After May 2007, the most common switching choice 9 
was pioglitazone (32%), followed by 24% metformin, 19% insulin, and 16% sulfonamide. 10 
Moreover, pioglitazone accounted for 47% of all switching choices in 2008 and 21% in 11 
2009. Many patients (n=150) discontinued rosiglitazone during June 2007–December 12 
2007, the period between the first EMA/FDA warnings and the TGA warning. 13 
Discussion 14 
In the AsteRx database, the diabetes prevalence (6.19%) was slightly higher than the 15 
Australian Health Survey 2011-2012, in which 4.6% of the Australian population self-16 
reported diabetes mellitus (Gladding et al. 2010). TZDs reached its highest share of overall 17 
antidiabetic prescriptions in 2007, which was considerably delayed compared to North 18 
America or Europe (between 2005–2006) (Starner et al. 2008; Stewart et al. 2009; Ruiter 19 
et al. 2012). Right at the peak of rosiglitazone use in May 2007, the FDA and EMA 20 
announced the warnings related to a meta-analysis study by Nissen on the risk of 21 
myocardial infarction and death (Nissen et al. 2007). A sharp decline of rosiglitazone was 22 
immediately observed after May 2007 and the change was statistically significant after 23 
fitting into the ARIMA model. This decreasing pattern is consistent with the overall 24 
rosiglitazone dispensing in the Australian PBS database as well as prescribing trends in 25 
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the US and Europe (Starner et al. 2008; Stewart et al. 2009; Ruiter et al. 2012; 1 
Niyomnaitham et al. 2014). The change in drug choice is more likely to be from an 2 
accumulation of events as opposed to a distinct singular effect from regulatory warnings. It 3 
is not possible to distinguish whether this decline was from discussion in the medical 4 
literature or initial safety warnings from the FDA and EMA. 5 
There was a 40% drop in rosiglitazone use during June 2007–December 2007 following 6 
two FDA warnings, two EMA warnings and many publications on the risk of myocardial 7 
ischemia (Lipscombe et al. 2007; Nissen et al. 2007; Singh et al. 2007). Consequently, the 8 
interrupted time series analysis suggested that the TGA warning in December 2007 did not 9 
have a further significant effect on the ongoing decline of rosiglitazone after adjustment for 10 
the previous EMA and FDA warnings. These findings indicate that Australian prescribers 11 
responded to the safety information from the literature and/or international warnings prior 12 
to the local TGA warning. There are many communication pathways for drug safety 13 
information including warnings, the literature, medical articles, or the media. The insight 14 
into sources of drug safety information is being conducted among Australian prescribers in 15 
a study linked to this project. 16 
The discontinuation rate of rosiglitazone after May 2007 was significantly higher than 17 
before the warnings. A sensitivity analysis of 2-year periods before and after the warnings 18 
also shows a higher discontinuation rate of rosiglitazone after the warnings on the risk of 19 
myocardial infarction. Pioglitazone was the most popular antidiabetic alternative among 20 
patients who switched from rosiglitazone after May 2007. In 2008 when pioglitazone 21 
surpassed rosiglitazone prescriptions, almost half of those prescribed pioglitazone was as 22 
a switched drug choice. Pioglitazone rose more than 200% from June 2007 to September 23 
2008 as a result of studies that showed no clinical evidence of myocardial infarction 24 
associated with pioglitazone (Dormandy et al. 2005; Lincoff et al. 2007). However, the use 25 
of pioglitazone was not sustained following the increased use of DPP4 in 2010 (Figure 4 26 
and 5). Studies in the US and UK showed a decline in pioglitazone prescriptions and an 27 
increase in prescriptions for new antidiabetic drugs such as sitagliptin and exenatide after 28 
the warnings in 2007. This difference is not surprising as there was no alternative third-line 29 
drug for diabetes treatment in Australia until sitagliptin was first listed on the PBS in August 30 
2008. 31 
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Figure 5 shows that the trend of pioglitazone prescribing started dropping at the end of 1 
2009. When we fitted pioglitazone prescriptions into the ARIMA model, the warnings on 2 
bladder cancer in 2011 did not change the magnitude of the declining pioglitazone. It is 3 
likely that due to a low incident rate of bladder cancer (3 cases per 1000 pioglitazone 4 
users) compared to the risk of cardiovascular disease, prescribers did not immediately 5 
stop prescribing pioglitazone as seen with rosiglitazone. They may consider that the 6 
benefits in glycemic control of pioglitazone outweigh the possible risk of bladder cancer. 7 
Changes in pioglitazone prescriptions may be observed if prescribing data was analysed 8 
after the end of the current study period (May 2012). 9 
Although the number of patients in the AsteRx database is a small proportion of 10 
Australians, the prescribing patterns of rosiglitazone and pioglitazone were comparable to 11 
the PBS dispensing trends indicating generalisability to the overall Australian population 12 
(Niyomnaitham et al. 2014). The AsteRx database allowed us to describe the changes in 13 
prescribing and antidiabetic preferences among Australian prescribers. 14 
Conclusions 15 
Our findings suggest that Australian prescribers discontinued rosiglitazone following 16 
warnings from the FDA and EMA on the risk of myocardial infarction. The TGA warning in 17 
December 2007 did not significantly add to the effect of the declining trend of rosiglitazone. 18 
Pioglitazone was the preferred choice for switching from rosiglitazone after May 2007. 19 
Differences were observed between the impact of cardiac warnings on rosiglitazone and 20 
bladder cancer warnings on pioglitazone, with the warnings related to the possible risk of 21 
bladder cancer in 2011 having no impact on the trend of pioglitazone prescriptions. A 22 
future qualitative study is designed to determine sources of drug safety information among 23 
Australian prescribers. 24 
ABBREVIATIONS 25 
TGA = Therapeutic good administration; EMA = European medicines agency; FDA = US 26 
food and drug administration; TZD = Thiazolidinedione; PBS = Pharmaceutical benefit 27 
scheme; ATC = Anatomical Therapeutic Chemical Classification; DPP-4 = Dipeptidyl 28 
peptidase-4 inhibitors; ARIMA = Auto-regressive, integrated, moving average; ACF = 29 
Autocorrelation functions; PACF = Partial autocorrelation functions; IRR = Incidence rate 30 
ratio; CI = Confidence interval; US = United States; UK = United Kingdom 31 
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4. Chapter conclusion 6 
There are very few studies in Australia that have examined the trends of drug use at 7 
patient level data in relation to the PBS data, especially compared the impacts of 8 
regulatory warnings between these databases. Figure 9 depicts the dispensing trends of 9 
thiazolidinediones in the PBS database and the prescribing trends in the AsteRx database. 10 
From visual observation of slope and statistical results from ARIMA model, the trends of 11 
rosiglitazone and pioglitazone use in these two database are comparable therefore the 12 
prescribing trends in the AsteRx represents the national trends of these two drugs well. 13 
 14 
Figure 9. Trends in utilisation of rosiglitazone and pioglitazone in the PBS (above) 15 
and prescribing rosiglitazone and pioglitazone in the AsteRx (below) 16 
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A decrease of rosiglitazone use was associated with the warnings issued by the key 1 
international regulators who announced the cardiovascular concern prior to the TGA. 2 
Since a decline of prescribing rosiglitazone in late 2007, pioglitazone had increased and 3 
surpassed the rosiglitazone in 2009. Pioglitazone had no evidence of increased 4 
myocardial events that had been confirmed by well-recognise medical associations and 5 
regulators during cardiac concern with rosiglitazone. These may explain the rise in 6 
pioglitazone initiations and switches from rosiglitazone to pioglitazone. To gain a greater 7 
insight into the impact of drug safety warnings on clinical practice, information on the 8 
sources of drug safety information among prescribers are needed. How prescribers 9 
receive and respond to warnings will help us understand the differences in changes to the 10 
pattern of rosiglitazone and pioglitazone. Further study on the sources of drug safety 11 
information and prescribers’ perspective toward rosiglitazone and pioglitazone will be 12 
assessed in chapter 6.  13 
 14 
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Chapter 5. Impact of drug interaction warnings on concomitant use of 1 
proton pump inhibitors and clopidogrel 2 
1. Synopsis 3 
The previous chapter investigated the impact of more conclusive warnings on the adverse 4 
events of thiazolidinediones. This chapter examines the complicated and conflicting case 5 
of the clopidogrel-PPI interaction for which clinical studies could not provide meaningful 6 
outcomes as shown in in vitro studies. Despite the warnings issued by the FDA and EMA 7 
on the possible cardiovascular events related to concomitant use of clopidogrel and proton 8 
pump inhibitors, the TGA took no action toward this interaction. The findings in this study 9 
suggested that there was a significant association between the international 10 
recommendations and the coprescribing of antisecretory agents among clopidogrel users 11 
in the AsteRx database. The recommended PPI—pantoprazole significantly increased 12 
following the EMA warning in May 2009. This is likely to be due to an increase in switches 13 
from PPIs of concern—omeprazole and esomeprazole to pantoprazole.  14 
2. Overview 15 
Gilard et al. (2006) demonstrated a reduction in measures of platelet aggregation when a 16 
PPI was co-administered with clopidogrel (Gilard et al. 2006). Studies investigated PPIs as 17 
a group and found a decrease in platelet response and active metabolites of clopidogrel. 18 
Subsequently, research studies indicated that the clopidogrel-PPI interaction might not be 19 
from the PPI drug class but rather through CYP2C19 enzyme activity, which plays an 20 
important role in converting clopidogrel to its pharmacologically active metabolite (Cuisset 21 
et al. 2009; Ho et al. 2009). Omeprazole is a potent inhibitor of CYP2C19 therefore it 22 
would attenuate the antiplatelet efficacy of clopidogrel. Pantoprazole has less effect on the 23 
CYP2C19 metabolic pathway, and therefore might be a better alternative for concomitant 24 
use with clopidogrel (Angiolillo et al. 2011). Most of data from pharmacodynamic studies 25 
supported this hypothesis; however, clinical trials have presented inconsistent results on 26 
cardiovascular outcomes (Kwok et al. 2011; Kwok et al. 2013).  27 
The FDA and EMA issued several announcements on the proposed clopidogrel and PPI 28 
interaction with updated contents according to the research findings during 2009–2010. 29 
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The announcements and context have been extensively discussed in Chapter 2. A 1 
summary in a chronological order is listed below. 2 
Release date: 26 January 2009 3 
§ FDA—“Early Communication about an Ongoing Safety Review of Clopidogrel 4 
bisulfate (marketed as Plavix).” The FDA pointed out its awareness of the 5 
clopidogrel-PPI interaction and a review was in progress. In the meantime, the FDA 6 
suggested healthcare professionals re-evaluate the necessity of PPI treatment in 7 
patients receiving clopidogrel and indicated that there was no evidence of changes 8 
in the antiplatelet activity of clopidogrel by H2RAs (FDA 2009). 9 
Release date: 29 May 2009 10 
§ EMA—“Public statement on possible interaction between clopidogrel and proton 11 
pump inhibitors.” The EMA indicated the existent of an interaction and advised 12 
against using all members of the PPI class with clopidogrel. The product information 13 
for all clopidogrel-containing medicines was updated to discourage concomitant use 14 
of PPI with clopidogrel, unless absolutely needed (EMA 2009).  15 
Release date: 17 November 2009 16 
The clopidogrel manufacturer was asked by the FDA to update the safety information 17 
label indicating against the concomitant use of CYP2C19 inhibitory medicines (e.g. 18 
omeprazole) with clopidogrel (FDA 2009).  19 
§ FDA—Public Health Advisory: Updated Safety Information about a drug interaction 20 
between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as 21 
Prilosec and Prilosec OTC) (FDA 2009). Clopidogrel users were recommended to 22 
consult healthcare providers if they are currently taking or considering omeprazole. 23 
The update indicated the FDA believed that ranitidine, famotidine, and nizatidine did 24 
not interfere with the efficacy of clopidogrel. 25 
§ FDA—Information for Healthcare Professionals: Update to the labeling of 26 
Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a 27 
drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) (FDA 28 
2009). Omeprazole and esomeprazole (a component of omeprazole) as CYP2C19 29 
inhibitors should be avoided in combination with clopidogrel.  30 
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§ FDA—Follow-up to the January 26, 2009, Early Communication about an Ongoing 1 
Safety Review of Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole 2 
(marketed as Prilosec and Prilosec OTC) (FDA 2009). 3 
Release date: 17 March 2010 4 
§ EMA—Public statement. Interaction between clopidogrel and proton-pump 5 
inhibitors. CHMP updates the warning for clopidogrel-containing medicines. The 6 
EMA changed from avoiding all PPIs to only omeprazole and esomeprazole in 7 
combination with clopidogrel due to the update evidence on CYP2C19 inhibitory 8 
activity.  9 
Release date: 27 October 2010 10 
§ FDA—“Reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole” 11 
The FDA issued a reminder on the clopidogrel and omeprazole interaction. This 12 
time they emphasised the less potent CYP2C19 inhibitory effect of pantoprazole 13 
and recommended this as an alternative in patients with high risk of GI bleeding 14 
(FDA 2010). 15 
In October 2011, the TGA updated the advisory statement 223 “Ask your doctor or 16 
pharmacist before use if you are taking other medicines regularly.” on the label of proton 17 
pump inhibitors including omeprazole, pantoprazole, rabeprazole and lansoprazole. The 18 
required advisory statements for medicine labels update 6 stated “TGA considers that it 19 
would be misleading if consumers are only warned about this particular interaction and not 20 
to other interactions and may assume that they do not need to check if they are not taking 21 
Clopidogrel. Therefore the TGA is of the opinion that the advisory statement 223 is 22 
sufficient in addressing the issue of all possible interactions between PPIs and 23 
Clopidogrel.” (TGA 2011) Therefore, there was no specific warning on the clopidogrel-PPI 24 
interaction from the TGA.  25 
Because of the worldwide connection via media and online resources, it is likely that the 26 
safety communication released by the FDA and EMA, for two of the highest medicines by 27 
cost and number of prescriptions would be seen by Australian prescribers. However, the 28 
impact of these communications on prescribing patterns of concomitant use of clopidogrel 29 
and PPI were unknown and are difficult to predict due to the uncertainty of clinical 30 
evidence and no specific action from the TGA.  31 
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3. Chapter aims 1 
This chapter investigates the changes in the coprescribing of antisecretory drugs in 2 
patients using clopidogrel in clinical practice after the warnings on the drug-drug 3 
interaction between clopidogrel and PPIs.  4 
4. Submitted Manuscript entitled “Pattern of the concomitant use of 5 
antisecretory drugs with clopidogrel in Australia including changes 6 
after the international clopidogrel-PPI warnings” 7 
The manuscript entitled “Impact of regulatory warnings on the prescribing rosiglitazone 8 
and pioglitazone in Australia” is submitted to Pharmacoepidemiology and drug safety, 9 
2014. 10 
The co-authors contributed to the manuscript as follows: PhD candidate, Suvimol 11 
Niyomnaitham, designed the study under the supervision of Dr Alesha Smith and Dr Adam 12 
La Caze. The PhD candidate performed all data collection and data analysis. Suvimol 13 
Niyomnaitham took the lead role in manuscript preparation and writing. All co-authors 14 
revised the manuscript for intellectual content and approved the final manuscript. 15 
  16 
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Pattern of the concomitant use of antisecretory drugs with 1 
clopidogrel in Australia including changes after the 2 
international clopidogrel-PPI warnings 3 
Suvimol Niyomnaitham1,2, Adam La Caze1, Alesha Smith1,3 4 
1School of Pharmacy, University of Queensland, Australia, 2Faculty of Medicine Siriraj 5 
Hospital, Mahidol University, Thailand, 3School of Pharmacy, University of Otago, New 6 
Zealand 7 
ABSTRACT 8 
Background 9 
Antisecretory agents consisting of proton pump inhibitors (PPIs) and histamine 2 receptor 10 
antagonists (H2RA) are often coprescribed with clopidogrel to reduce the risk of 11 
gastrointestinal bleeding. Several pharmacodynamic studies demonstrated that PPIs, 12 
specifically omeprazole and esomeprazole, reduced the efficacy of clopidogrel by inhibiting 13 
metabolic enzyme CYP2C19 and suggested pantoprazole and H2RA as alternatives. Due 14 
to a lack of consistent cardiovascular outcomes from clinical studies, no definite warning 15 
was announced from Australian Therapeutic Goods Administration (TGA). On the other 16 
hand, the United States Food and Drug Administration (FDA) and European Medicines 17 
Agency (EMA) recommended avoiding omeprazole and esomeprazole concomitant with 18 
clopidogrel and suggesting pantoprazole and H2RA as an alternative.  19 
Objective 20 
We examined the patterns of coprescribing of antisecretory drugs in patients using 21 
clopidogrel. The changes of coprescribing patterns before/after the international warnings 22 
on the drug-drug interaction between clopidogrel and PPIs were also investigated.  23 
Methods 24 
The prescribing of antisecretory medicines within 30 days of clopidogrel prescribing was 25 
identified during January2006–December2011 in the AsteRx database. AsteRx is a de-26 
identified clinical database that collects data from more than a hundred of primary 27 
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practices in Australia. Monthly trends of coprescribing clopidogrel with PPIs and H2RA 1 
were examined. The impacts of three safety warnings by the EMA in May 2009 and March 2 
2010 and by the FDA in November 2009 were analysed using the interrupted time-series 3 
analysis called autoregressive integrated moving average (ARIMA) model. Number of 4 
switches and initiations of coprescribing antisecretory agents with clopidogrel before and 5 
after warnings were also investigated. 6 
Results 7 
There were a total of 7,757 coprescriptions of antisecretory agents with clopidogrel during 8 
2006–2011. Approximately 90% of those were the coprescribing of proton pump inhibitors. 9 
Esomeprazole was the most frequent PPI to be coprescribed with clopidogrel, followed by 10 
pantoprazole and omeprazole. The coprescription of omeprazole with clopidogrel 11 
decreased from 2006. No significant change in esomeprazole coprescribing after the 12 
regulatory warnings were observed in the ARIMA model. The proportion of pantoprazole 13 
coprescribing significantly increased after the EMA warning in May 2009 (p=0.011). There 14 
was no significant change in H2RA coprescribing. 15 
After the warning in May 2009, 42% switched from omeprazole to pantoprazole compared 16 
to 22% before the warning. There was a significant increase in switches from 17 
esomeprazole to pantoprazole after May 2009 (p=0.003). There was a total of 815 18 
antisecretory initiations in clopidogrel users after May 2009 and pantoprazole was the 19 
most frequently initiated antisecretory agent in patients taking clopidogrel (35.09%), 20 
compared to 24.95% before the warning in May 2009. 21 
Conclusions 22 
It appears that after the warnings on clopidogrel-PPI interaction, esomeprazole was 23 
continually the most coprescribed antisecretory drug with clopidogrel. However, 24 
pantoprazole coprescribing significantly increased after the safety warnings in 2009. This 25 
increasing trend could be explained by the switches from omeprazole and esomeprazole 26 
to pantoprazole, the suggested alternative PPI. 27 
Introduction 28 
Clopidogrel and proton pump inhibitors (PPIs) have been in the top 5 list of high-cost drugs 29 
on the Australia Pharmaceutical Benefits Scheme (PBS), a national subsidised formulary 30 
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(PBS 2010) for the past decade. PPIs and histamine 2 receptor antagonists (H2RAs) are 1 
antisecretory agents that are often prescribed prophylactically to prevent gastrointestinal 2 
complications in patients taking clopidogrel (Lev et al. 2007; Schafer et al. 2010). In vitro 3 
studies demonstrated that PPIs attenuate the antiplatelet efficacy of clopidogrel and 4 
provide evidence that CYP2C19 enzyme activity might contribute to this clopidogrel-PPI 5 
interaction (Gilard et al. 2008; Cuisset et al. 2009). A potent CYP2C19 inhibitor such as 6 
omeprazole and its S-isomer, esomeprazole may interfere with the effectiveness of 7 
clopidogrel in preventing cardiovascular events but not pantoprazole, as pantoprazole has 8 
less effect on CYP2C19. However, the clinical relevance of this interaction remains 9 
unclear, and clinical trials have not provided consistent evidence in relation to the effect of 10 
PPI-clopidogrel coprescription on cardiovascular outcomes (Bhatt et al. 2010; Kwok et al. 11 
2013). 12 
Regulatory authorities are responsible for ensuring the safety and efficacy of marketed 13 
medicines by taking prompt action towards any emerging risks. The degree of regulatory 14 
response depends on evidence and severity of the risk whether it be a market withdrawal 15 
or updated safety information. Additionally, a regulatory warning containing safety 16 
information and recommendations will be issued to healthcare providers. In Australia, the 17 
Therapeutic Goods Administration (TGA) assesses the risk of marketing drugs and 18 
updates to their product information. The TGA informs healthcare professionals through an 19 
‘Alert’ on the TGA website or subscribed email. The ‘Medical safety update’ is published 20 
every two months on the TGA website and in the Australian Prescriber. The effectiveness 21 
of the safety warning process in Australia has been under question and led to the public 22 
recommendation for regulatory reforms such as more transparency and improving 23 
communication (TGA 2011). 24 
In Europe, the European Medicines Agency (EMA) collaborates with a network of 25 
expertise across the European Union to evaluate and take timely action to the possible 26 
hazard of medical products. ‘Public statement’ and ‘Press Release’ containing safety 27 
warnings are publicly announced (EMA). Similarly, the United States Food and Drug 28 
Administration (FDA) works closely with manufactures to analyse the risks of concerned 29 
drugs. A safety communication is issued by the FDA to alert healthcare professionals to a 30 
new risk and also includes a recommendation on related treatment (FDA). 31 
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Given global access to medicines and the importance of timely communication on new 1 
safety concerns, drug safety regulation has an international focus. Medicine use in 2 
Australia is influenced not only by the local drug authority, but also key international drug 3 
regulatory bodies such as the FDA and EMA. The EMA released its first warning in May 4 
2009 and recommending against the combination of all PPIs with clopidogrel. Later in 5 
March 2010, the recommendation was changed to avoid only omeprazole and 6 
esomeprazole in patients taking clopidogrel (EMA 2010). In November 2009, the FDA 7 
updated the label for clopidogrel recommending to avoid using clopidogrel with 8 
omeprazole and esomeprazole (FDA 2009). Both the FDA and EMA emphasised that 9 
there was no sufficient evidence on other PPIs and most H2RAs (ranitidine, famotidine, 10 
nizatidine) on the anti-clotting function of clopidogrel. On the other hand, in Australia, the 11 
TGA refrained from the safety labelling change or the safety communication on the 12 
clopidogrel-PPI interaction.  13 
The impacts of warnings issued by the EMA and FDA on patterns of drug use have been 14 
examined in several studies (Dorsey et al. 2010; Dusetzina et al. 2012; Ruiter et al. 2012). 15 
The observed prescribing trends do not always follow the recommendation but depend on 16 
many factors such as the certainty of evidence and tendency to prescribe highly advertised 17 
drugs (Dusetzina et al. 2012). Studies in the UK show a significant increase in the 18 
omeprazole substitution rate with another PPIs (except esomeprazole), or a H2RA after 19 
their warning came out (Thomas et al. 2013). Previous studies have shown the influences 20 
of the major international warnings on the changes of local drug trends (Leal et al. 2013; 21 
Kashour et al. 2014; Niyomnaitham et al. 2014). Although there is no local regulatory 22 
warning on the concomitant use of clopidogrel and PPI, it is thought that Australian 23 
prescribers might be aware of the warnings from the FDA and EMA. This study 24 
investigated the patterns of coprescribing antisecretory agents with clopidogrel and 25 
changes following the warnings issued by the FDA and EMA. 26 
Methods 27 
Data collection 28 
1. Coprescribing antisecretory agents with clopidogrel 29 
All prescriptions of clopidogrel, PPIs, and H2RA from January 2005–December 2011 were 30 
identified from the AsteRx database. AsteRx has collected medical data from >100 primary 31 
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practices located all over Australia since 2003. There are a total of seven million 1 
prescriptions from half a million patients recorded in a de-identified manner. Details of 2 
prescriptions include prescribing date, chemical name, strength, quantity, and drug codes. 3 
Drugs of interests were extracted using a combination of chemical name, the WHO 4 
Anatomical Therapeutic Chemical Classification (ATC) system, and Australian 5 
Pharmaceutical Benefits Scheme (PBS) item codes for the completeness of data capture. 6 
The PBS codes are used for dispensing purposes from the government reimbursement 7 
formulary. Other information such as diagnoses, consultations, laboratory results are 8 
recorded in plain text.  9 
Omeprazole, esomeprazole, rabeprazole, lansoprazole, and pantoprazole were the PPIs 10 
included in the analyses. Ranitidine, famotidine, and nizatidine were grouped into H2RAs 11 
in this study. The coprescribing of PPIs and H2RAs with clopidogrel was defined as PPIs 12 
and H2RAs prescribed within 30 days before and after a clopidogrel prescription. 13 
2. Switches and initiations of coprescribed antisecretory agents 14 
Switches were counted every time that the coprescribed antisecretory agent with 15 
clopidogrel was not the same as the previous agent within individual patients. In this study, 16 
the number of switches from omeprazole to another PPI or an H2RA and number of 17 
switches from esomeprazole to another PPI or an H2RA were examined. 18 
Initiations were identified when an antisecretory agent was first coprescribed with 19 
clopidogrel in patients who did not have any previous record of a coprescribed 20 
antisecretory agent during the study period.  21 
Analyses 22 
1. Impacts of warnings on coprescribing trends 23 
The percentages of the monthly coprescribing of each PPI and H2RA were calculated 24 
thorough the study period. Monthly data on the coprescribing of PPIs and H2RA with 25 
clopidogrel were depicted and fitted into the time series analysis called auto-regressive, 26 
integrated, moving average (ARIMA) model. The impacts of the warnings from the EMA 27 
and FDA on coprescribing trends were analysed using the ARIMA model. Three safety 28 
warnings—the first warning by the EMA in May 2009 (EMA1), the second warning by the 29 
EMA in March 2010 (EMA2), and the warning by the FDA in November 2009—were 30 
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investigated as interventions in the ARIMA model. The ARIMA model has been used to 1 
investigate the trend of time-series data and the impact of health care interventions on 2 
trends of drug use (Ferrand et al. 2011; Langley et al. 2011; Ruiter et al. 2012). The 3 
ARIMA (p,d,q) model is an applied time-series model developed by Box-Jenkins (Box 4 
1976; Griffiths et al. 2000) to forecast future observations that occur at equal time intervals 5 
and determine the effect of an intervention in time series data. Firstly, the integration 6 
process is differenced (d) to make stationary data. Dickey-Fuller test was also used to 7 
confirm the stationary data (Dickey 1979). Autoregressive model of order p explains the 8 
accumulated effect of the preceding data and moving average model of order q indicates 9 
the most recent random shock carries over from one period to the next. The appropriate 10 
model (p, q) is obtained from the visibility to the plots of autocorrelation functions (ACF) 11 
and partial autocorrelation functions (PACF) of time-series values (McDowall 1980). The 12 
best fitted model for analysis was also examined using the Bayesian Information Criteria 13 
(Schwarz 1978). An abrupt and permanent effect from the warnings by the EMA and FDA 14 
on subsequent prescribing trends was assumed and represented by coefficient (ω) 15 
(McDowall 1980; Griffiths et al. 2000).  16 
2. Switches and initiations before and after the warnings 17 
The rate of switching from omeprazole/esomeprazole to another antisecretory agent 18 
before and after the warning in May 2009 was analysed using Poisson regression 19 
(Cameron et al. 2013). The rates of each antisecretory initiation before and after the 20 
warning in May 2009 were also investigated using the same statistical analysis. STATA 21 
12.1 (StataCorp, College Station, TX) was used to perform all statistical analyses with a 22 
5% significance level. 23 
Results 24 
Out of 8,100 patients who were prescribed clopidogrel, 3,499 patients (43% of clopidogrel 25 
users) were coprescribed at least one antisecretory drug between January 2006 and 26 
December 2011. A total of 7,757 coprescriptions of antisecretory agents were included in 27 
the analyses. Figure 7 displays the percentage that each PPI and H2RA contributes to the 28 
total co-prescriptions in each month. Esomeprazole was the most frequent antisecretory 29 
coprescribed with clopidogrel, followed by pantoprazole, omeprazole, rabeprazole, 30 
H2RAs, and lansoprazole, respectively during the study period. Omeprazole 31 
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coprescriptions continuously decreased from 2006 until the end of study period. H2RA 1 
coprescriptions were approximately less than 10% of all antisecretory coprescriptions. The 2 
dashed lines in Figure 10 represent the months of warnings that were investigated as 3 
interventions in the ARIMA model.  4 
 5 
Figure 10. Percentage of each coprescribed antisecretory drug with clopidogrel in 6 
the AsteRx database from January 2006–December 2011.  7 
Dashed lines indicate the warnings issued by regulatory authorities. H2RA: histamine 2 receptor antagonist, 8 
EMA1: First warning by the European Medicines Agency, EMA2: Second warning by the European 9 
Medicines Agency, FDA: Food and Drug Administration 10 
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There were no seasonal autocorrelation detected for the patterns of coprescribing 1 
antisecretory agents with clopidogrel in the AsteRx database. All prescribing data are 2 
stationary from the Dickey-fuller test. The visual observation of PACF and ACF plots 3 
suggested an ARIMA (1,0,1) model to best characterise all coprescribing data.  4 
Table 12 describes the coefficients and significant changes (p-value) of the subsequent 5 
trends of omeprazole, esomeprazole, pantoprazole and H2RAs in the ARIMA model. The 6 
increased trend of pantoprazole coprescribing was significantly associated with the first 7 
warning by the EMA (EMA1), the FDA warning, and the second warning by the EMA 8 
(EMA2). After adjustment for the previous warnings, the increased trend of pantoprazole 9 
coprescribing was not significantly associated with the FDA warning (adjusted coefficient 10 
2.840, 95%CI [-2.70,8.38], p=0.315) nor with the EMA2 (adjusted coefficient 1.657, 95%CI 11 
[-1.58,4.89], p=0.315). A continuing decrease in the trend of omeprazole coprescribing 12 
was observed; however, no significant change was associated with the EMA1 or FDA after 13 
fitting into the ARIMA model. Only the more specific EMA warning on avoiding omeprazole 14 
and esomeprazole in March 2010 (EMA2) was significantly associated with a decline in 15 
omeprazole coprescribing (p<0.0001). There was no significant change in esomeprazole 16 
coprescribing after the warnings; moreover, esomeprazole was the antisecretory drug 17 
which had the highest proportion of coprescribing with clopidogrel after the warnings. 18 
EMA2 coincided with a significant decline in the trend of coprescribing H2RAs. No 19 
significant associations between warnings and the coprescribing of lansoprazole or 20 
rabeprazole were observed in the ARIMA model. 21 
Table 12. Impacts of authority warnings on the trends of coprescribing 22 
antisecretory drugs with clopidogrel in ARIMA models 23 
Warnings by authorities Month-
year 
Adjusted for Coefficienta 
(ω) 
95%CIb p-valuec 
Omeprazole ARIMA(1,0,1)      
EMA1 May 2009 - 0.460  [-5.42, 6.34] 0.878 
FDA Nov 2009 - -1.208  [-3.41, 0.99] 0.282 
EMA2 Mar 2010 - 
EMA1, FDA 
-3.104 
-2.948 
 [-4.75, -1.46] 
 [-4.64, -1.25] 
<0.0001 
0.001 
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Esomeprazole ARIMA(1,0,1)      
EMA1 May 2009 - 0.594  [-6.88, 8.07] 0.594 
FDA Nov 2009 - 1.680  [-5.85, 9.21] 0.662 
EMA2 Mar 2010 - 
EMA1, FDA 
-1.391 
-1.652 
 [-8.63, 5.85] 
 [-8.68, 5.38] 
0.707 
0.645 
Pantoprazole ARIMA(1,0,1)      
EMA1 May 2009 - 2.769  [0.64, 4.89] 0.011 
FDA Nov 2009 - 
EMA1 
3.153 
2.840 
 [0.51, 5.80] 
 [-2.70, 8.38] 
0.019 
0.315 
EMA2 Mar 2010 - 
EMA1, FDA 
3.030 
1.657 
 [0.372, 5.69] 
 [-1.58, 4.89] 
0.025 
0.315 
H2RA ARIMA(1,0,1)       
EMA1 May 2009 - -1.053  [-11.07, 8.96] 0.837 
FDA Nov 2009 - -1.441  [-7.04, 4.16] 0.614 
EMA2 Mar 2010 - 
EMA1, FDA 
-3.223 
-3.030 
 [-5.34, -1.11] 
 [-7.78, 1.72] 
0.003 
0.211 
aCoefficient (ω): Coefficients were changes in magnitude and direction after the intervention, bCI: confidence 1 
interval, cStatistical significance at p value <0.05 is presented in bold., H2RA: histamine 2 receptor 2 
antagonist, EMA1: First warning by the European Medicines Agency, EMA2: Second warning by the 3 
European Medicines Agency, FDA: Food and Drug Administration 4 
 5 
The number of switches from omeprazole and esomeprazole coprescriptions to other 6 
antisecretory agents before and after the warning in May 2009 are displayed in Table 13 7 
and 11, respectively. Out of 141 switches from coprescribed omeprazole before the 8 
warning, 24.82% switched to pantoprazole. There was a significant increase in the rate of 9 
switches from omeprazole to pantoprazole after the warning with an incidence rate ratio 10 
(IRR) of 1.708 (95%CI [1.08,2.70], p=0.022). Although there was an observed decline in 11 
switching from omeprazole to esomeprazole from 44% to 34% after the warning, there was 12 
no statistical significance suggested by the Poisson regression (p=0.226). 13 
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Table 13. Number of switched coprescriptions from omeprazole to other 1 
antisecretory drugs 2 
Warning Period Esomeprazole Pantoprazole Lansoprazole Rabeprazole H2RA Total switches 
Before            
(Jan06–May09) 
62 (43.97%) 35 (24.82%) 4 (2.84%) 25 (17.73%) 15 (10.64%) 141 
After                                         
(Jun09–Dec11) 
31 (33.69%) 39 (42.39%) 0 11 (11.96%) 11 (11.96%) 92 
IRR, 95%CI 
p-value 
0.766, [0.50,1.18] 
p=0.226 
1.708, [1.08,2.70] 
p=0.022 
7.588, [0,∞] 
p=0.994 
0.674, [0.33,1.37] 
p=0.276 
1.124, [0.52,2.45] 
p=0.769 
 
IRR: Incidence rate ratio, CI: confidence interval, Statistical significance at p-value<0.05 is presented in bold, 3 
H2RA: histamine 2 receptor antagonist 4 
An increase in switching from esomeprazole to pantoprazole was shown from 41% before 5 
the warning to 53% but this increase was not significant in the Poisson regression. A 6 
significant decline in the rate of switching from esomeprazole to omeprazole was detected 7 
after the warning with an IRR of 0.454 (p=0.012). There were no significant changes in the 8 
rates of switching to lansoprazole, rabeprazole, and H2RA between periods before and 9 
after May 2009 (Table 14). 10 
Table 14. Number of switched coprescriptions from esomeprazole to other 11 
antisecretory drugs 12 
Warning Period Omeprazole Pantoprazole Lansoprazole Rabeprazole H2RA Total switches 
Before                   
(Jan06–May09) 25 (17.24%) 59 (40.69%) 3 (2.07%) 18 (12.41%) 40 (27.59%) 145 
After                                         
(Jun09–Dec11) 17 (7.86%) 116 (53.46%) 8 (3.69%) 25 (11.52%) 51 (23.51%) 217 
IRR, 95%CI 
p-value 
0.454, [0.24,0.84] 
p=0.012 
1.314, [0.96,1.79] 
p=0.088 
1.782, [0.47,6.72] 
p=0.394 
  0.928, [0.51,1.70] 
p=0.809 
0.852, [0.52,2.45] 
p=0.448 
 
IRR: Incidence rate ratio, CI: confidence interval, Statistical significance at p-value <0.05 is presented in 13 
bold, H2RA: histamine 2 receptor antagonist 14 
For the initiations, esomeprazole was the most commonly initiated antisecretory agent in 15 
patients taking clopidogrel with 32.04% of total initiations before the warning. After May 16 
2009, pantoprazole became the most initiated antisecretory medicine at 35.09%, 17 
compared to 24.95% before the warning (Table 15). After the warning in May 2009, a 18 
significant increase in the rate of pantoprazole initiations was suggested with an IRR of 19 
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1.419 (p<0.0001). Whereas there were significant decreases in the rates of omeprazole, 1 
lansoprazole and rabeprazole initiations after this warning (p=0.001, p=0.049, and 2 
p=0.009, respectively). 3 
Table 15. Number of coprescribed antisecretory initiations before and after the 4 
warning in May 2009 5 
Warning 
Period Omeprazole Esomeprazole Pantoprazole Lansoprazole Rabeprazole H2RA 
Total 
initiations 
Before                   
(Jan06–May09) 
200 
(18.52%) 
346 (32.04%) 
268  
(24.95%) 
44 (4.07%) 157 (14.54%) 65 (5.02%) 1080 
After                                         
(Jun09–Dec11) 
102
(12.52%) 
267 (32.76%) 
286  
(35.09%) 
20 (2.45%) 83 (10.18%) 57 (6.99%) 815 
IRR               
95%CI                   
p-value 
0.676, 
[0.53,0.86]    
p=0.001 
1.023, 
[0.87,1.20]       
p=0.784 
1.419, 
[1.20,1.68]      
p<0.0001 
0.589, 
[0.35,0.99]      
p=0.049 
0.701, 
[0.54,0.91]       
p=0.009 
1.162, 
[0.81,1.66]       
p 0.408 
 
IRR: Incidence rate ratio, CI: confidence interval, Statistical significance at p-value<0.05 is presented in 6 
bold., H2RA: histamine 2 receptor antagonist 7 
 8 
Discussion 9 
Esomeprazole was the leading antisecretory drug coprescribed with clopidogrel throughout 10 
the study period. Although the regulatory warnings and publications suggested the same 11 
possible CYP2C19 inhibitory effect of esomeprazole on the antiplatelet activity of 12 
clopidogrel as of omeprazole, they had no impact on the trend of coprescribing 13 
esomeprazole. There are several influential factors on prescribing decisions. 14 
Esomeprazole was the highest PPI used in Australia due to the influence of new drug 15 
marketing strategies. Studies show that medical research, training activities or 16 
conferences endorsed by pharmaceutical companies may lead to an associated 17 
subconscious bias in decision-making process by attending clinicians (Jones et al. 2001; 18 
Hansen et al. 2005; Fugh-Berman et al. 2006; Brody 2009; Sah et al. 2013). Advertising 19 
and sale representatives were also influential on the switching within drug class (Hansen 20 
et al. 2005) and prescribing decisions (Vancelik et al. 2007). A previous study shows that 21 
omeprazole use has decreased once it was no longer under patent with far less marketing 22 
activities (Hollingworth et al. 2010). For coprescribing omeprazole, a decreased trend was 23 
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observed during the study period. Our analysis found that the significant decline in the 1 
coprescribing of omeprazole was concurrent with the specific warning on avoiding 2 
omeprazole and esomeprazole issued by the EMA in March 2010. Table 13 and 14 show 3 
that the switching between omeprazole and esomeprazole occurred less after the warning 4 
while switching from omeprazole and esomeprazole to another PPI was more frequent. 5 
These changes were similar to the rates of switching to an alternative PPI in European 6 
studies (Sanchez Ruiz-Gordoa et al. 2011; Thomas et al. 2013). However, there was no 7 
significant change to the coprescribing of H2RAs compatible with the recommendations 8 
issued by regulatory bodies. Moreover, coprescribing of H2RAs decreased following these 9 
warnings. 10 
Results from the ARIMA model demonstrated that a significant increase was observed in 11 
the trend of coprescribed pantoprazole following the release of the first warning on the 12 
clopidogrel-PPI interaction by the EMA in patients taking clopidogrel. During the May 2009 13 
warning, published evidence on the potential interaction of clopidogrel and 14 
omeprazole/CYP2C19 inhibitors suggested that pantoprazole had less of an effect on 15 
clopidogrel’s antiplatelet function (Gilard et al. 2008; Sibbing et al. 2009; Siller-Matula et al. 16 
2009). Prescribers may have been triggered by the EMA warning in May 2009 and 17 
changed their practice to coprescribe pantoprazole in patients who needed a PPI. In later 18 
announcements by the FDA in November 2009 and the EMA in March 2010, pantoprazole 19 
was specified as an alternative PPI to omeprazole and esomeprazole therefore the trend 20 
in coprescribing pantoprazole continuously increased following these warnings. Physicians 21 
seemed to switch from omeprazole and esomeprazole to pantoprazole after the warning in 22 
May 2009. These may explain why a subsequent increase in the trend of coprescribing 23 
pantoprazole was shown.  24 
Although a clinically meaningful impact of the clopidogrel-PPI interaction on cardiovascular 25 
outcomes has not been established, the evidence of in vitro studies suggested an impaired 26 
effectiveness of antiplatelet activity of clopidogrel. The FDA and EMA had updated 27 
labelling for PPIs and clopidogrel and issued several warnings including a reminder on the 28 
interaction between omeprazole and clopidogrel by the FDA in October 2010. However, 29 
the TGA has not issued any recommendations on prescribing these drugs. Presumably the 30 
thresholds of changing the label or issuing a warning are different between the TGA and 31 
these two international authorities as shown in less frequent warnings on other adverse 32 
events (Buckley et al. 2011; Alves et al. 2014). The TGA may consider this interaction has 33 
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insufficient supporting evidence and decided that it is not significant enough to inform the 1 
public. Despite the absence of TGA’s warning, our results implied that prescribers 2 
changed their coprescribing of PPI and clopidogrel after the warnings released by key 3 
international authorities. A proportion of Australian prescribers may be aware of this 4 
interaction but not sure how to apply it to their practice.  5 
Part of the TGA’s responsibility includes ensuring the safe use of medicines and 6 
communicating emerging risks to health care providers and patients. The importance of 7 
efficient drug safety communication was highlighted in recent literature (Dusetzina et al. 8 
2012; Edwards et al. 2012). This communication should provide evidence supporting the 9 
risk and the clinical implication appropriate for safe medical treatment. However, 10 
practitioners’ compliance with regulatory warnings has not always successfully been 11 
achieved (Yu et al. 2010). Rather, it depends on several components. Firstly, the existence 12 
of the evidence is important on the potential impact on prescribers’ decision. The clinical 13 
relevance of the clopidogrel-PPI interaction remains unclear therefore it appears that the 14 
impact of EMA and FDA warnings has not affected the prescribing of esomeprazole and 15 
H2RAs in Australia. The content of warnings must be summarised and focused directly on 16 
the risk and management, including alternative treatment options to receive a targeted and 17 
widespread response (Dusetzina et al. 2012). The EMA and FDA warnings did suggest 18 
pantoprazole and H2RAs as alternative treatment if an antisecretory drug is necessary in 19 
patients taking clopidogrel. The FDA’s strategy in reinforcing their risk communications 20 
over time through a reminder seems to increase the uptake and adherence to the 21 
recommendation (Dusetzina et al. 2012). Lastly, the recommendations need to be 22 
distributed and promoted through other prescribing support systems. For example, the 23 
National Prescribing Service (NPS) MedicineWise and Medicare locals in Australia can 24 
help distribute the safety communication and provide educational programs to health 25 
professionals in their network. 26 
Limitations  27 
The time-series analysis ARIMA model incorporates the past values and directions over a 28 
period of time to better describe the trend of data and investigates the impact of the 29 
intervention on this trend (Piening et al. 2012). However confounding effects on data were 30 
assumed to be similar both before and after the intervention periods.  31 
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Since the information regarding this interaction was updated multiple times and different 1 
sources provided conflicting data, it is impossible to know what specific sources of 2 
information prescribers were relying on to make their decisions.  This research is not able 3 
to disentangle the impact of research publications from warnings or between different 4 
warnings on prescribing decisions.  5 
The trends of prescribing data in the AsteRx database has been shown to be similar to the 6 
national dispensing trends in previous studies (Niyomnaitham et al. 2014). There were no 7 
changes in drug listings or major prescribing criteria that we are aware of during the study 8 
period. The diagnoses in the AsteRx were recorded as free text therefore it was difficult to 9 
fully examine the clinical reason for switching to another PPI or H2RA. Therefore factors 10 
that influenced prescribing changes of PPIs and clopidogrel in Australia would need a 11 
further investigation.  12 
Conclusions 13 
Results from this study show that international warnings are associated with the changes 14 
in the coprescribing of PPIs with clopidogrel in Australian practices. Although there was no 15 
significant change in esomeprazole, a significant increase in pantoprazole and a decline in 16 
omeprazole were consistent with the recommendations from the FDA and EMA. As there 17 
was a lack of information from the TGA and conflicting clinical evidence on the clopidogrel-18 
PPI interaction, prescribers may have difficulties in managing patients with an indication 19 
for clopidogrel and a PPI. An effective system to communicate risk and safety of drug 20 
needs to be established in order to ensure public safety and help practitioners translate the 21 
information into their practice. 22 
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5. Chapter conclusion 1 
A common combination of proton pump inhibitors and clopidogrel led to the drug-drug 2 
interaction in which CYP2C19 inhibitory effects of PPIs may attenuate the effectiveness in 3 
preventing the cardiovascular event of clopidogrel. Due to conflicting outcomes from 4 
clinical studies, the TGA refrained from any specific warning on the clopidogrel-PPI 5 
interaction. The key international regulatory agencies such as the FDA and EMA issued 6 
warnings on concomitant use of clopidogrel and potential CYP2C19 inhibitors, omeprazole 7 
and esomeprazole. With supporting information from literature and experts’ opinion in 8 
cardiology and gastroenterology, the FDA and EMA suggested pantoprazole as an 9 
alternative PPI for patients taking clopidogrel. 10 
Results from this chapter show the changes in the coprescribing of antisecretory agents 11 
with clopidogrel in Australian practice even though there was no specific warning from the 12 
TGA. A significant increase in pantoprazole and a decline in omeprazole corresponded to 13 
the warnings issued by international authorities whereas there was no change to 14 
prescribing esomeprazole among clopidogrel users. It is difficult to determine whether 15 
these significant changes in Australian practice were influenced by the international 16 
warnings or the literature. Moreover, the continuation of esomeprazole in combination with 17 
clopidogrel may be due to the lack of a local warning of regarding the interaction.  18 
In the next chapter we will gain further qualitative data to complement the prescribing data 19 
presented in this chapter. We assessed prescribers’ perception of the interaction between 20 
clopidogrel and PPIs. Sources of information on this interaction and their influence on 21 
prescribing decision were also examined among Australian prescribers.  22 
 23 
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Chapter 6. Prescribers’ perspective on drug safety warning 
1. Synopsis 
In chapters 3–5, quantitative analyses were undertaken on the impact of drug safety 
warnings on patterns of drug use in Australia. The combined qualitative and quantitative 
methods in this chapter examines prescribers’ perspective on current drug authority 
warnings and their impact on practice using two case studies of thiazolidinediones and 
clopidogrel-PPI interaction. Findings were obtained from interviews and an electronic 
survey of general practitioners (GPs) in Australia. The findings suggest that direct 
communication with GPs has not been achieved through regulatory communication. 
Although the majority of respondents were aware of cardiovascular events related to 
rosiglitazone, there was low awareness of the risk of bladder cancer associated with 
pioglitazone. Despite no communication on the possible risk of proton pump inhibitors 
(PPIs) on the antiplatelet effect of clopidogrel by the Australian authority, half of the 
respondents knew about this interaction and of those 69% changed their prescribing. 
Results from this chapter help to explain the small changes in pioglitazone use and the 
coprescribing of PPIs with clopidogrel from the previous studies. Going forward, the TGA 
may need to review their actions on new safety information and whether a prescribing 
decision needs to be changed to ensure the safety use of medicines. Cooperation with risk 
communication experts may improve the communication with health professionals and 
meet their expectation to be a reliable source of information for clinical practice (Lofstedt 
2010).  
2. Introduction 
Unexpected adverse effects of marketed drugs, for example, the increasing number of 
heart attacks and stroke events related to rofecoxib treatment since the first spontaneous 
report, require a prompt response from all parties to prevent further public harm (Strom 
2006). Previous studies show that an effective system of safety communication has 
positive impacts on health outcomes such as fewer adverse events (Lofstedt 2005; 
Lofstedt 2008). Social mechanisms that involve many influential stakeholders including 
pharmaceutical industry, government agencies, academia, and the media may affect 
perceptions, acceptance and eventually decisions regarding a response to emerging risk 
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(Fischhoff 2009). Actions of these stakeholders can amplify or attenuate the risk and 
explain why certain risks have received more attention than others (Poortinga et al. 2003).  
As discussed in previous chapters, the Therapeutic Goods Administration (TGA) is a 
regulatory authority in Australia responsible for evaluating the risks and benefits of medical 
products (TGA 2014). Briefly, the TGA plays an important role in requesting updated 
product information and releasing safety communication of marketed products. These 
communications contain new safety information and recommendations for using the 
concerned drugs. The main TGA communications are ‘Alerts’ published on the TGA’ 
website, ‘TGA-SAFETYINFO’ email subscription, and ‘Medicine Safety Update’ articles 
published every two months on the TGA’s website and Australian Prescriber (TGA).  
Besides the safety warning from the TGA, other medical organizations are also involved in 
distributing safety information and promoting efficient drug use. The National Prescribing 
Service (NPS) provides up-to-date drug information through NPS MedicineWise in the 
Australian Prescriber (NPS 2014). Medical associations such as the Royal Australian 
College of General Practitioners, the Heart Foundation and the Endocrine Society of 
Australia also provide updated safety information according to the drug of interest. Other 
available sources of drug safety information are the Australian Medicines Handbook, 
Therapeutic Guidelines, and MIMS (monthly index of medical specialties). Previous 
research indicated changes in the use of medicines in Australia to be associated with the 
warnings issued by key international regulators such as the FDA and EMA (Niyomnaitham 
et al. 2014).  
In the past few years, the TGA’s regulatory roles have been reviewed and recommended 
for reform. The reform issues include improving the understanding of the TGA’s role as a 
regulator, improving the public’s confidence in regulatory decisions, and providing 
increased access to information used to evaluate medical products. The public have also 
called for further transparency around risk communication, specifically, strategies to 
promote and distribute safety information to healthcare providers and consumers as well 
as mechanisms for improving timely communication of alerts and recalls (TGA 2011).  
Understanding how prescribers perceive and act on current drug safety warnings is 
valuable in planning for improved drug safety communication. Whilst aggregated 
prescribing data allows an investigation into the association between warnings and 
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patterns of drug use, influences from other confounders cannot be distinguished (Chapters 
3–5). There is limited work on how Australian prescribers obtain safety information. The 
qualitative study in this chapter assessed the sources of drug safety information among 
prescribers and the level of awareness regarding emerging risks. Prescribers 
characteristics such as specialties, years of experience, or practice settings were also 
examined since they had been associated with the response to the warnings in previous 
research (Wagner et al. 2006; Piening et al. 2012; Sanderson et al. 2013).  
Two recent drug safety warnings on the adverse events of thiazolidinediones and the drug 
interaction between clopidogrel and proton pump inhibitors (as presented in Chapter 2) are 
used as case studies to assess the impact of different contexts of warnings and certainty 
of risks on clinical decisions.  
Interview and survey methods are used to acquire Australian prescribers’ perception of 
current drug warnings and their opinions towards two recent warnings. 
3. Aims 
This study aims to ascertain Australian prescribers’ perspective regarding drug safety 
warnings. The specific objectives are:  
§ To determine sources of drug safety information among general practitioners 
§ To obtain participants’ opinions on local drug safety warnings 
§ To examine the awareness and response towards two recent drug warnings 
§ To identify the impact of regulatory warnings and other factors on prescribing 
decisions using two recent drug warnings 
4. Methods 
The study was approved by the School of Pharmacy Ethics Committee, the University of 
Queensland in accordance with the National Health and Medical Research Council's 
guidelines, approval number 2013/16 and 2013/17 (Appendix 2, 3). 
Study design 
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Firstly, semi-structured interviews to elicit prescribers’ views regarding drug safety 
warnings were conducted. The data gathered from these interviews were then used to 
develop an online survey. The online survey was piloted with health professionals before 
the main data collection phase. 
4.1.1 Semi-structured interview 
The primary aim of the semi-structured interviews was to gather interviewees’ opinions 
and experience regarding the current safety warnings and two case studies and inform the 
development of a survey. We conducted semi-structured interviews with a convenient 
sample of general practitioners (GPs), cardiologists, and drug regulatory personnel. 
Informed consent was obtained from all participants (Appendix 4). The interviews were 
undertaken by a single researcher (SN) for consistency until theme saturation was 
reached.  
TGA 
The interviewee participated in a telephone interview and was asked about the TGA’s 
roles and actions in response to emerging safety issues and differences from other 
international drug authorities. The strategies regarding the distribution of safety 
communication to target audiences and the measurements used for evaluating the 
effectiveness of the TGA’s warnings were also included in the interview questions 
(Appendix 5).  
Physicians 
Face-to-face interviews with GPs and specialists contained two sections, both with open-
ended questions (Appendix 6). Section one, elicited participants’ opinion on the drug 
warning system in Australia, sources of drug safety information, and the influence of each 
source of information on their practice.  
The questions on participants’ knowledge of two recent safety issues and 
recommendations regarding the use of concerned drugs were included in section two. In 
the case where the interviewees knew about these safety issues, they were asked to 
explain how these warnings affected their prescribing decision.  
Recruitment for the interview  
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An invitation email was sent to TGA officers who were involved in the safety regulation of 
marketed drugs for an interview. A convenience sample of ten practitioners working in 
Brisbane were recruited to take part in a face-to-face interview with the researcher at their 
workplace over a 2-month period during October–November 2013. The practice managers 
of the practice sites were contacted to distribute an email inviting practitioners to 
participant in the interview.  
The interviews took approximately 20–30 minutes. Permission to record the interview 
using a voice recorder for transcribing later was obtained prior to the interview. The 
transcripts were labelled with a specific identification code and no identifying information 
was collected.  
The principle investigator undertook a basic thematic analysis of results from the 
interviews. The data collected from these interviews were used to construct an online 
survey to elicit GP’s perceptions of drug safety warnings. The data gathered from the TGA 
interview and section one of the prescribers interview were used to construct the 
selection/answer choices of drug safety information and dissemination methods of the 
TGA’s safety communication in the main survey. Information acquired from section two of 
the prescribers interview was used to develop answer choices for each case study. For 
example, the treatment options after the safety concern of the clopidogrel-PPI interaction 
was released and the prescribing decisions in response to the adverse cardiovascular 
events of rosiglitazone.  
4.1.2 Online survey 
Before the survey was distributed to the larger group of participants, it was piloted on GPs 
(approximately 10 in total). Recruitment was done during December 2013–January 2014. A 
survey feedback section was included to ensure ease of completion and understanding. 
The survey was then modified to improve the robustness and feasibility for this study 
according to the feedback from the pilot study. The final survey was made available online 
through a web-based survey provider, Survey Monkey (SurveyMonkey® 2014). 
The survey included multiple-choice questions and was estimated to take 10–15min to 
complete. The survey was divided into 5 parts. Part one elicited demographic information: 
years of practicing medicine, medical specialty, and practice settings. Part two was 
designed to assess sources of drug safety information and opinions of the TGA’s safety 
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communication. Part three to five contained questions on the awareness and prescribing 
responses to the clopidogrel-PPI interaction, the cardiac events of rosiglitazone, and the 
bladder cancer risk of pioglitazone, respectively (Appendix 7).  
Recruitment of GPs for the online survey 
Each email and advertisement was sent between February–August 2014 contained 
participant information and a link to the survey on SurveyMonkey. The consent form on the 
first page of the survey included a data confidentiality statement, procedure and contact 
details. Participation in this study was voluntary. All data were collected and stored 
anonymously and confidentially.  
The response rates from previous studies varied from 4% to 60% among GPs (or family 
physicians) (Watkins et al. 2003; Krantz et al. 2007; Berg et al. 2008; Karpel et al. 2009). A 
recent survey study has a response rate of 16.1% with GPs in NSW (Garg et al. 2014).  
A number of strategies were employed to recruit GPs. General practitioners were recruited 
through two Medicare Locals: Metro North Brisbane and Greater Metro South Brisbane, 
which includes 1,112 and 954 general practitioners, respectively (PHIDU 2014). Both 
Medicare Locals advertised the survey through their upcoming Newsletter. Following poor 
recruitment, a further two Medical Locals were enlisted to advertise the survey to their 
members (Townsville-Mackay and West Moreton-Oxley). Medicare Locals who agreed to 
participate were asked to advertise the survey in their newsletters and repeat in their 
following issues until the survey closed in August 2014. An example of the survey 
advertisement placed in the Medicare Local newsletter is shown in Appendix 8. A number 
of practices around Brisbane were also invited via phone calls or a visit by the researchers 
at practice sites. 
Analysis plan 
Results were collected and reported in an aggregated form to evaluate overall practitioner 
perception towards drug safety warnings. Data were analysed using statistical software 
STATA 12 (Statacorp, College Station, TX). Descriptive analyses were used. Chi-square 
tests and Fisher’s test were used to assess the associations between baseline 
characteristics and a binary variable.  
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5. Results 
Interviews 
Of the ten invites, six face-to-face interviews were completed (response rate, 60%). The 
interviewees comprised of two specialists, three GPs, and one TGA officer (job title not 
released to protect confidentiality). Both specialists were aware of international warnings 
from the case studies because they subscribed to email lists from an international medical 
association (e.g. American Heart Association) and Medscape (Medical News), which 
always include new warnings from the FDA. Five interviewees did not receive direct 
information from the TGA either by using the TGA’s website or subscribing to TGA emails. 
Two GPs interviewed typically heard about the TGA’s warnings from reading the 
Australian Prescriber (paper version) and the NPS MedicineWise website. Hospital or 
medical practices of the interview participants did not have any internal drug safety 
communication system in place. 
The TGA officer believed that the regulatory process of the TGA and its regulatory actions 
were not different from other international regulatory bodies. The TGA’s decision may be 
influenced by the key international regulators’ opinions and vice versa. The TGA officer 
also confirmed that the TGA does not conduct new research regarding a new risk nor does 
it investigate the effectiveness of drug safety warnings and their impact on changes to 
prescribing. It was noted that the TGA is obligated to notify consumers and practitioners on 
the safety of products and tries to cooperate with the NPS, medical societies, and 
Medicare locals to distribute safety information. The TGA considers these dissemination 
methods to be more widespread compared with the TGA’s website or email. 
Web-based Survey 
Demographics of participants 
Thirty GPs completed the survey during the study period. 43.3% (13/30) were experienced 
GPs who had been practicing for more than 20 years, 20% 15–19 years, 3.3% (1/30) 10–
14 year, and 33.3% less than 10 years of experience. 67% practiced in a private 
hospital/clinic, 30% in community medical centre, and 13% public hospital. 
Drug safety warnings 
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Using the list compiled from the interviews, participants were asked to rank the sources of 
drug safety information they used for the drug safety warnings. Ten GPs (33%) ranked the 
TGA as the first source of drug safety warnings, followed by the NPS MedicineWise and 
the Australian Prescriber (Figure 11). Medical Association and medical research 
publications were ranked as number four and five, respectively. Other sources of drug 
information that participants suggested were MIMs, Australian Medicines Handbook and 
Therapeutic Guidelines.  
 
Figure 11. Sources of information regarding drug safety warnings and their ranking 
from highest to lowest scores. 
Twenty (66.7%) of respondents did not directly receive the drug safety information through 
the primary communication methods provided by the TGA such as TGA’s website and 
email subscription. Of those who received information from the TGA, three participants 
obtained this from the TGA website, seven participants received this from the Medicine 
Safety Update published in Australian Prescriber and two participants received both the 
Australian Prescriber and the TGA subscribed email. Receiving the TGA safety information 
was associated with higher years of practice (>=15 years) (Fisher’s test, p-value 0.031). Of 
the ten participants who received drug safety information from the TGA, 80% think the 
information provided by the TGA is adequate for their practice and 60% think the TGA’s 
warning is more timely than the FDA and EMA. The respondents understanding of the 
TGA’s role varied as shown in Figure 12.  
0 2 4 6 8 10 12 
Discussion with pharmacists 
News or other media 
Medscape 
International authorities e.g. FDA, EMA 
Drug package inserts 
Conferences/meetings 
Discussion with physician colleagues 
Medical research publication 
Medical association e.g. Diabetic, Heart association 
Australian prescriber 
NPS MedicineWise 
Therapeutic Goods Administration (TGA) 
Average ranking 
What are your main sources of information regarding drug safety 
warnings? (Please rank) 
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Figure 12. Level of familiarity with the TGA’s role 
Adverse events of thiazolidinediones 
Majority of participants (90%) were aware of the cardiovascular risk associated with 
rosiglitazone and all of those who indicated that they had changed their practice in relation 
to rosiglitazone, 33.3% reported they would switch their patient from rosiglitazone to other 
antidiabetic drug class while 18.5% would switch to pioglitazone (same drug class as 
rosiglitazone).  
Twelve respondents (40%) were aware of the increased risk of bladder cancer associated 
with long-term use of pioglitazone among participants. Of those who knew, 41.7% made 
no prescribing changes in patients using pioglitazone after the safety warnings whereas a 
quarter would discontinue pioglitazone even if the patient had no history of bladder cancer 
(Table 16). 
Table 16. Responses of general practitioners on the management of patients who 
were using pioglitazone  
Management in patients who were using pioglitazone Response count (%) 
Made no changes 5  (41.7%) 
Continued pioglitazone with bladder cancer screening 0  (0.0%) 
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Discontinued pioglitazone in patients with high risk of bladder 
cancer 2  (16.7%) 
Discontinued pioglitazone in all patients 3  (25.0%) 
Switched to another antidiabetic drug class 1  (8.3%) 
Other (please specify):  
 
1  (8.3%) 
Monitoring information 
 
Drug interaction between clopidogrel and proton pump inhibitors 
About half the respondents (53.3%) were aware of the interaction between clopidogrel and 
proton pump inhibitors. Participants were able to choose more than one source of 
information regarding this drug interaction. Seven respondents answered that the TGA 
was their source of information on this interaction while other answers were NPS 
MedicineWise(6), medical research publication(5), and the media(5). Among the GPs who 
were aware of this interaction, most of them (75%) indicated that they changed their 
prescribing behaviour in response. Half of them would prescribe a PPI with a weak 
inhibitor effect on CYP2C19 and two respondents (12.5%) indicated they would prescribe 
a histamine 2 receptor antagonists (Table 17). 
Table 17. Responses on the management of patients who were coprescribed 
clopidogrel and a PPI 
Management in patients who were coprescribed clopidogrel 
and a PPI 
Response count (%) 
Made no changes 3  (18.8%) 
Prescribed PPI with dosage adjustment 2 (12.5%) 
Prescribed PPI with a weak inhibitory effect on CYP2C19 (e.g. 
pantoprazole) 7 (43.8%) 
Prescribed histamine 2 receptor antagonists (e.g. ranitidine) 
instead of PPI 2 (12.5%) 
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Stopped prescribing all proton pump inhibitors 0 
Other (please specify) 4 (25.0%) 
 If a new initiation of a PPI is needed, 75% would choose pantoprazole and 83.1% would 
not initiate omeprazole or esomeprazole in patients taking clopidogrel.  
There was no association between outcomes and years of practice or practice settings 
based on analyses using Fisher’s exact test. 
Comments from respondents suggested that there are different preferences for sources of 
drug safety information among prescribers. Instead of tracking down every source of 
information, one reliable or ‘one-stop service’ may be needed. Some examples of open-
ended responses from the survey are quoted below: 
“Unless information is put in MIMs or published in Medical Journal Australia then it is 
unlikely to become widely and rapidly known” 
“Too many cooks, and lots of assumption that one or more will have warned us at the 
coalface. It has reached the stage where it seems I am obliged to actively track down 
every possible source, just in case they have some info I might not have heard. We need a 
"one-stop-shop", so we aren't tossing away the newsletters with the other superfluous junk 
mail.” 
“Perhaps if the various groups—NPS, Australian Prescriber, TGA etc—were singing from 
the same song sheet simultaneously?” 
“Should know more about it” 
6. Discussion 
The majority of the interviewees were familiar with the TGA and its role in issuing drug 
safety warning; however, they did not receive direct communication from the TGA (e.g. 
TGA’s website, TGA subscripted email list, or TGA published article in medical journal). 
One of possible reasons is that there were other available sources of drug information in 
which each practitioner assessed on a regular basis. For instance, specialists subscribed 
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to the newsletter of their medical associations to receive not only drug information but also 
updated guidelines that are essential for their practice.  
The timing of receiving a warning and responding to this new safety information was 
difficult to determine based on the data extracted from the interviews. This was due to the 
different sources of drug safety information used by different healthcare practitioners. It 
appears that it may take at least a year for general practitioners who only receive safety 
updates from the Australian prescriber handbook or e-therapeutic guidelines to know 
about this new safety information and subsequently change their practices.  
Another issue raised from the interviewees’ responses was a lack of an established 
system to circulate emerging drug safety information or drug warnings in hospitals and 
practice sites. Establishing such system could be a potential area for the TGA to enhance 
safety communication. This would need to be done in conjunction with healthcare facilities 
to ensure the distribution of safety drug information reached all healthcare professional. 
The TGA, NPS MedicineWise, and Australian Prescriber were the main sources of drug 
safety information among general practitioners surveyed. However, the findings suggest 
that current methods to disseminate drug safety warnings used by the TGA, which 
consists of ‘Alert’ or ‘Medical safety Update’ via the TGA website and email subscription, 
are not widely read by GPs. One third of respondents directly received or accessed 
information provided by the TGA from a secondary source and only a few respondents 
accessed the TGA website or subscribed to the TGA’s safety information email list.  
Studies in chapters 3–5 indicated that the changes in patterns of Australian dispensing 
and prescribing data were associated with the warnings issued by key international 
regulators such as the FDA and EMA. However, these international agencies were not 
ranked as highly as local sources of drug safety information in this survey. Prescribers 
may receive overseas safety warnings from NPS MedicineWise or medical associations 
who usually publish reviews of evidence regarding emerging risks and updated warnings 
(NPS 2009; GESA 2010). In 2010, NPS MedicineWise and the Gastroenterological 
Society of Australia published articles on the interaction between clopidogrel and proton 
pump inhibitors (PPIs) on their websites while no action was taken from the TGA. NPS 
articles provided the recommendations that were often suggested by the FDA and well-
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recognised medical associations, for example, the American Heart Association on the 
preferable PPI in clopidogrel users.  
The high awareness of cardiovascular events associated with rosiglitazone treatment was 
expected because the evidence was compelling and many actions had been taken by the 
TGA and PBS. The survey indicated that most practitioners would switch their patients 
from rosiglitazone to another antidiabetic medicine, which correlates with the sharp decline 
in the patterns of dispensing and prescribing rosiglitazone seen in the PBS and AsteRx 
data. This may help explain why there was an 18.5% switching rate from rosiglitazone to 
pioglitazone in the prescribing data right after the warnings on rosiglitazone. 
Although the TGA issued a warning on the bladder cancer risk related to long-term 
pioglitazone use, only 40% of respondents knew about this issue. Besides the small 
awareness among respondents, only 58% indicated that they would make a change to 
pioglitazone management. The low awareness of safety warnings issued by the regulatory 
agencies have been shown in the ‘Dear Doctor letter’ containing warnings of malaise in 
infants after the administration of certain brands of vitamin D in France and many other 
cases that led to market withdrawal of medicines (van Grootheest et al. 2002; Theophile et 
al. 2011). The insignificant change of pioglitazone use shown in the dispensing data 
(Chapter 3–4) following the TGA warning may be associated with the small awareness of 
its safety alert. Other explanations for this limited change are the lower incidence of the 
risk and a new availability of dipeptidyl peptidase-4 inhibitors during the release of the 
bladder cancer warning.  
Surprisingly, GPs were aware of the clopidogrel-PPI interaction from the TGA despite the 
fact that the TGA had not issued any specific warnings on this. This finding could 
demonstrate that GPs might pick up this information via other sources but inaccurately 
attribute it to the TGA, or that they were providing what they thought were “socially 
acceptable” answers. Even though the TGA had no action toward this interaction, 53% of 
respondents knew about it. Moreover, most of the survey responses regarding the 
changes in management of coprescribing a PPI correspond with recommendations from 
key international regulators and international guidelines. This was also seen with the 
significant increase in the coprescribing of pantoprazole in the AsteRx database. 
Pantoprazole was the preferred PPI from the survey and the majority of respondents 
would not initiate omeprazole or esomeprazole. The preferences of prescribers observed 
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in this study are consistent with the increase in the coprescribing of pantoprazole with 
clopidogrel in the AsteRx database. In chapter 5, although the switching rates from 
omeprazole and esomeprazole to pantoprazole increased following the EMA warning, the 
overall trend of esomeprazole did not change. Moreover, esomeprazole was still the 
highest coprescribed PPI with clopidogrel.  
The findings and comments from both interview and survey parts suggested that there was 
considerable diversity in the source of drug safety information among participants. This 
could lead to difficulty in predicting changes in clinical practice after an emerging adverse 
event. Prescribers sometimes feel a burdensome responsibility to track the latest 
information; or in making a decision based on the various recommendations, which may 
vary between sources. Whereas some practitioners did not know about these new risks 
until it was published in the routine drug manual. The educational programmes from the 
TGA and the Quality Use of Medicines Policy could help provide guidelines for managing 
emerging drug safety information for practitioners and patients. 
Limitations in this study 
Although an electronic survey has the advantage of being issued immediately to a large 
population with minimal budget, low-response rates are a well-known limitation 
(Sturkenboom et al. 1994). Meta-analyses show both monetary and non-monetary 
incentives were associated with increased survey response rates among physicians 
(Kellerman et al. 2001; Edwards et al. 2009; James et al. 2011; Pit et al. 2014), but such 
incentives were not possible in this study. Shorter questionnaires, pre-notification by 
phone, up to 3 reminders with a copy of questionnaires may also improve response rates 
(Jepson et al. 2005; Cook et al. 2009; Edwards et al. 2009; Pit et al. 2014). The Medicare 
locals agreed to advertise the surveys on 2–5 follow-up newsletters (one placed the 
advertisement in 5 editions, 2 placed it in 3 editions, and 2 placed it in 2 editions). The 
length of questionnaires was kept less than 15 minutes and 20 multiple-choice questions. 
Studies show that physicians increasingly receive requests to participant in research, 
especially in the modern era of social media, our passive approach and lack of incentive 
therefore encountered the above problems (Moore et al. 1999; Cook et al. 2009). 
The low response rate observed in this study mean it is open to survey bias including a 
lack of validity and generalisability (Groves et al. 2008). Healthcare professionals who paid 
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attention to the newsletter may be better at keeping up-to-date with new information and 
tend to know about these warnings. Moreover, practitioners who failed to respond may be 
distinct from those who participated in the survey. Like all survey-based and interview 
studies, our questionnaire may suffer from recall bias. As seen in answers in obtaining the 
risk of clopidogrel-PPI interaction from the TGA therefore questions addressing choice of 
prescribing decision may or may not reflect actual practices in the last few years (Delgado-
Rodriguez et al. 2004). 
7. Conclusions 
This survey provides information on the sources of drug safety information used by 
general practitioners in Australia. Prescribers considered the TGA as the main source of 
new drug safety information. NPS MedicineWise and Australian Prescriber are well-
recognised source among practitioners where they may come across overseas 
recommendations or emerging issues such as the clopidogrel-PPI interaction.  
The level of awareness of the case studies differed. The issuing of warnings by the TGA 
does not necessary result in a higher awareness or a change in prescribing decision, as 
was the case with pioglitazone after the release of the TGA’s warning on bladder cancer. 
Other factors that may influence prescribers’ decision such as certainty of the evidence, 
promoting strategy, and an available treatment alternative were discussed in previous 
chapters.  
Combining quantitative and qualitative approaches can improve the robustness of 
research finding and answer different types of questions (Creswell 2008; Lobe 2008). The 
strengths of a quantitative approach (e.g. interrupted time-series analyses) are the impact 
size of drug safety warnings on overall patterns of concerned drug use and also 
generalisation of findings from the survey study.  
The combined interview and survey study provides insight into how prescribers obtain 
safety information and how respondents changed their prescribing behaviour. The survey 
findings offer a possible link between the period of change in prescribing patterns and 
sources of drug safety information used when making decisions as well as the explanation 
as to why changes were observed in certain drugs but not others. Results from the 
interrupted time-series analyses and the survey were largely consistent. Levels of 
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awareness and tendency to change prescribing between rosiglitazone and pioglitazone 
are relevant to the differences in trends of these two drugs following their warnings. Survey 
participants who were aware of the clopigorel-PPI interaction chose pantoprazole as the 
coprescribed PPI choice, which can help explain the incline in the coprescribing of 
pantoprazole in the AsteRx database. Very little research has used this mixed method 
approach to show the impact of drug safety warnings in Australia or for 
pharmacoepidemiology studies. Combining a quantitative and qualitative approach in this 
thesis helps reflect the current situation of drug safety warnings and their impact on 
practice. 
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Chapter 7. Summary and future direction 
1. Background of the study 
This research examined the impact of drug safety warnings on the trend of overall drug 
use in Australia. Dispensing and prescribing data from the time-series analysis were 
interpreted together with the findings from the survey study to assess prescribers’ sources 
of drug safety information and decisions in response to drug safety warnings. Prompt 
identification of and response to drug safety signals is a matter of international importance. 
Drug safety warnings issued by key international drug authorities such as the FDA and 
EMA have an influence on medicine use in Australia as well as those from the TGA (Dean 
et al. 2007).  
2. Findings in this study 
The impacts of warnings from the FDA, EMA, and TGA on the trends in utilisation of 
rosiglitazone and pioglitazone in the PBS national dispensing data from January 2004–
July 2012 were investigated using the ARIMA model. Using the prescribing data in the 
AsteRx database, the impact of these warnings was further examined, looking for specific 
changes to patterns of prescribing for rosiglitazone and pioglitazone from January 2005–
May 2012. The switching rates and switching choice from rosiglitazone to other 
antidiabetic drugs in the AsteRx data before and after the warnings were analysed. The 
coprescribing patterns of proton pump inhibitors among clopidogrel users were examined 
using the AsteRx database to assess the impacts of various warnings issued by the major 
regulators. These following findings incorporate results in the PBS, and AsteRx data with 
the survey study.  
2.1 Impacts of myocardial infarction warnings on the use of rosiglitazone  
Rosiglitazone utilisation reached its highest peak in January 2007 at 
1.96DDD/1000population/day and stayed at 1.88DDD/1000population/day in May 2007. 
The first warning from the FDA and EMA in May 2007 was significantly associated with 
decline in rosiglitazone utilisation at the decreased rate of 15.04% per month (coefficient    
-15.04, p<0.001). The rosiglitazone utilisation had fallen to 1.49DDD/1000population/day 
by December 2007; however, the first TGA warning in December 2007 was not 
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significantly associated with the decreasing trend of rosiglitazone after adjustment for the 
previous FDA and EMA warnings.  
Similar to the PBS dispensing data, a significant decline of prescribing rosiglitazone was 
found immediately after the FDA and EMA warning in May 2007 in the AsteRx database 
(p=0.001) but was not associated with the TGA warning in December 2007. These findings 
suggested that international warnings influenced local rosiglitazone use. Although the 
findings from the survey study did not rank the EMA and FDA as main sources of drug 
safety information, prescribers may be alerted by publications or other sources that often 
include international warnings such as medical associations and Medscape. The survey 
findings also mirror the impacts found in the time-series analysis, with a high awareness of 
ischemic heart events relating to rosiglitazone use and subsequent changes made in the 
management of patients taking rosiglitazone.  
The cardiovascular warnings of rosiglitazone in May 2007 also influenced the use of 
pioglitazone in both the PBS and AsteRx databases, where an increasing trend was seen.  
Pioglitazone was the most popular antidiabetic alternative for patients who switched from 
rosiglitazone after May 2007 in the AsteRx database. Additionally, the survey indicated 
that most practitioners would switch their patients from rosiglitazone to another antidiabetic 
medicine and one third of those would switch to pioglitazone. In 2008 when pioglitazone 
use surpassed rosiglitazone, almost half of those prescribed pioglitazone had switched 
from rosiglitazone.  
The 200% rise of pioglitazone from June 2007 to September 2008 may have resulted from 
the lack of clinical evidence around myocardial infarction associated with pioglitazone use 
and no alternative third-line drug for diabetes treatment. However, the use of pioglitazone 
was not sustained following the introduction of sitagliptin to the PBS in August 2008 
(Dormandy et al. 2005; Lincoff et al. 2007; PBS 2008). This trend in Australian pioglitazone 
use following the rosiglitazone warning is different from US and European studies that 
showed a decline in pioglitazone prescriptions and an increase in prescriptions for other 
available antidiabetic drugs such as sitagliptin and exenatide after the warnings in 2007 
(Hurren et al. 2011; Ruiter et al. 2012; Leal et al. 2013).  
Chapter 7 
 154 
2.2 Impacts of warnings about the risk of bladder cancer related to 
pioglitazone 
Since 2010, the use of pioglitazone gradually decreased in both PBS and AsteRx data, 
with 4.7% of total antidiabetic drugs in April 2010 to 3.4% in May 2011. Although a small 
decline in the dispensing and prescribing of pioglitazone were observed after the warnings 
issued by the local and international regulatory bodies on bladder cancer in June–July 
2011, this decline was not significant in the ARIMA model. In the AsteRx database, 
prescribers did not immediately stop prescribing pioglitazone after the warnings came out 
as seen with rosiglitazone. This insignificant decline of pioglitazone could be explained by 
the findings from the survey study which indicated there was a low awareness of the 
bladder cancer risk related to pioglitazone treatment and only 58% of those who were 
aware of the risk would change the management in patients taking pioglitazone. Another 
explanation could be due to the low incident rate of bladder cancer (3 cases per 1000 
pioglitazone users) compared to the high prevalence of ischemic heart disease, therefore 
prescribers may have been likely to consider that the benefits in glycaemic control of 
pioglitazone outweighed the possible risk of bladder cancer (Mamtani et al. 2012). 
2.3 Impacts of drug interaction warnings on the concomitant use of 
clopidogrel and proton pump inhibitors 
Approximately 90% of antisecretory agents coprescribed in clopidogrel users were PPIs 
during 2006–2011. Following the May 2009 EMA warning, to avoid omeprazole and 
suggesting pantoprazole as alternative PPI, the proportion of pantoprazole coprescribing 
significantly increased (p=0.011). A significant decrease in the coprescribing of 
omeprazole was not observed until after the second warning from the EMA in March 2010. 
The effects of warnings did not change the overall trend in the coprescribing of 
esomeprazole during the study period, which continued to be the leading coprescribed PPI 
choice in patients who were taking clopidogrel. There were significant increases in 
switching rates from esomeprazole and omeprazole to pantoprazole as well as an 
increased prevalence of pantoprazole initiations after May 2009. Despite the absence of 
local regulatory action, changes to the coprescribed proton pump inhibitors were seen in 
Australian data. In the survey study, half of respondents were aware of this interaction and 
most of them changed antisecretory agents from omeprazole and esomeprazole to 
pantoprazole in patients taking clopidogrel. An incline in the coprescribing of pantoprazole 
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after the overseas warning was likely to be from prescribers’ increased awareness of the 
reduced antiplatelet effect of clopidogrel when used concomitantly with CYP2C19 
inhibitors and the subsequent response of choosing pantoprazole over omeprazole or 
esomeprazole. Survey respondents suggested that they received safety information on the 
clopidogrel/PPI interaction from NPS Medicinewise, medical associations and the media 
that commonly reviewed the new evidence and provided or presented the 
recommendation not only from local but also key international authorities such as the FDA 
and EMA.  
3. Key points from the findings 
§ Regulatory warnings regarding two case studies were very different from three 
regulatory authorities. This suggests that we lack a uniform framework for 
assessing evidence and providing the recommendations for healthcare 
professionals and patients. 
§ Local dispensing and prescribing is influenced by many factors, including 
international drug warnings as seen by the significant decline in the use of 
rosiglitazone following the FDA and EMA warnings and the changes in the 
coprescribing of proton pump inhibitors with clopidogrel. Local systems such as 
available treatment choices in the national subsidised list are also important for 
changes to local trends (Hurren et al. 2011; Ruiter et al. 2012; Leal et al. 2013).  
§ Local prescribers vary in how they receive information about drug safety. The 
research literature as well as local and international warnings may not be directly 
accessed by practitioners but rather through articles or newsletters distributed by 
secondary sources or local organisations. Moreover, very few have a specific 
approach or strategy for receiving safety information.  
4. Possible future work 
4.1 Improving the framework for assessing and communicating drug safety  
The variability in response to safety signals from different regulatory bodies seen in the 
case studies described in this thesis illustrates the opportunity for future work on how 
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safety signals should be identified, assessed and communicated to healthcare 
professionals. 
Although several scales have been developed to assess the quality of studies on drug 
effects, most are not specific for evaluating pharmacoepidemiology studies (Loke et al. 
2007; Cornelius et al. 2009). Unlike randomised control trials, these studies reflect the use 
of drugs in real-life situations and are often confounded by many factors (e.g. confounding 
by indication) (Hermann et al. 2012).  
A well-established conceptual framework to assess the contribution of studies to the 
available evidence on an emerging safety issue is needed at either a national level or an 
international level. National regulatory agencies should come together to set up a guideline 
for appropriately assessing the quality and significance of evidence as a means to 
generate standard responses and recommendations. 
The benefits of this assessment framework are not only to improve the quality of regulatory 
decision making on an emerging safety events but also to facilitate the transparency and 
consistency of the regulatory process. 
Given that evidence regarding drug safety is often complex and emerges over time, to 
what degree should regulatory bodies provide prescribing guidance when the evidence is 
unclear. Currently, each national authority body has adopted different methods in 
response to this problem. The FDA often starts with the early communication stating 
‘safety issues are under review’ and issues reminders as the evidence emerges (Lester et 
al. 2013), whereas others may take no specific actions. The optimal mixture of guidance 
and evidence needs to be further assessed. 
4.2 Evaluation of the impact of safety warnings  
After the establishment of a framework for providing the recommendations regarding the 
use of the drug concerned, the effectiveness of a drug safety warning system should be 
evaluated. The evaluations will provide an understanding of the impact of warnings on 
utilisation patterns of products and help ensure that these warnings are suitable for the 
target prescribers and patients.  
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The analyses of utilisation data will help inform the current situation and provide data on 
whether changes have occurred as expected. If prescribing continued in an unsafe 
manner, further regulatory actions such as repeated warnings, increased restriction, or 
withdrawal may be needed (Smalley et al. 2000). These evaluations could also help 
identify the obstacles of the current system, which should be considered in the TGA’s 
strategies to reform safety communication.  
The assessment of a larger scale public expectation for drug safety warnings would guide 
the regulatory body in constructing a framework of safety communication. Firstly, the 
preference of methods and dissemination of safety communication may vary among health 
services (e.g. primary and secondary care), healthcare settings (e.g. urban and remote 
area) and different specialties. As this study did not concentrate on the methods of 
distribution, it would help improve the efficiency of safety communication by examining the 
preference of distribution methods such as a paper-based mail or electronic materials (e.g. 
email and website). Secondly, the contents required by different types of healthcare 
providers (e.g. physicians, nurses, pharmacists) and patients need to be assessed in order 
to receive an appropriate response from each target group.  
The impact of drug safety warnings on the use of drugs at a community level would differ 
from secondary or tertiary healthcare settings, especially when government subsidisation 
differs between States and/or hospitals. Appropriate study designs are needed to 
investigate the impact of safety warnings on drug use in hospital settings and also to 
provide a causal relationship between clinical reasons and changes in prescribing choice.  
5. Conclusions 
Evaluations of the impact of drug safety warnings on overall drug utilisation in Australia 
and prescribing data in the AsteRx database suggest an association between local drug 
use/prescribing decisions and international warnings. This study used a mixed method 
approach to assess the relationship between the level of awareness to safety warnings 
and the changes to dispensing and prescribing data. Whilst there was a small response 
rate in the survey study, the integrated results from changes of drug use in databases and 
perception from prescribers provide an overall understanding of impact of drug safety 
warning in Australia. Reminders of risk over time and the provision of treatment 
recommendations are associated with clear changes on drug utilisation. Apart from the 
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regulatory warnings, the influential factors on prescribing decisions are certainty of 
evidence, prevalence/incidence of adverse events, and treatment options.  
The combined approach taken in this project provides a basic guideline for investigating 
the impacts of drug safety warnings in Australia. The findings of this research provide an 
overview of current drug safety warnings and also suggest the potential areas for 
improvement to the local drug warning system. 
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Appendix 1RESEARCH ARTICLE Open Access
Utilisation trends of rosiglitazone and pioglitazone
in Australia before and after safety warnings
Suvimol Niyomnaitham1,2*, Andrew Page3, Adam La Caze1, Karen Whitfield1 and Alesha J Smith1,4Abstract
Background: A series of drug safety warnings have recently been made by drug authorities relating to adverse
effects of rosiglitazone and pioglitazone on cardiovascular diseases and bladder cancer. The changes to the
patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health
authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Agency
(EMA) press releases or U.S. Food and Drug Administration (FDA) is unknown. This study investigated the utilisation
patterns of rosiglitazone and pioglitazone in Australia before and after warnings of major drug authorities.
Methods: We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit Scheme (PBS)
subsidised drug dispensing data for the Australian population from February 2004 to July 2012. The World Health
Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the
drug utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, which first occurred
in May 2007. The DDD/1000population/day were examined in a series of time-series regression analysis with the
drug safety warnings specified as interventions.
Results: Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 1.96/1000population/day in
January 2007. Then rosiglitazone use decreased significantly after the initial EMA press release and FDA warning on
cardiovascular risk in May 2007 (with a 15.04% average monthly decline, p-value <0.001), however use did not
significantly decrease after the TGA warning or subsequent EMA and FDA warnings. Pioglitazone utilisation
proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day during 2009–2010. However,
pioglitazone utilisation has slightly declined after the FDA, EMA, and TGA warnings related to bladder cancer.
Conclusions: Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone utilisation in
Australia. Rosiglitazone began to decline prior to TGA warnings in December 2007, which suggests that Australian
prescribers may have acted in response to scientific evidence or international safety warnings (EMA, FDA), prior to
the response of the TGA. Minor effects were observed after bladder cancer warnings on pioglitazone utilisation.
Keywords: Rosiglitazone, Pioglitazone, Safety warningsBackground
Thiazolidinediones (TZDs) were approved for type 2 dia-
betes mellitus (DM) treatment based on efficacy studies,
which showed a decrease in HbA1c, by 0.8-1.5% and im-
proved insulin sensitivity [1,2]. Both TZDs, rosiglitazone
and pioglitazone, were listed on the Australian Pharma-
ceutical Benefit Scheme (PBS) as subsidised second line* Correspondence: suvimol.niyomnaitham@uq.net.au
1School of Pharmacy, University of Queensland, 20 Cornwall Street,
Woolloongabba, Australia
2Faculty of Medicine Siriraj Hospital, Mahidol University, Wanglang Road,
10700 Bangkok, Thailand
Full list of author information is available at the end of the article
© 2014 Niyomnaitham et al.; licensee BioMed
Creative Commons Attribution License (http://
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.therapy with either metformin or a sulfonylurea in
November 2003 and later extended to triple oral therapy
with metformin and a sulfonylurea and in combination
with insulin [3].
In May 2007, a meta-analysis by Nissen and Wolski
found a small increased risk in myocardial infarction and
a borderline increase in cardiovascular death in patients
treated with rosiglitazone [4]; however, another ongoing
clinical trial evaluating cardiovascular outcomes of rosi-
glitazone showed cardiovascular events associated with
rosiglitazone [5] to be inconclusive. Because cardiovas-
cular disease can be a lethal complication in patientsCentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Appendix 1with diabetes mellitus, several studies have tried to es-
tablish the adverse cardiovascular effect associated with
rosiglitazone treatment [6,7].
Since then, drug regulatory authorities have investigated
these cardiovascular effects [8] and issued several warn-
ings on the use of rosiglitazone [9,10]. The Australian
regulatory authority, the Therapeutic Goods Administra-
tion (TGA) is responsible for ensuring the safety of med-
ical products within Australia [11]. The TGA distributes
safety information to healthcare professionals through
the “Safety Advisory” on the TGA’s website, similar to
that of the U.S. Food and Drug Administration (FDA)
drug safety communication [12] and European Medicines
Agency (EMA) press releases [13].
Since late 2008, PBS steadily limited the subsidisation of
rosiglitazone use in combination with insulin and triple
oral therapy [14]. On 1st July 2011, the PBS restricted
prescription of rosiglitazone by requiring prior telephone
approval [15].
While the meta-analysis raised a concern around the
cardiovascular risk of rosiglitazone, a study of pioglita-
zone showed that in comparison it was a safe alternative
with an insignificant increase in mortality, myocardial
infarction and stroke [16]. Pioglitazone also reduced the
risk of hospitalization for acute myocardial infarction in
patients with type 2 diabetes in comparison with rosigli-
tazone [16,17]. In June 2011, a French study suggested
an increased risk of bladder cancer in patients who were
treated with pioglitazone for more than one year leading
to a temporary withdrawal of pioglitazone by the French
Agency [18]. Another study in the US also indicated a
possible increase in bladder cancer risk in patients on
pioglitazone for more than 2 years, compared with dia-
betes patients who were not receiving pioglitazone [19,20].
The TGA, as well as FDA and EMA, announced safety
warnings outlining a possible risk of bladder cancer re-
lated to pioglitazone use in June-July 2011; however, there
have been no further updates on this issue [21-23].
The increasing risk of cardiovascular disease with
rosiglitazone led to a decrease in the utilisation pat-
terns, in the US [24,25] and some countries in Europe
[26,27]. It is expected that after the bladder cancer
warnings, pioglitazone will follow a similar utilisation
trend to that of rosiglitazone. However, it is plausible
that pioglitazone use may have slightly changed as a re-
sult of prescribers weighing up the benefit in blood
sugar control and prevention of cardiovascular events
versus the possible increased risk of bladder cancer, which
has a very low incidence (3 cases per 1000 pioglitazone
users) [19,20]. The dispensing patterns of rosiglitazone
and pioglitazone following the emerging cardiovascular
event and safety warnings have not been described in
Australia, although it is hypothesised that the trends will
follow that of the US and Europe. This study aims toescribe the patterns of rosiglitazone and pioglitazone use,
nd investigate the influential factors on changes of utilisa-
ion in Australia, with special focus on the safety warningsethods
ata sources
rug utilisation among populations over time can be ex-
mined using the World Health Organization Anatomic
herapeutic Chemical (ATC)/Defined Daily Dose (DDD)
ystem [28]. Data on monthly dispensed medicines were
btained from the PBS database, a national administrative
cheme which records drugs subsidised by the Govern-
ent for Australian citizens. The PBS database captures
ll subsidized drug formulations, cost and amount of dis-
ensing and period of drug dispensed by pharmacists for
atients used at home [29]. Drug dispensed data on the
BS database were used in research studied and shown to
epresent trends of drug utilisation in Australia [30,31].
osiglitazone and pioglitazone are listed as subsidised
rugs for all Australians therefore a complete record of
ispensed medicines was obtained [3]. Denominator pop-
lations from Centrelink [32] and the Australian Bureau
f Statistics [33] were used to calculate the DDD per 1000
opulation per day (the proportion of the population
eceiving a DDD of this drug per day). All the data for
his study were aggregated, routinely collected data and
ublically available via government sources, therefore
thics approval was not required.
Australian drug safety warnings for rosiglitazone and
ioglitazone were acquired from safety alerts and safety
nformation for health professionals on the TGA website
34]. We accessed the EMA’s safety announcements, called
press releases” [35], and the FDA drug safety communica-
ion [36] from their official websites. Since mid-2007,
ajor drug authorities have issued safety warnings related
o rosiglitazone and pioglitazone. The first TGA announce-
ent which highlighted the increased risk of ischemic
eart disease associated with rosiglitazone was issued in
ecember 2007 (TGA1) [37], followed by a second warn-
ng to avoid using rosiglitazone in patients with ischemic
eart disease in September 2010 (TGA2) [38]. The FDA
ad three announcements related to cardiovascular risk of
osiglitazone [39]; firstly, a safety alert in May 2007 (FDA1)
40], a label update on heart-related risks in August 2007
FDA2) [41], and then restrictions on rosiglitazone use in
eptember 2010 (FDA3) [42]. There were four EMA press
eleases on risk of ischemic heart disease in May 2007
EMA1) [43], October 2007 (EMA2) [44], January 2008
EMA3) [45] and September 2010 (EMA4) [46]. While the
GA and FDA still allowed rosiglitazone on the market,
he EMA suspended all medical products containing rosi-
litazone across Europe in September 2010 [46].197
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Appendix 1For pioglitazone, the FDA issued a warning on a possible
increased risk of bladder cancer in patients who used pio-
glitazone for longer than one year in June 2011 [23],
followed by the same warnings in the EMA press release
[21] and the TGA safety advisory [22] in July 2011.
Whilst there were other plausible types of information
sent to prescribers with regards to the drug safety, it is
recognized that the warnings from the FDA, EMA and
TGA have a large influence on drug safety communica-
tion. For example, the pharmaceutical companies market-
ing these medicines did not implement changes to the
Product Information until after the TGA announcement.
In Australia, medical media picked up this side effect once
it came out from the FDA as well as medical associations
issued the FDA warning on their articles.
Analyses
Monthly dispensing data of rosiglitazone and pioglita-
zone from January 2004 to July 2012 were converted to
DDD/1000population/day. Descriptive trends in rosigli-
tazone and pioglitazone utilisation were examined in the
time series of DDD/1000pop/day. The auto-regressive,
integrated, moving average model (ARIMA) integrates
the temporal size and direction dependency (autocorrel-
ation) inherent in time-series data to better characterize
changes in data over a period of time [47]. Autocorrel-
ation functions (ACF) and partial autocorrelation func-
tions (PACF) was used to obtain the best fitted model
for analysis as well as the Bayesian Information Criteria.
The percentage change in DDD/1000pop/day was used
to remove the trend component of the time series before
fitting into ARIMA models. The separate and combined
effects of the announcement of the EMA, FDA, and
TGA warnings on trends in rosiglitazone and pioglitazone
utilisation were also investigated by fitting into ARIMA
models. Impacts of drug safety warnings (interventions)
on the subsequent observations were then investigated
using the ARIMA model as a step-function (having a per-
manent and immediate impact on any subsequent trends).
All statistical analyses were performed with a 5% statistical
significance level using STATA 12.1 (StataCorp, College
Station, TX).
Results
A total of 1,686,087 rosiglitazone prescriptions and
2,405,881 pioglitazone prescriptions were dispensed dur-
ing January 2004-July 2012. We calculated the monthly
utilisation (DDD/1000population/day) using Australian
population data, which was in the range of 20.1 million
in 2004–22.9 million in 2012. As shown in Figure 1, the
rosiglitazone utilisation increased steadily from 2004 and
reached the peak in January 2007 with a defined daily
dose of 1.96 per 1000 people per day. However, in May
2007, the trend of rosiglitazone utilisation startedecreasing and remaining lower than 0.50 DDD/
000pop/day in May 2009 and 0.15 DDD/1000pop/day
n July 2011. Pioglitazone utlisation has exceeded rosigli-
azone use since September 2008 and remained stable
uring 2009–2010 (1.5-1.7 DDD/1000pop/day). Never-
heless, the trend of pioglitazone utilisation appeared to
ecrease in September 2011.
There are no seasonal autocorrelation detected for
oth rosiglitazone and pioglitazone utilisations. Based on
isual inspection of PACF and ACF plots, an ARIMA
1,0,2) model best characterised for rosiglitazone data
nd pioglitazone data was best characterised as an
RIMA (1,0,1). Findings from ARIMA models indicated
hat the utilisation of rosiglitazone decreased signifi-
antly after the EMA1 and FDA1 warnings with −15.04%
er month (p-value <0.001) (Table 1). Additionally, the
tilisation of rosiglitazone also significantly decreased fol-
owing warnings from FDA2, EMA2, TGA1, and EMA3.
owever, after adjustment for FDA2, EMA2, TGA1, and
MA3 for preceding warnings, effects were attenuated
nd were no longer statistically significant (Table 1). Later
arnings relating to EMA4, FDA3, and TGA2 were not
ignificantly associated with decreases in rosiglitazone
se (Table 1).
For pioglitazone, although we can see a decline after
he FDA, TGA, and EMA warnings on bladder cancer in
une-July 2011, there is no statistically significant effect
n subsequent pioglitazone use after fitting this into
RIMA model (Table 1).
iscussion
he changes of rosiglitazone and pioglitazone utilisation
ere observed between 2004 and 2012 in Australia. It is
lways difficult to attribute cause to utilisation trends,
owever it is likely that increased marketing of TZDs
ay have contributed to the increasing trend of rosigli-
azone during 2004–2006 or that fewer alternatives to
etformin, sulfonylurea, and insulin were available at
his time. Our results show a decreasing trend in rosigli-
azone utilisation in the period after the drug authorities’
arnings in 2007–2008. Although the numbers of rosi-
litazone prescriptions in Australia are relatively low in
omparison to the UK, and North America, the overall
rends are consistent with those shown in Europe and
orth America [24,26,27,48]. There are two possible ex-
lanations for the dip seen in April 2007. It might be a
easonal trend as the same fluctuation was noted in
arch-April 2006; however, this was not sensitive
nough to be detected by the ARIMA model. Secondly,
he dip is an artifact of the data, this is actually the util-
sation on its way up which is demonstrated by the
igher use again in May 2007.
The sharply decreasing utilisation trend is significantly
ttributable to the safety alert from meta-analysis study198
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Figure 1 Utilisation of rosiglitazone and pioglitazone by the Australian population between 2004–2012. The drop-down lines indicate
months of drug safety warnings issued. Notes: Rosiglitazone warnings: EMA1-Reminded the risk of rosiglitazone in patients with cardiac failure
and other cardiac disorders including myocardial infarction. FDA1-Advised to evaluate the antidiabetic treatment options other than rosiglitazone
in patients who have underlying heart disease and high risk of heart attack. FDA2-Adds box warnings for heart-related risks of rosiglitazone.
EMA2-Suggested that rosiglitazone should only be used after careful evaluation of ischemic heart disease. TGA1-dvised that rosiglitazone should
not be prescribed for patients with known ischemic heart disease or at high risk for ischemic heart disease. EMA3-Suggested that rosiglitazone
must not be used in patients with an acute coronary disease. EMA4-Recommended suspension of all rosiglitazone-containing products. FDA3-Restricts
access to rosiglitazone due to an elevated risk of cardiovascular events. TGA3-Reinforced that rosiglitazone should not be used in patients with known
ischemic heart disease. Pioglitazone warnings: FDA-Announced the warnings on a possibly increased risk of bladder cancer in patients who used
rosiglitazone for longer than one year. TGA-Advised the prescribers that use of pioglitazone for more than a year may be associated with an
increased risk of bladder cancer. EMA-Recommends new contraindications and warnings for pioglitazone to reduce small increased risk of
bladder cancer. TGA = Therapeutic Good Administration; EMA = European Medicines Agency; FDA = U.S. Food and Drug Administration.
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Appendix 1and the initial warnings from the EMA and FDA in May
2007. For the reason that the FDA issued the cardiovas-
cular alert of rosiglitazone on the same day as publication
by Nissen et al. [4], we could not distinguish the effects
between the authority warnings and the publication. O
Table 1 Effects of drug warnings on the utilisation of rosiglita
Drug authorities Time Warnings Adjusted fo
Rosiglitazone: ARIMA (1,0,2) model
EMA1_FDA1 May 2007 Ischemic heart
FDA2 Aug 2007 Label update heart related EMA1_FDA1
EMA2 Oct 2007 Ischemic heart EMA1_FDA1
TGA1 Dec 2007 Ischemic heart EMA1_FDA1
EMA3 Jan 2008 Ischemic heart EMA1_FDA1
FDA3, TGA2, EMA4 Sep 2010 EU suspended, EMA1_FDA1
US restriction
Pioglitazone: ARIMA (1,0,1) model
FDA June 2011 Bladder cancer
EMA, TGA July 2011 Bladder cancer
aCoefficient = Percentage change in magnitude and direction after the intervention.
bCI = confidence interval.
cStatistical significance at p value <0.05.
TGA = Therapeutic Good Administration; EMA = European Medicines Agency; FDA =
of America.urthermore, the effects of these warnings and associ-
ted literature are likely to be cumulative rather than a
iscrete effect on the following utilisation. Several re-
trictions in rosiglitazone subsidies from the PBS during
ctober 2008-Febraury 2009 were also examined; however,
zone and pioglitazone in Australia
r Coefficienta 95% CIb p value
- −15.04 [−21.86, −8.22] <0.001c
−2.61 [−40.41, 35.20] 0.893
, FDA2 1.94 [−95.49, 99.36] 0.969
, FDA2, EMA2 −5.25 [−38.01, 27.51] 0.837
, FDA2, EMA2, TGA1 −0.39 [−80.06, 79.28] 0.992
, FDA2, EMA2, TGA1, EMA3 1.25 [−8.99, 11.49] 0.811
- −5.76 [−13.91, 2.39] 0.166
- −6.57 [−14.80, 1.65] 0.117
U.S. Food and Drug Administration; EU = European Union; US = United States
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Appendix 1these impacts are not significant after adjustment for
previous warnings. As a result of the consecutive series
of cardiovascular warnings on rosiglitazone since 2007
and the limited access on PBS, the numbers of rosiglita-
zone prescriptions have remained lower than 5,000 per
month since 2010.
Australian utilisation of pioglitazone was less than half
of rosiglitazone during 2005–2007 and the increasing
trend in use was moderate compared to the Netherlands
and the US [25,27]. From 2008–2010, when peak levels
were reached, the increase in pioglitazone nearly mirrors
the decline in rosiglitazone. The findings suggest that
prescribers might have replaced rosiglitazone with the
same drug class pioglitazone [24,49], due to the reported
cardiovascular benefits of pioglitazone, and no clinical
outcome associated with an increase risk of ischemic
heart disease that was seen with rosiglitazone [7,17].
While the decreasing trend of pioglitazone was observed
in the US and Europe in 2008 [27,49], Australian pioglit-
azone utilisation plateaued until 2011. The delay in de-
creasing trend compared to that of other countries may
be attribute to limited availability of second-line and
third-line therapy alternatives such as sitagliptin (was not
PBS subsidised until August 2008) or exenatide (was not
PBS subsidised until August 2010) [50]. The US and UK
data [49,51] show that the number of other new drugs,
which were available in their markets since 2007 such as
sitagliptin and exenatide, increased after the cardiovascu-
lar alerts of TZD. Nevertheless, Figure 1 shows the decline
in the utilisation of pioglitazone after July 2011. This de-
creasing trend may have been caused by more alternative
treatments on the PBS or the safety concern of increased
risk of bladder cancer in long-term users of pioglitazone.
Although, this decline was of a lesser magnitude than
for rosiglitazone, prescribers may consider the risk/benefit
ratio, where the benefits of pioglitazone in lowering blood
sugar outweigh the possible risk of bladder cancer [52].
However, more data points following this bladder cancer
risk might be needed to examine the true effect of this
warning.
Since TGA safety warnings are considered by the
Australian Department of Health and Aging to be first-
line alerts to Australian prescribers, we would expect to
see a significant effect on these utilisations. However, the
fact that a) the decline in rosiglitazone use occurred prior
to the first TGA warning, and b) after we adjusted for the
preceding EMA, FDA warnings, we could not see a sig-
nificant effect of the TGA warning on utilisation trends
suggests that Australian prescribers were aware of the
international warnings as well as the safety information
from the literature. This might be associated with the way
that information was delivered, since Australian warnings
were delayed, less frequently communicated, and accessed
compared to the FDA and European warnings [38,53].ustralian prescribers may receive safety information
rom medical articles or media that referred to the US
r European warnings. A further qualitative study is being
onduct to gain the insight into sources of drug safety
nformation among Australian prescribers.
Since time series model prediction is based on the pat-
ern of drug use in the past confounding influences on
ata may be difficult to disentangle. Although trends can
e impacted by temporal changes in drug supply or the
ay data are recorded, we did not find those problems
uring study period. Furthermore, the Australia PBS data
s aggregated data collected for administrative purposes,
hich does not link utilisation to the prescribing data in
linical settings. Therefore, clinical reasons for the de-
rease in dispensing cannot be fully investigated, nor
rimary non-compliance in patients be established.
The strength of this study is that it captures almost all
rescriptions dispensed over 2004–2012 in total Australian
opulation (private prescriptions represent a very small
ercentage of all prescriptions). This is achieved because
osiglitazone and pioglitazone are ‘high’ cost drugs that are
overnment subsidised in Australia. This allowed us to in-
estigate the patterns of population based thiazolidine-onclusions
he utilisation of rosiglitazone significantly decreased fol-
owing the authorities’ safety warnings on ischemic heart
isease. The pattern of rosiglitazone utilisation started de-
lining significantly prior to the TGA warning in December
007; therefore it appears that Australian prescribers were
lerted by the literature and international warnings such
s EMA and FDA. In contrast, pioglitazone utilisation in-
reased during the rosiglitazone warning period during
007–2010. In comparison to the US and Europe, the de-
line in pioglitazone trend was much more deferred due
o no available second and third line therapies in Australia.
espite concerns surrounding the possible risk of bladder
ancer with long term use of pioglitazone, this study
howed weaker effects of safety warnings on bladder can-
er and pioglitazone utilisation. A number of publications
ave studied the effect of authorities’ warnings in the US
nd Europe to improve their warning systems [27,54,55].
his is one of the first studies to date that has investigated
tilisation patterns in relation to drug safety warnings in
ustralia and suggests that TGA warnings may not affect
rescribing in cases such as this where prescribers may be
ttuned to particular medicine safety issues described in
arlier international warnings or literature. Further re-
earch is needed to understand how and when prescribers
btain drug safety information in Australia. This is par-
icularly pertinent as Australia and New Zealand look to
ombine their drug safety warning systems.200
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Appendix 1Abbreviations
TGA: Therapeutic good administration; EMA: European medicines agency;
FDA: U.S. food and drug administration; PBS: Pharmaceutical benefit scheme;
DDD: Defined daily dose; TZD: Thiazolidinedione; DM: Diabetes mellitus;
ARIMA: Auto-regressive, integrated, moving average model;
ACF: Autocorrelation functions; PACF: Partial autocorrelation functions;
CI: Confidence interval.
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Participant Information Sheet (Version 1, 9 September 2013) 
 
Semi-structured interview: Prescriber perspectives towards the drug safety warning in Australia using the 
warnings on clopidogrel and thiazolidinediones as case studies 
 
Principal Investigator: Suvimol Niyomnaitham 
Co Investigators:  Alesha Smith 
   Adam La Caze 
   Karen Whitfield 
 
1. Your Consent 
You are invited to participate in a semi-structured interview because you are prescribers and regulatory 
perssonel in Australia. 
 
This participant information and consent form contains detailed information about the research project. Its 
purpose is to explain to you as openly and clearly as possible all the procedures involved in this project 
before you decide whether or not to take part in it.  
Please read this participant information sheet carefully. Feel free to ask questions about any of the 
information in the document.   
Once you understand what the project is about and if you agree to take part in it, you will be asked to sign 
the Consent Form. By signing the Consent Form, you indicate that you understand the information and that 
you give your consent to participate in the research project. 
You will be given a copy of the participant information sheet and consent form to keep for your records. 
2. Background and purpose 
Changes in prescribing occurred following the release of regulatory safety warnings regarding the 
clopidogrel and proton pump inhibitor interaction and adverse effects of thiazolidinediones. Prescriber 
perspectives towards the drug warning system in Australia and prescribing decisions in response to these 
warnings will inform how these prescribing changes take place. 
This study conducted by researchers at the University of Queensland aims to investigate prescribers’ 
attitudes toward the current drug warning system in Australia and investigate prescribing decisions in 
response to emerging safety warnings. 
3. Procedures 
Participation involves a one-on-one interview with the principal researcher.  The interview will last 15–20 
minutes. You will be asked to respond to questions regarding sources of drug safety information, opinion on 
drug safety processes in Australia and prescribing decisions in response to drug safety information. 
The interview will be recorded and later transcribed by the principal investigator. No identifying information 
will be recorded. 
There are no right or wrong answers to any of the questions in the interview; it is your view and opinion that 
is important. 
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4. Possible Benefits and Risks 
Your experience will help us understand how prescribers respond to the drug warning system in Australia 
and provide information on the impact of drug warnings on prescribing decisions. These data may lead to 
improved communication and collaboration between drug authorities and prescribers. 
It is not anticipated that any risks will be associated with participating in the project. No identifying 
information will be collected during the interview. You can stop the interview at any time. 
5. Participation, Privacy, Confidentiality and Disclosure of Information 
Participation is voluntary. If you decide to take part and later change your mind, you are free to withdraw 
from the study anytime without giving a reason. 
The information collected from you will be stored in a locked filing cabinet in a locked office. Access will 
only be given to researchers involved in this project. The data will be stored for a period of 7 years and then 
will be destroyed. 
All information collected as part of this research will be collected, stored and reported in non-identifiable 
manner (no names or other personal identifiers will be collected). 
6. Results of the Project 
The data from the study will be analysed by the research team at the University of Queensland and the 
aggregated results will be published in health care journals to inform other health care professionals and 
researchers. You may request a summary of the results from Dr Suvimol Niyomnaitham. 
 
8. Further Information or Any Problems 
If you have any concerns or questions about this study or the way it has been carried out, you should contact: 
Dr Suvimol Niyomnaitham at the University of Queensland, School of Pharmacy Phone: (07) 3346 1995 
email: suvimol.niyomnaitham@uq.net.au 
 
9. Other Issues   
This study has been approved by the School of Pharmacy Ethics Committee in accordance with the National 
Health and Medical Research Council's guidelines. If you would like to speak to an officer of the University 
not involved in the study, you may contact the Ethics Officer on 3365 3924.  
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Pharmacy Australia Centre of Excellence         Woolloongabba Qld 4102 Australia F +61 7 3346 1999                  W  www.uq.edu.au/pharmacy 
The University of Queensland 
PARTCIPANT CONSENT FORM 
 
Semi-structured interview: Prescriber perspectives towards the drug safety warning in Australia using 
the warnings on clopidogrel and thiazolidinediones as case studies 
 
• I confirm that I have read and understand the information sheet for the above study and have had the 
opportunity to consider the information, ask questions and have had these answered satisfactorily. 
•  I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my legal rights being affected. 
• I understand that all my information and the data generated will be kept anonymous and confidential 
• I agree to being interviewed 
• I give consent for the researchers to record my voice in the interview 
• I give consent for the researchers to the use anonymised quotes from my interview in reports or 
publications. 
 
 
By signing this document I agree to participate in this project.  
 
Full Name of Participant (printed):………………….………………….…….……………… 
 
Signature of Participant:………………………………….………  Date:….…/……/………. 
  
 
 
Full Name of Researcher (printed):………………… ………...…………………………….. 
 
Signature of Researcher:…………………..……………….....…..  Date:……./……/…..…. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr Suvimol Niyomnaitham 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Ph: 0 7 3346 1995 
E: suvimol.niyomnaitham@uq.net.au 
Dr Alesha Smith 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Ph: 0 7 3346 1900 
E: asmith@pharmacy.uq.edu.au
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Semi-structured interview: The impacts of the drug safety warnings on prescribing in 
Australia 
Target participants: Therapeutical Goods Administration (TGA) personnel 
Principal Investigator: Dr Suvimol Niyomnaitham 
Co Investigators:  Dr Alesha Smith, Dr Adam La Caze, and Dr Karen Whitfield School of 
Pharmacy, University of Queensland 
Objective: This interview is aiming to assess the TGA’s roles on emerging safety 
concerns in post-marketed drugs. It is hypothesised that regulatory safety warnings are 
one of the primary influences on the changes in prescribing behaviour. 
Interview questions:  
1. How does the TGA decide when a safety signal requires a warning?  
2. How would you compare the TGA’s approach to the US and European regulatory 
bodies? How do the international warnings such as FDA and EMA have any 
influence on TGA’s warning? 
3. What are strategies that TGA used for promoting drug safety warnings? 
4. What is the relation between the TGA and the Pharmaceutical Benefit Scheme 
(PBS) regarding the emerging of safety signal of drugs listed in the PBS?  
5. From the TGA aspect, currently, what is the most effective tool for drug safety 
communication between the TGA and Healthcare professionals? 
6. What do you think is the primary influence on prescribing behaviour following a 
safety signal? 
7. How does the TGA evaluate the effectiveness of drug safety warnings in Australia? 
8. What do you think are the key challenges for the TGA in identifying a safety signal 
and in distributing a safety communication? 
 
Dr Suvimol Niyomnaitham 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Phone: 0 7 3346 1995                                             
E: suvimol.niyomnaitham@uq.net.au 
 
Dr Alesha Smith 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Phone: 0 7 3346 1995                                             
E: asmith@pharmacy.uq.edu.au 
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Semi-structured interview: Prescribers perspective towards drug safety warnings in 
Australia 
Target participants: General practitioners and specialists 
Principal Investigator: Dr Suvimol Niyomnaitham 
Co Investigators:  Dr Alesha Smith, Dr Adam La Caze, and Dr Karen Whitfield School of 
Pharmacy, University of Queensland 
Objective: This interview is aiming to assess the prescribers perspective towards current 
drug safety warnings and two recent drug safety warnings on thiazolidinediones and 
clopidogrel and proton pump inhibitor interaction 
Interview questions:  
Part One: Drug safety information on emerging concerns 
1. What are your sources of drug safety information when there is a new side effect or 
contraindication of a post-marketed drug? 
2. How do these safety information influence your practice? 
3. How familiar are you with the process of drug safety warning from the Therapeutic 
Goods Administration (TGA)? 
4. How do you usually find out about TGA drug safety warnings? 
5. What are your opinions on how TGA communicate with you regarding the drug 
safety information in term of access to the safety warning and information for your 
practice? 
6. Are you aware of warnings issued by overseas regulatory bodies such as European 
Medicine Agency (EMA) or the United States Food and Drug Administration (FDA)? 
 
Part Two: Recent drug safety warnings  
 
Adverse effects of rosiglitazone and pioglitazone 
 
1. Are you aware of the cardiovascular risk of rosiglitazone and bladder cancer risk 
associate with pioglitazone? 
2. How did you find out about these safety issues? 
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3. How did the safety warnings on these adverse effects influence your prescribing 
decision? Do you make a decision on prescribing these drugs by yourself or consult 
the specialists? 
4. How did your decision on these adverse effects changed as the evidence or 
warnings have been updated over time? 
 
Interaction between clopidogrel and proton pump inhibitors 
 
5. Are you aware of the interaction between clopidogrel and proton pump inhibitors? 
6. How did you find out about this safety issue? 
7. How did the safety warnings on this interaction affect your prescribing practice? Do 
you make a decision on prescribing these drugs by yourself or consult the 
specialists? 
8. Have your opinions on these warnings changed over time as the different evidence 
or warnings have come out? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr Suvimol Niyomnaitham 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Phone: 0 7 3346 1995                                             
E: suvimol.niyomnaitham@uq.net.au 
 
Dr Alesha Smith 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Phone: 0 7 3346 1995                                             
E: asmith@pharmacy.uq.edu.au 
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Participant Information Sheet 
Survey study: Prescriber perspectives of drug safety warnings 
Principal Investigator: Suvimol Niyomnaitham 
Co Investigators: Alesha Smith, Adam La Caze, Karen Whitfield 
What is the purpose of the study? 
This study conducted by researchers at the University of Queensland aims to investigate prescribers’ 
attitudes toward the current drug warning system in Australia and investigate prescribing decisions in 
response to emerging safety warnings. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. You are free to withdraw from the study at any time 
without giving a reason.  
What will happen to me if I take part? 
We would like you to fill in an online survey. This should take no more than 10-15 minutes to complete. The 
survey is available via https://www.surveymonkey.com/s/ImpactOfDrugWarning. By completing the survey, 
you consent to participate in this study. 
What are the possible benefits of talking part? 
Your experience will help us understand the impact of drug warning systems in Australia, which may lead to 
improved communication and collaboration between drug authorities and prescribers. 
Will my taking part in the study be kept confidential? 
Yes. All the information you provide in the survey will be anonymous and confidential. You will not be 
identified in any publications or documents arising from this study.  
What if there is a problem or I have further questions? 
If you have any concerns or questions about this study or the way it has been carried out, you should contact: 
Dr Suvimol Niyomnaitham at the University of Queensland, School of Pharmacy Phone: (07) 3346 1995 
email: suvimol.niyomnaitham@uq.net.au  
What will happen to the results of the research study? 
The data from the study will be analysed by the research team at the University of Queensland and the 
aggregated results will be published in health care journals to inform other health care professionals and 
researchers. You may request a summary of the results from Dr Suvimol Niyomnaitham.   
Who has reviewed the study? 
This study has been approved by the School of Pharmacy Ethics Committee in accordance with the National 
Health and Medical Research Council's guidelines. If you would like to speak to an officer of the University 
not involved in the study, you may contact the Ethics Officer on 3365 3924. 
Dr Suvimol Niyomnaitham 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Ph: 0 7 3346 1995 
E: suvimol.niyomnaitham@uq.net.au 
Dr Alesha Smith 
School of Pharmacy 
The University of Queensland, QLD, 4102 
Ph: 0 7 3346 1900 
E: alesha.smith@uq.edu.au
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Prescriber perceptions of drug safety warnings
1. How many years have you been practicing medicine (post­internship)?
2. What is your medical specialty?
3. Where do you practice? (can choose more than 1 place)
Part I. Demographics
*
*
<5nmlkj
5­9nmlkj
10­14nmlkj
15­19nmlkj
>=20nmlkj
General practitionergfedc
Internal medicinegfedc
Cardiologygfedc
Gastroenterologygfedc
Endocrinologygfedc
Geriatricsgfedc
Pharmacygfedc
Other (please specify)gfedc
Private hospital/clinicgfedc
Public hospitalgfedc
Community medical centregfedc
Other (please specify)gfedc
Other 
Other 
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Prescriber perceptions of drug safety warnings
4. What are your main sources of information regarding drug safety warnings?
(Can choose more than one)
5. Are there any other sources that you used other than specified in Question 4?
6. Do you receive drug safety information from TGA?
Part II. Drug safety warnings
*
6 Therapeutic Goods Administration (TGA) gfedc N/A
6 International authorities e.g. U.S. Food and Drug Agency (FDA), European Medicines Agency (EMA) gfedc N/A
6 Medical research publication gfedc N/A
6 Medical association e.g. Diabetic association, heart association, etc. gfedc N/A
6 Medscape gfedc N/A
6 Australian prescriber gfedc N/A
6 NPS MedicineWise gfedc N/A
6 Drug package inserts gfedc N/A
6 Conferences/meetings gfedc N/A
6 Discussion with physician colleagues gfedc N/A
6 Discussion with pharmacists gfedc N/A
6 News or other media gfedc N/A
*
Nonmlkj
Yes, please specifynmlkj
Yesnmlkj
Nonmlkj
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Prescriber perceptions of drug safety warnings
7. What is your main communication tool from the TGA for drug safety information?
(can choose more than 1)
8. The emerging drug safety information provided by the TGA is adequate to make an
informed decision for my practice.
9. The TGA drug safety information is more timely than the U.S.FDA or the European
Medicines Agency information.
10. I am familiar with the TGA's role.
During 2009­2010, many drug authorities issued warnings on the interaction between clopidogrel and proton pump 
inhibitors (PPIs) via enzyme CYP2C19, especially omeprazole and esomeprazole; indicating that, PPIs may reduce 
the antiplatelet effect of clopidogrel.  
11. Are you aware of ther interaction between clopidogrel and proton pump
inhibitors?
Strongly disagree Somewhat disagree Neutral Somewhat agree Strongly agree
nmlkj nmlkj nmlkj nmlkj nmlkj
Strongly disagree Somewhat disagree Neutral Somewhat agree Strongly agree
nmlkj nmlkj nmlkj nmlkj nmlkj
Strongly disagree Somewhat disagree Neutral Somewhat agree Strongly agree
nmlkj nmlkj nmlkj nmlkj nmlkj
Part III. Coprescribing of clopidogrel and proton pump inhibitors
*
TGA websitegfedc
TGA_SAFETYINFO subscribed emailgfedc
RSS feedsgfedc
Medicine Safety Update articles on the Australian Prescribergfedc
Other (please specify)gfedc
Yesnmlkj
Nonmlkj
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Prescriber perceptions of drug safety warnings
12. Which source did you rely on the most for the interaction between clopidogrel and 
proton pump inhibitors? (can choose more than 1)
13. How did the drug safety warnings on the interaction between clopidogrel and 
proton pump inhibitors affect your management of patients who were taking 
clopidogrel? (can choose more than 1)
*
Therapeutic Goods Administration (TGA)
 
gfedc
International authorities e.g. U.S. Food and Drug Agency (FDA), European Medicines Agency (EMA)
 
gfedc
Medical research publication
 
gfedc
Medical association e.g. diabetic association, heart association
 
gfedc
Medscape
 
gfedc
Australian prescriber
 
gfedc
NPS MedicineWise
 
gfedc
Drug package inserts
 
gfedc
Conferences/meetings
 
gfedc
Discussion with physician colleagues
 
gfedc
Discussion with pharmacists
 
gfedc
News or other media
 
gfedc
Other (please specify)
 
 
gfedc
Made no changes
 
gfedc
Prescribed PPI with dosage adjustment
 
gfedc
Prescribed PPI with a weak inhibitory effect on CYP2C19 (e.g. pantoprazole)
 
gfedc
Prescribed histamine 2 receptor antagonists (e.g. ranitidine) instead of PPI
 
gfedc
Stopped prescribing all proton pump inhibitors
 
gfedc
Other (please specify)
 
 
gfedc
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Prescriber perceptions of drug safety warnings
14. What is your antisecretory drug of choice to prescribe in patients who are taking 
clopidogrel?  
e.g. Discharge medication for a 65­year­old patient with history of upper GI who was 
hospitalised with ischemic heart disease.
15. Would you initiate a new prescription of omeprazole or esomeprazole in patients 
taking clopidogrel?
During 2007­2010, several drug authorities issued safety warnings on the risk of cardiovascular disease associated 
with rosiglitazone. 
16. Are you aware of the cardiovascular risk associated with rosiglitazone?
 
Part IV. Rosiglitazone
*
 
Omeprazole
 
nmlkj
Pantoprazole
 
nmlkj
Lansoprazole
 
nmlkj
Esomeprazole
 
nmlkj
Rabeprazole
 
nmlkj
Histamine 2 receptor antagonist (e.g. ranitidine, famotidine, nizatidine)
 
nmlkj
Other (please specify)
 
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
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Prescriber perceptions of drug safety warnings
17. Which source did you rely on the most for the cardiovascular risk of rosiglitazone? 
(can choose more than 1)
18. How did the drug safety warnings on rosiglitazone affect your management of 
patients who were using rosiglitazone? (can choose more than 1)
In 2011, several drug authorities had announced that long­term use of pioglitazone might be associated with an 
increased risk of bladder cancer.  
19. Are you aware of an increased risk of bladder cancer associated with long­term 
pioglitazone use?
 
Part V. Pioglitazone
*
 
Therapeutic Goods Administration (TGA)
 
gfedc
International authorities e.g. U.S. Food and Drug Agency (FDA), European Medicines Agency (EMA)
 
gfedc
Medical research publication
 
gfedc
Medical association e.g. diabetic association, heart association
 
gfedc
Medscape
 
gfedc
Australian prescriber
 
gfedc
NPS MedicineWise
 
gfedc
Drug package inserts
 
gfedc
Conferences/meetings
 
gfedc
Discussion with physician colleagues
 
gfedc
Discussion with pharmacists
 
gfedc
News or other media
 
gfedc
Other (please specify)
 
 
gfedc
Made no changes
 
gfedc
Discontinued rosiglitazone in patients with high risk of cardiovascular disease
 
gfedc
Discontinued rosiglitazone in all patients
 
gfedc
Switched to pioglitazone
 
gfedc
Switched to other antidiabetic drug class
 
gfedc
Other (please specify)
 
 
gfedc
Yes
 
nmlkj
No
 
nmlkj
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Prescriber perceptions of drug safety warnings
20. Which source did you rely on the most for the bladder cancer risk of pioglitazone? 
(can choose more than 1)
21. How did the drug safety warnings on pioglitazone affect your management of 
patients who were using pioglitazone? (can choose more than 1)
22. Please let us know if you have any further comments about the Australian drug 
safety warning system.
 
 
Thank you for your participation.
5
6
Therapeutic Goods Administration (TGA)
 
gfedc
International authorities e.g. U.S. Food and Drug Agency (FDA), European Medicines Agency (EMA)
 
gfedc
Medical research publication
 
gfedc
Medical association e.g. diabetic association, heart association
 
gfedc
Medscape
 
gfedc
Australian prescriber
 
gfedc
NPS MedicineWise
 
gfedc
Drug package inserts
 
gfedc
Conferences/meetings
 
gfedc
Discussion with physician colleagues
 
gfedc
Discussion with pharmacists
 
gfedc
News or other media
 
gfedc
Other (please specify)
 
 
gfedc
Made no changes
 
gfedc
Continue pioglitazone with bladder cancer screening
 
gfedc
Discontinue pioglitazone in patients with high risk of bladder cancer
 
gfedc
Discontinue pioglitazone in all patients
 
gfedc
Switched to other antidiabetic drug class
 
gfedc
Other (please specify)
 
 
gfedc
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Evidence into Action – GMSBML’s 
Commitment to General Practice 
Greater Metro South Brisbane 
Medicare Local conducted an 
evaluation of the expectations of 
GPs and practice employees to 
gain an understanding of how 
GMSBML can improve their 
services to meet the future needs 
of General Practice in 2014/15. 
GMSBML CEO Simon James 
said the Medicare Local is 
making a strong commitment to 
local health service providers to 
ensure that the organisation 
continues to deliver responsive 
services based on the identified 
priorities. 
“Medicare Locals provide a vital link between our General 
Practices, allied health providers and the public and private 
hospital system.  Fostering these relationships at the local level 
and knowing the needs and priorities for our community’s health 
providers is fundamental to what we do. 
“The more we learn about the unique needs of our diverse health 
provider community then the stronger the services GMSBML can 
provide,” Mr James said. 
One of GMSBML’s highest rated programs is Positive Impact. 
“It was no surprise that Positive Impact rated so well. The 
program recently celebrated its 2000th participant.  That’s over 
2000 lives that have been changed due to the ongoing 
partnership between our General Practices and this Medicare 
Local,” Mr James said. 
Other services that ranked well include: 
 Access to Allied Psychological Services (ATAPS) 
 After Hours and  
 Immunisation. 
“We are committed to continue building on this strong foundation 
to deliver responsive services to our GPs and their practice 
teams,” Mr James said. 
Read the full Evidence into Action report here. 
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2000 Participants and Counting for Positive Impact  
GMSBMLs Positive 
Impact program recently 
celebrated its 2000th 
participant. The program 
has quadrupled the 
number of participants in 
the last 12 months.  
Positive Impact can 
support your patients who 
want help with weight loss 
but can’t afford it or don’t 
qualify for a care plan. 
The service offers a free 
6 or 12 month program 
that promotes sustainable 
lifestyle changes and is 
delivered over the phone 
by Phone Coaches 
(dietitians and 
nutritionists). 
To find out how you can refer patients into the Positive Impact program visit http://www.gmsbml.org.au/Positive-
Impact-Health-Professionals.php or phone our Positive Impact Team on 07 3390 2466. 
GMSBML’s Bee Wise Immunise Bike Comp is back 
GMSBML launched their popular 4-year-old bike 
competition for the second year running to coincide with 
World Immunisation Week on 24-30 April. 
The 2014 theme is Immunise for a healthy future: Know, 
Check, Protect.  
GMSBML continues to support practices to continue their 
great work in promoting flu vaccinations, school based 
programs and childhood immunisations. 
If your practice would like to register for the bike 
competition or would like any support around immunisation 
please contact Carmel Vellacott and Jenny Pethoe on 
1300 467 265 or immunisation@gmsbml.org.au.  
Teddy Bear Hospital Helps to Educate Children 
Building health literacy within our community is a key activity for GMSBML. 
To have the greatest chance of success we need to start this process as 
early as possible.  
GMSBML are partnering with Griffith University medical students and 
Hope4Health to deliver the Teddy Bear Hospital to early primary school 
students. The first of three sessions kicks off on Monday 5 May. More than 
100 year three students from Woodridge and Marsden State Schools will be 
treated to a fun and informative session talking about healthy eating, 
exercise, hygiene, dental health and visiting the doctor and dentist. To 
support this initiative GMSBML are developing age appropriate materials for 
the kids and resources to help schools continue to deliver the message to 
students. We hope to be able to offer this program to more schools in our 
service area next financial year. 
 
 
 
 
  
GMSBMLs Positive Impact Team 
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REMINDER: Bonus payment for GP After Hours Providers 
As reported in last fortnight’s newsletter, as a result of the 
negotiations with the Medical Deputising Service, 
GMSBML is now in a position to share these savings with 
you in recognition of the contribution the participating 
practices have made to maintaining after hours service 
delivery during the 2013/14 year. 
Bonus payments will be paid to practices upon receipt of 
the completed January – March After Hours reports (and 
any other outstanding reports) and a correctly rendered 
invoice, including GST being submitted.  
There are still over 40 reports outstanding and will be 
required to be completed to receive the bonus payment. 
For each report please ensure that: 
 Your practice name is on your report. If you think you 
may have sent back your report without your 
practice’s name, please contact us. 
 The full report is returned. If you do not have any information to enter for some parts of the report, write 
nil in the space provided and return all pages. 
 The report page regarding operating hours is returned. 
For further information on the After Hours reporting requirements please contact our After Hours Service on 
1300 467 265 or email afterhours@gmsbml.org.au. 
GMSBML Supports Expansion of Healthy Start Program 
For the past two years GMSBML have supported 
Hope4Health to deliver the Healthy Start program. Healthy 
Start provides easy to understand information on visiting a 
GP, medicine safety, healthy eating and hygiene as well as 
men’s and women’s health messages for recently settled 
refugees. Many of these people have lived for considerable 
periods of time in camps with limited health care. GMSBML 
is committed to ensuring they are supported in their 
navigation of the Australian health care system.  
Healthy Start has recently expanded its team of facilitators 
from Griffith University to include students from 
Queensland University of Technology, University of 
Queensland and Bond University which will ensure the 
program is able to be delivered more widely and help more 
refugees. To fund this expansion Hope4Health have 
dedicated the funds raised by their annual dinner dance 
towards the Healthy Start program. 
The Jazz Dinner Dance will be attended by over 350 
doctors and medical students. Each year this black tie 
charity ball raises money to support a different health 
project. 
This year and with your help, Hope4Health are hoping to 
raise even more funds for Healthy Start to enable the 
project to be maintained in Queensland as well as expand 
into other universities including Australian National 
University, University of Western Sydney and James Cook 
University. Visit hope4health.org.au to see the range of 
work they are involved in. 
Put Saturday 13 September as a date claimer in your calendar and help support this program. Tickets are on 
sale soon. 
 
  
Workshop participants at Multicultural 
Development Association (MDA) 
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PCEHR – GMSBML’s First Allied Health Provider on Board 
Greater Metro South Brisbane Medicare Local’s eHealth team has 
signed up their first allied health provider to be fully compatible with and 
ready to use the Personally Controlled Electronic Health Record 
(PCEHR) system. 
 
This is the first of many providers who are well on their way to being  
connected to the national system. The PCEHR provides many benefits 
to healthcare providers and their patients. The system allows timely 
access to patient information, such as medications, shared health 
summaries, event summaries, immunisations, discharge summaries and 
allergies.  
 
The following allied health scenario demonstrates the benefits of the 
PCEHR:  
 
A woman in her mid 40’s presents to a dietician: The woman is a busy person, with many competing priorities. 
When asked by the dietician her current medications and previous medical history, the woman cannot 
remember correctly or accurately. 
 No PCEHR  With a PCEHR 
Medical history and current 
conditions 
Disjointed, fragmented information 
is given.  
The dietician can see: previous 
medical history and current health 
conditions, in around 10 seconds.  
Current medical conditions Some medications mentioned.  The current medications are known. 
Allergies None mentioned. All allergies and adverse reactions 
listed clearly. 
  
When the women goes to see her exercise physiologist:  
 No PCEHR With a PCEHR 
Treatment The session with the dietician is not 
recalled well and there is nothing 
about the dieticians appointment in 
the GP’s faxed notes.  
Exercise physiologist can see the 
diagnosis and treatment prescribed 
by the woman’s dietician and GP.  
If your Allied Health practice is interested in becoming connected to the PCEHR system, please contact 
Jenaya Wyatt on 1300 467 265 or email eHealth@gmsbml.org.au. 
Health and Wellbeing Programs Assisting Hundreds 
GMSBML has delivered 74 health and wellbeing sessions 
over the period of October 2013 to March 2014.  The team 
has assisted a total of 226 participants to achieve and 
maintain a healthy lifestyle.  Participants came along for a 
period of 6-10 weeks to learn new skills and recap on some 
old skills to make their day to day life more bearable when 
living with a long term health conditions or those at risk.  The 
most common feedback received is that participants are so 
grateful they are able to meet with others who know what 
they are going through and can support each other to make 
lifestyle changes. 
One of our past participants said;  
“I thought prior to commencing the course that I had heard it 
all before and possibly had. However this program clarified 
much and has greatly assisted me to understand how I can 
help myself more. I thoroughly recommend it to others” 
For further information about the health and wellbeing programs visit http://www.gmsbml.org.au/Health-
Professionals-Services-Health-and-Wellbeing-Group-Programs.php or contact Susan Tippett 
(stippett@gmsbml.org.au) or Michelle Nielsen (mnielsen@gmsbml.org.au) on 3290 3733. 
  
 
 
The Pain Self-Management Program group at 
the Browns Plains Library  
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Secure your spot at GMSBML’s Popular Annual Forum 
GMSBML are holding the second Healthy Communities Consultation Forum on 27 May 2014 at Brisbane 
Technology Park. If you have received an invitation please book your place as soon as possible as numbers 
are strictly limited. 
Click here to register http://goo.gl/z5pZtv. 
Please note as a private health professional you will be renumerated as per GMSBML’s remuneration policy 
for your attendance at this event, however places are limited.  
 
 
 
 
 
 
 
 
 
 
 
Yarning Sessions Identify Opportunities 
As part of our Health Literacy Program GMSBML is delivering and supporting a number of initiatives focusing 
on Aboriginal and Torres Strait Islander communities. 
Yarning sessions with Aboriginal and Torres Strait Islander communities were held in April in Beenleigh and 
Beaudesert. These were aimed at identifying what barriers community members were experiencing. These 
Yarning sessions provide the framework for GMSBML to engage with the Aboriginal and Torres Strait Islander 
Community at a local level.  Further yarning sessions will be held in Brisbane South and the Bayside regions 
with local Elders and community members.  
The yarning sessions held to date provided feedback which included the need of more culturally appropriate 
services, and more engagement and coordination of local services for their community. GMSBML aims to 
address some of these local issues by working with the community to focus on solutions. 
 
  
Treasure Chest 
Strive for 5 - Are you  
missing pages? 
Some copies of Strive for 5 have been found 
to have pages missing from the first part of 
the booklet. Pages in these faulty booklets 
start at Appendix 1, so some recipients may 
not be aware that they have only received 
half a booklet.  
Your copy of Strive for 5 can be checked 
against the online version for missing pages. 
If you have a faulty copy please email 
editor@apna.asn.au. 
 
Beenleigh yarning session, from top left to right Sophia Seve 
(Centacare), Estelle Congoa, Jo-Ann Nicol (both Queensland Health), 
Colleen Power (Pathways Foster Care Agencies), Natalie Pakoa, 
Jason Roe, Florence Williams, Jenni Beetson-Mortimer (all GMSBML), 
Kym Alexander (Beenleigh State Primary School) 
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GMSBML Events 
Click on the below hyperlinks to view  
the event flyers and registration form. 
6 May Healthy Ageing Nursing Workshop 
At the completion of the workshop participants will be able to describe concepts of healthy ageing, understand the 
older population in general practice and identify the role of Practice Nurses to promote healthy ageing. 
7 May Department of Human Services: Disabilities Focus Group 
This is an opportunity to work with the Department of Human Services on improvements that can make processes 
more streamlined for General Practice. 
14 May The Role of Physical Activity in the Prevention and Management of Chronic Disease  
In partnership with Exercise is Medicine Australia. Presented by a local accredited exercise physiologist. The 
resources available to participants support the assessment, management and referral of patients. 
16 May  GMSBML Adolescent and Young Adult Health and Service Plan - Stakeholder Consultation 
GMSBML are conducting workshops with key community stakeholders to understandthe issues and propose 
solutions to a range of barriers impacting adolescent and young adult (15-24) community members. 
22 May Diabetes and the High Risk Foot 
Come along to find out more about the new series of referral pathways in our region and refresh your skills in 
preventing, assessing and managing foot complications in your patients with diabetes. 
27 May Perform CPR (HLTAID001) – Wynnum 
Two hour practical course run by B.L.S First Aid Training. 
17 June Primary Care Nurse Network Meeting 
Come and join us for our next Primary Care Nurse Network meeting. It is a great opportunity to network, share 
and learn from each other. 
July Allied Health Networking Meetings 
Connect with local primary health care providers, promote your services to other health professionals, discuss 
local issues in a multidisciplinary setting and find out about new initiatives in the GMSBML region. 
External Events 
Wesley LifeForce Suicide Prevention Workshop 
Two workshops designed to teach people how to identify the signs that someone may be at risk of suicide and 
appropriate action to take. Thursday 22 May for practice staff and Saturday 24 May for GPs and Nurses. 
A Fresh Approach to FPS – Focused Psychological Strategies 
Provides participants with skills in the provision of Focused Psychological Strategies, with a focus on those 
strategies specifically derived from Interpersonal Therapy (IPT). Saturday 24 May and Saturday 31 May 2014. 
For more information view the invitation. 
Working with Refugees Training 
A one day accredited training course to develop competency in working with refugees. Tuesday 3 June 2014. For 
more information view the invitation. 
Australian Winter School Conference 
A unique forum for people working in the alcohol and other drug sector to share experiences and update skills. 
Wednesday 23 to Friday 25 July 2014. For more information visit the website. 
 
 
  Online Education 
By 2025, it is predicted that nearly 80% of Australian adults will be either overweight or obese. Are you 
managing a lot of patients struggling with excess weight? Consider taking part in ThinkGP’s module – Weight 
management – evidence and practical strategies for a higher protein, low GI diet - examining the benefits of 
higher protein, low GI diets for encouraging patients to achieve weight management and meet nutritional 
requirements. 
Please visit the Education and Events page on our website for a full list of events. 
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Australian Hearing GP Hearing Program 
Maintaining patients’ health and wellbeing through regular 
screening programs is a key goal of GP practices. At Australian 
Hearing we are committed to providing easily accessible hearing 
health screening programs as well as public education and 
awareness about hearing services across Australia.  Your 
patient’s hearing needs are our highest priority. Australian 
Hearing offer two hearing health screening programs for GP 
practices, both of which are free of charge: 
1. Hearing screening for patients, where a claim for the service 
can be made under the MBS. 
2. Hearing screening for patients which is not claimable under 
the MBS. 
The program that would suit your practice depends upon the 
demographic make-up of your practice’s patients. Australian 
Hearing Logan are happy to discuss your practice’s requirements 
with you via 07 3387 6600. 
Prescriber Perspectives of Drug Safety Warnings   
The researcher team from the University of Queensland is 
conducting a survey study to assess the prescribers’ point of 
view on the current drug safety warnings in Australia. 
Healthcare professionals are inviting to participate in a short 
electronic survey on recent emerging drug safety and sources 
of information. This should take no more than 10 minutes. All 
responses will be aggregated and individual responses will 
remain confidential. Your experience will help us understand 
the impact of drug warning systems, which could lead to 
improve communication and collaboration between drug 
authorities and prescribers. 
Click the link: https://www.surveymonkey.com/s/PrescriberPerceptionDrugSafety  
For further information contact Dr. Suvimol Niyomnaitham via suvimol.niyomnaitham@uq.net.au or phone 
07 3346 1995. 
Chronic Disease Self Management Post Graduate Qualification 
This is a unique opportunity for nurses to complete a Post Graduate Qualification in Advising on Chronic 
Disease Self Management. At the completion of the program, successful students will have the skills and 
knowledge necessary to work as CDSM Advisors providing an integrated and collaborative healthcare 
approach enabling a wider network of support for self management of chronic diseases. 
The first two days of training are Tuesday 27th and Wednesday 28th May. As a special offer to fill the 
remaining places, we are offering students a significant discount, reducing the cost of the program from 
$4250 to $2750. 
Attached course pack includes registration information. 
Resources for GPs in Managing Patients with Chronic Pain 
NSW's Agency for Clinical Innovation (ACI) has developed a new website devoted to providing information 
to patients and practitioners on how to manage chronic pain. Early assessment and effective management 
of pain is essential to prevent its progression to chronic pain. Best evidence for effective management and 
prevention of chronic pain is to use an interdisciplinary bio-psychosocial approach to people in pain. 
Tools and resources are available at the Pain Management Network website: http://www.aci.health.nsw. 
gov.au/chronic-pain/health-professionals.  
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New Resources: Better Living With Your Lung Disease 
Lung Foundation Australia has produced a new range of resources in lung disease focusing on self-
management titled Better Living With your Lung Disease (BLLD) - Health Professional’s Kit. This kit is 
targeted towards GPs, practice nurses, domiciliary, community and tertiary healthcare providers.  
This all-in-one package was developed to assist health professionals to promote self-management to their 
patients with lung disease. BLLD is a 10-part DVD series that enables patients to learn more about self-
management and how to manage their disease and its symptoms. The kit also includes BLLD collateral such 
as brochures and posters suitable for a practice waiting room or centre. This information encourages patients 
to find out more about how they can improve their general wellbeing and quality of life.  
How will BLLD benefit lung disease patients? 
 Improved self-management skills 
 Achieve their care plan goals 
 Learn more about managing their disease, its symptoms and 
how they can live better with their lung disease 
 Learn how to access supportive and palliative care services 
 Will better inform carers and family members on what to 
expect 
How can you help? 
 Place the attached article in your weekly newsletter 
 Add the Health Professional Kit to your website under 
resources or where suitable 
 Distribute promotional material to GP practices in your area 
 Display postures and brochures in your waiting room 
The Health Professional Kit is available from our online shop for $65 + postage, please visit 
www.shop.lungfoundation.com.au. 
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Practice Manager, RN, Medical Receptionist 
Needed 
A growing modern general practice is seeking  
a full-time/part-time medical receptionist/RN  
to manage a busy environment. Practice is  
bulk billing, open seven days a week and has 
Allied heath, pathology and skin clinic on  
site. For further details please send CV to 
wcmedicalcentre@gmail.com or phone  
0400 025 649. 
Visiting Allied health required  
A growing modern general practice in logan 
area is seeking for following allied health: 
Dietitian, Diabetic nurse educator, Podiatrist, 
Physiotherapist (22 sqm room available), 
excercise physiologist and Psychologist.  
For further details please send CV to  
wcmedicalcentre@gmail.com or call  
0400 025 649. 
VR GP Wanted 
Our well established practice (1983), requires a 
VR GP male/female, as sadly one of our team 
is relocating to the Gold Coast in March. If you 
would like to work in a friendly family 
atmosphere, with full RN support, accredited, 
private billing, fully computerised, and onsite 
pharmacy, pathology, please phone Kay or 
Carolyn at Shailer Medical on 3287 6699. 
Doctor, Are You Looking For A Change?  
Garden City Family Doctors located in the 
newly renovated Westfield Garden City is 
seeking GPs for weekend/evening work. This 
highly sort after location is open seven days 
bulk billing with provision of evening work. Car 
parking provided for doctors. We are offering 
flexible days and hours. Fully computerised 
Pracsoft/MD. We are a modern privately owned 
practice with an established patient database 
plus potential to establish your own! Come join 
our experienced team of Doctors/Nursing  
and Administration staff. Well supported  
by allied health, onsite pathology and 
pharmacy. Attractive remuneration. Phone Di 
on 0427 909 298. 
 
Casual Medical Receptionist Wanted 
For small bulk-billing General Practice at Norman Park. 
Initially to fill-in for two weeks in early June with further 
hours to be considered in the near future. Experience 
with Medical Director or similar NOT required. Please 
phone Fay or Margo for an interview between 8:30am 
and 12:30pm Monday to Friday on 3398 2457. 
Doctor Required 
Sunnybank Hills Family Practice is looking for a friendly 
Doctor to be part of our working family. We are located 
inside Sunnybank Hills Shopping town within a 
Priceline Pharmacy. We offer great remuneration and 
flexible working hour arrangement. With nurses and 
administration staff by your side. Feel free to contact 
Fabienne on 0415 961 089 I will be more than happy to 
help and show you around the practice. 
Visiting Allied Health Professionals Wanted  
Busy Medical Centre in Underwood and Nerang is 
seeking visiting Allied Health Professionals (Physio, 
Podiatry, Hearing, Clinical Psychologist) to join our 
team. Options include room rental or percentage of 
billings. Contact rajesh.sharma@qualitashealth.com.au 
or 0422 852 000. 
Rooms Available at Bay Terrace Specialist Centre 
Modern spacious consulting rooms available for 
sessional lease. Situated within a landmark heritage-
listed building only a short stroll to the Wynnum 
waterfront.  Including: reception services, furnished 
examination rooms, staff facilities, off-street parking, 
sterilsation facilties and Registered Nurse available. 
For further information phone 3893 1244 or email 
pauldollardental@bigpond.com.  
Registered Nurse Required 
Looking for a team focused, experienced Registered 
Nurse to join our friendly medical centre located in 
Alexandra Hills for approximately 16-20 hours per 
week. Medical centre experience is essential. Minimum 
two years. Become part of a team in a well-established 
centre with dedicated, experienced Doctors and 
longstanding, loyal patients. Hourly Rate is negotiable 
depending on experience. Contact Annette on  
07 3824 3882. 
 
Hurry, Ending Soon: Complimentary Trial of BMJ Best Practice 
British Medical Journal (BMJ) are offering general practices in the 
Greater Metro South Brisbane Medicare Local region a 
complimentary 30-day trial of their online clinical decision support 
tool, BMJ Best Practice. The tool combines the latest evidence, 
guidelines and expert advice into a single source to give busy 
clinicians an instant second opinion at the point of care.  
To find out more or request a trial for your practice, please visit 
http://bestpractice.bmj.com/anztrial. Offer ends 15 May 2014. 
 
 
  
 
 
 
  
Positions Vacant 
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Positions Vacant continued 
 
 
Contact Details 
To submit articles or for further information please email: engagewithus@gmsbml.org.au  
Deadline is 5pm Friday for inclusion in Wednesday publication.  
Greater Metro South Brisbane Medicare Local 
PO Box 6435, Upper Mt Gravatt QLD 4122   |   t  07 3864 7555  or  1300 467 265   |   f  07 3864 7599  
Opening Hours: 8:00am – 5:00pm Monday to Friday        ABN 53 151 707 765 
 www.facebook.com/sthbrisbanemedlocal  www.twitter.com/sthbrismedlocal    
 
Full-time / 2 x Part-time Cleveland GP 
Opportunity available in the great lifestyle 
location of Cleveland on Brisbane Bayside for a 
VR preferably full-time GP looking to establish 
themselves in a friendly, innovative, non-
corporate environment with full support from 
staff and nurses running diabetes, respiratory 
and weight loss clinics. Visit our website: 
www.clevelandmedical.com.au. Please email a 
CV and arrange a visit to the practice with 
Melinda: pm@clevelandmedical.com.au. 
Capalaba Central Doctors seeking VR GPs 
Bulk-billing medical centre located in busy 
shopping centre seeking full-time/part-time VR 
GPs.  Fully computerised, full equipped room 
with full-time nurse. $150PH or high %. Choose 
your own hours. Contact Kylie White on  
3808 3300 / 0450 738 401 / 0412 888 067 or 
ccd4157@yahoo.com.au. 
GP Wanted! 
Full-time or part-time VR GPs welcome. DWS 
doctors are invited to apply as well.  
Well-equipped medical centre, 15 mins south  
of Brisbane. Skin cancer work available. Up  
to 70 % of billings. Busy location, along  
Logan Road with excellent exposure. Position 
available from early June 2014. If interested, 
please contact Dr J KU at j_k_ku@hotmail.com 
or 0413 932 445. 
Casual Endorsed Enrolled Nurse Required 
Currently seeking Casual Practice Nurse to join 
our friendly team. Zedmed experience preferred 
but not essential. General Practice Treatment 
Room experience essential. Must be flexible 
and be available some weekends. Please 
forward resume to holmview@qmedical.net.au.  
Casual Receptionist Required 
Currently seeking a Casual Medical 
Receptionist to join our friendly team. Zedmed 
experience preferred but not essential. Must be 
available to work some weekends. Please 
forward resume to holmivew@qmedical.net.au. 
 
VR GP Required 
VR GP required for busy Southside privately 
owned, well established practice. New modern 
premises, fully computerised with full RN support. 
Psychologist, Dietitian and S & N Pathology on 
site. Come and join our experienced friendly team, 
please email bryantss@bigpond.net.au. 
Registered Nurse Camp Hill 
Registered Nurse required with minimum of  
three years experience for a large busy  
General Practice, Camp Hill Healthcare. Casual / 
part-time. Expressions of interest to 
camphillmedical@ozdoc.com.au. 
Full-time/Part-time Doctor Required Slacks 
Creek Medical Centre 
Replacing existing doctor in busy, well established 
practice. Doctor owned, accredited, fully 
computerised, not DWS. Conveniently located 20 
minutes from Brisbane, 35 minutes form  
Gold Coast. Friendly experienced team including 
nurse and visiting allied health. Pathology and 
pharmacy next door. Excellent remuneration  
with initial guaranteed minimum. Contact Dr Stone 
on 0419 660 019, 3209 3911 or email 
mstone_77@Hotmail.com. Visit our website: 
slackscreekmedicalcentre.com. 
RN Wanted 
RN with PAP Smear training to offer clinic sessions. 
Times negotiable. Generous remuneration. Contact 
Karen or Robyn on 5547 0541 or info@pioneer-
lv.com.au. 
Wembley Rd Medical Centre Seeking VR GP 
Newly renovated non-corporate bulk-billing medical 
centre located in Logan Central seeking full-
time/part-time VR GP to work with our friendly team 
of four doctors. High number of patients, very high 
rate you will never refuse. Full-time nursing support. 
Choose your hours. We open from 8:30am to 
11pm. 19AB exemption after 6pm, A0N positions 
available. AH period ideal for non-VR temporary 
residents. Contact Kylie White on 3808 3300, 0412 
888 067 or email wembleyrd@outlook.com.au. 
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